

Department of Health & Human Services
Centers for Medicare & Medicaid Services



Annual Report to Congress
on the
Open Payments Program
April 2016

The Centers for Medicare & Medicaid Services (CMS) strives to make information available to all. Nevertheless, portions of our files including charts, tables, and graphics may be difficult to read using assistive technology.

Persons with disabilities experiencing problems accessing portions of any file should contact CMS through e-mail at 508_Compliance@cms.hhs.gov.

Executive Summary

Open Payments is a national program that promotes transparency by publishing data on the financial relationships between the health care industry (applicable manufacturers and group purchasing organizations, or GPOs) and health care providers (physicians and teaching hospitals). CMS is dedicated to promoting transparency, including through education, outreach, partnership, strategic communications, and data releases; the Open Payments program is one way in which we do this. In 2015, CMS published 11.4 million payment records, transfers of value, or instances of ownership/investment interest that occurred during calendar year 2014. These financial transactions totaled \$6.49 billion. CMS also re-published 2013 data, due to updates made by industry such as additions/deletions of records, resolution of disputes, and release of delay in publication records, so that the public has access to nearly one and a half years of fully identified data.

The Affordable Care Act requires the Secretary of the Department of Health and Human Services (HHS) to collect and display information on payments and other transfers of value and ownership/investment interest annually. CMS publishes information for each reporting year on its public website, and updates the website annually with an additional full year of data. This public website is designed to increase access to, and knowledge about, healthcare industry financial relationships and provide the public with information to enable them to make informed decisions about their healthcare. Disclosure of the financial relationships between the industry and health care providers is not intended to signify an inappropriate relationship, and Open Payments does nothing to prohibit such transactions. The public can search, download, and evaluate the reported data. The data displayed on the Open Payments website are self-reported by applicable manufacturers and GPOs.

To ensure that the healthcare industry is compliant with Open Payments reporting requirements, CMS has the authority to impose civil monetary penalties for late, inaccurate, and incomplete reporting. In 2014 CMS focused Open Payments compliance and enforcement activities on physician-owned distributors (PODs), generally a subset of GPOs, and failures to report in the Open Payments program. Through a focused outreach campaign, entities identified as potentially non-compliant were educated about Open Payments reporting requirements and brought into compliance as appropriate, without issuing any civil monetary penalties.

Partner engagement and outreach efforts are a priority for CMS. Open Payments stakeholders, including medical college faculty, teaching hospital employees, industry professional groups, physicians, attorneys, and compliance professionals, received Open Payments outreach throughout the past year. CMS hosts regular open forum discussions to share program updates and obtain feedback directly from stakeholders. CMS continues to improve the usability of the public website and Open Payments system.

Beginning with this report, which includes 2014 calendar year data, annual data publications will include a full calendar year of new payment data, as opposed to the

partial year of data reported for 2013. CMS will publish financial data for each program year by June 30th of each following year as well as updates from previous program periods. In addition, CMS will update or “refresh” the Open Payments data at least once, annually, after its initial publication. The refreshed data will include data corrections made since the initial publication of data that were submitted by applicable manufacturers and GPOs.

The summary table below shows the number of records and value of payments published and held for future publication through 2014.

Summary of Program Year Data

	2013 ¹	2014	Total Published (2013 and 2014)	2013 Delay in Publication ³	2014 Delay in Publication ³
Number of Records²	4.3 million	11.41 million	15.71 million	183,000	187,000
Value of payments	\$3.43 billion	\$6.49 billion	\$9.92 billion	\$454 million	\$1.26 billion

¹ This number varies from the previously published Report to Congress due to updates made by industry such as additions/deletions of records, resolution of disputes, and release of delay in publication.

² A record is defined as a single row in a dataset that was reported by an applicable manufacturer or GPO

³ The Open Payments final rule 42 CFR § 403.910 provides applicable manufacturers and GPOs the opportunity to request a delay in publication pursuant to certain research payments or under a product research or development agreement for a period not to exceed four calendar years after the date the payment or other transfer of value was made, or upon the approval, licensure or clearance of the covered drug, device, biological, or medical supply by the FDA.

Table of Contents

1. Program Overview and Implementation.....	6
Highlights From the Second Year of Open Payments:	6
Statutory Requirement	7
Overview and Implementation of the Open Payments Program.....	7
Program Participants and Roles	9
Engagement and Outreach Efforts.....	11
Program Timeline	12
2. Data Submission and Data Integrity.....	13
Data Submission	13
Data Integrity	14
Reporting Compliance.....	15
Process for Enforcement Actions	16
3. Data Publication: Open Payments System, Public Website and Policy Changes	17
Open Payments System: Planned Improvements for Program Participants.....	17
Open Payments Website: Today	17
Open Payments Website: Planned Enhancements.....	20
Open Payments Policy: Updates to the Final Rule	20
Appendix A. Transparency Reports and Reporting of Physician Ownership or Investment Interests, Sec. 1128G. [42 U.S.C. 1320a-7h].....	22
Appendix B. Aggregate Data by Applicable Manufacturer/Group Purchasing Organization.....	30

List of Figures

Figure 1. Overview of the Process for Open Payments	8
Figure 2. Example of Aids and Guides for Use With the Open Payments System	14
Figure 3. Example Company Making Payment Search: Summary Information (Search Tool)	19
Figure 4. Detailed Transaction Information (Search Tool)	19

List of Tables

Table 1. Program Year 2014 and Updated 2013 Open Payments Summary Information	9
Table 2. Program Participants and Roles	11
Table 3. Program Year Timeline	12
Table 4. Open Payments Program Categories	13
Table 5: Review and Dispute Summary	15

1. Program Overview and Implementation

The Affordable Care Act requires the Secretary of the Department of Health and Human Services (HHS) to collect and display information reported by applicable manufacturers and GPOs about the payments and other transfers of value these entities have made to physicians and teaching hospitals, and the ownership or investment interests physicians and their immediate family members have in these entities. CMS developed and implemented the Open Payments program, including the information system built to collect and publish payment information, to fulfill this requirement.

The Affordable Care Act also requires the Secretary to submit an annual report to Congress summarizing: 1.) Information aggregated by applicable manufacturers and GPOs (collectively referred to as industry or reporting entities), and 2.) Any penalties imposed by HHS related directly to Open Payments. CMS consulted with the Office of the Inspector General (OIG) in the development of this report. In addition to summarizing financial transaction information, this report includes plans for improving the program moving forward.

Highlights From the Second Year of Open Payments:

- On June 30, 2015, CMS published data records containing 11.41 million payments valued at \$6.49 billion in payments and transfers of value made to physicians and teaching hospitals in Calendar Year 2014. This includes ownership or investment interests in applicable manufacturers and GPOs held by physicians or their immediate family members, in addition to payments or transfers of value provided for items such as research activities, gifts, speaking fees, meals, or travel.
- CMS republished the publication of the prior year's data: 4.3 million payments or transfers of value made to physicians and teaching hospitals valued at \$3.43 billion for the last 5 months of 2013.
- As of June 30, 2015, CMS published data from 1,617 applicable manufacturers and GPOs about 15.71 million payment records, transfers of value, or instances of ownership/investment interest valued at \$9.92 billion. Included in the data submitted by reporting entities were over 683,000 physicians and 1,143 teaching hospitals.
- CMS has continued to work closely with multiple stakeholders to test the Open Payments system. CMS has hosted, and will continue to host, regular discussions to share planning activities and hear directly about concerns and challenges.
- As required, CMS has made the data available to the public on a searchable website. CMS will continue to improve public access to Open Payments information and data by making it easier to search and find relevant information to help inform consumers' decision-making. CMS also provides context about payments or transfers of value on the Open Payments website, and applicable manufacturers and GPOs have the ability to provide more context about additional payments.

- The payments and transfers of value displayed on the Open Payments website are self-reported by applicable manufacturers and GPOs. CMS launched an effort to identify applicable manufacturers and GPOs that should have submitted payment or ownership and investment information but did not in 2013. Through a focused outreach campaign, entities identified as potentially non-compliant were educated about Open Payments reporting requirements and brought into compliance as appropriate, without issuing any civil monetary penalties.

Statutory Requirement

Section 6002 of the Affordable Care Act amends the Social Security Act (the Act) to add Section 1128G, which mandates the creation of a transparency program. This program, known as Open Payments, requires applicable manufacturers of drugs, devices, biologicals, and medical supplies for which payment is available under Medicare, Medicaid, or the Children's Health Insurance Program (CHIP) to report payments and other transfers of value made to physicians and teaching hospitals (collectively referred to as covered recipients). Open Payments also requires applicable manufacturers and GPOs to report ownership or investment interests held by physicians or their immediate family members. Section 1128G of the Act generally preempts state laws that require disclosure of the same type of information by manufacturers.

The Act requires applicable manufacturers and GPOs to report the required information annually to CMS in an electronic format. Applicable manufacturers and GPOs are subject to civil monetary penalties for failing to comply with these reporting requirements. CMS is required to publish the reported data on a public website. The data must be downloadable, easily searchable, and aggregatable.

The Affordable Care Act requires the Secretary of HHS to submit an annual report to Congress and each state summarizing aggregate information by manufacturer and GPO and any penalties imposed by the Department. This report complies with the reporting requirements outlined in the Affordable Care Act. The Affordable Care Act also requires consultation with the Office of Inspector General (OIG). CMS consulted with the OIG in the development of this report. Appendix A contains the statutory language and Appendix B contains payments and transfers of value information aggregated by applicable manufacturer and GPO for all data.

Overview and Implementation of the Open Payments Program

Open Payments is a national disclosure program that promotes transparency by publishing data on the financial relationships between the health care industry (applicable manufacturers and GPOs) and health care providers (physicians and teaching hospitals) on a public website. This public website is designed to increase access to, and knowledge about, these relationships and provide the public with information to enable them to make informed decisions. The public can search, download, and evaluate the reported data.

Disclosure of the financial relationships between the industry and health care providers is not intended to signify an inappropriate relationship, and Open Payments does nothing to prohibit such transactions. Collaborations among the medical product industry, physicians, and teaching hospitals can contribute to the design and delivery of life-saving drugs, devices, biologicals, and medical supplies. However, these relationships may also influence research, education, and clinical decision-making in ways that compromise clinical integrity and patient care and may potentially lead to increased health care costs. While disclosure alone is not sufficient to differentiate between beneficial financial relationships and those that may create conflicts of interest, transparency aims to shed light on the nature and extent of the relationships that exist and discourage development of inappropriate relationships.

The Affordable Care Act requires CMS to collect and display information reported by applicable manufacturers and GPOs regarding the payments and other transfers of value these entities have made to physicians and teaching hospitals. Once the data is collected by CMS, physicians and teaching hospitals have the opportunity to register in the Open Payments system, review payments attributed to them, and dispute any information reported about them that may be inaccurate. Applicable manufacturers and GPOs then have the opportunity to review and correct information as necessary. CMS displays the data on the public website (Figure 1).

Figure 1. Overview of the Process for Open Payments



CMS published the Open Payments final rule on February 8, 2013 (78 FR 9458). For the 2014 program year, applicable manufacturers and GPOs were required to collect data on any payments or other transfers of value, or ownership and investment interests, occurring throughout the year. Reporting entities were required to report the data to CMS by March 31, 2015.

On June 30, 2015, CMS published Program Year 2014 data records containing \$6.49 billion in payments and transfers of value to physicians and teaching hospitals made in the Calendar Year 2014. In addition, CMS republished Program Year 2013 (August 1 – December 31, 2013) data records containing \$3.43 billion in payments and transfers of value. As required by the final rule, CMS performs an annual refresh of the published data. As of the June 30, 2015 publication, combining both Program Year 2013 and 2014, the Open Payments dataset totals \$9.92 billion in payments and transfers of value,

attributable to approximately 683,000 individual physicians and 1,143 teaching hospitals. In 2013, close to 190,000 records totaling \$551 million in value were not published because the applicable manufacturer requested a delay in publication. In June 2015, about 183,000 of those records totaling approximately \$454 million remained delayed and excluded from publication. Of payments made in 2014, 187,000 records totaling \$1.26 billion were marked for delay and excluded from the June 2015 publication.

All data publications will be performed annually and will include a full 12 months of payment and ownership and investment data. In addition, every year, CMS will update or “refresh” the Open Payments data at least once after its initial publication. The refreshed data will include corrections made since the initial publication of data that were submitted by applicable manufacturers and GPOs.

CMS published data records related to \$6.49 billion in payments and transfers of value, and ownership and investment interests, on the Open Payments website on June 30, 2015 (Table 1). Aggregate submission data by manufacturer and GPO, for all data, can be found in Appendix B.

Table 1. Program Year 2014 and Updated 2013 Open Payments Summary Information

Categories	Total
Program Year 2014	
Total value	\$6.49 billion*
Total number of records	11.41 million*
Total number of physicians	607,000*
Total number of teaching hospitals	1,121
Total number of applicable manufacturers and GPOs	1,444
Program Year 2013	
Value	\$3.43 billion*
Number of records	4.3 million*
Number of physicians	470,000*
Number of teaching hospitals	1,019
Number of applicable manufacturers and applicable GPOs	1,347
* rounded	

Program Participants and Roles

As defined in the Act, the term “applicable manufacturer” means a manufacturer of a covered drug, device, biological, or medical supply which is operating in the United States, or in a territory, possession, or commonwealth of the United States (Section 1128G(e)(2)). Further, the definition of a manufacturer of a covered drug, device, biological, or medical supply means any entity which is engaged in the production, preparation, propagation, compounding, or conversion of a covered drug, device,

biological, or medical supply (or any entity under common ownership with such entity which provides assistance or support to such entity with respect to the production, preparation, propagation, compounding, conversion, marketing, promotion, sale, or distribution of a covered drug, device, biological, or medical supply) (Section 1128G(e)(9)).

As defined in the Act, the term “applicable group purchasing organization” means a group purchasing organization (as defined by the Secretary) that purchases, arranges for, or negotiates the purchase of a covered drug, device, biological, or medical supply which is operating in the United States, or in a territory, possession, or commonwealth of the United States (Section 1128G(e)(1)). In the final rule, CMS clarified that the term “group purchasing organization” also captures entities like physician-owned entities or physician owned distributors (PODs) that purchase, arrange for or negotiate the purchase of covered drugs, devices, biologicals or medical supplies for resale or distribution to others (78 FR 9493).

The Act requires applicable manufacturers to annually report to CMS:

- Payments or other transfers of value made to covered recipients (physicians and teaching hospitals).
- Certain ownership or investment interests held by physician owners or investors and their immediate family members.

In addition, the Act requires GPOs to annually report to CMS:

- Certain ownership or investment interests held by physician owners or investors and their immediate family members.

As defined in the Act, the term “covered recipient” refers to a physician or a teaching hospital (Section 1128G(e)(6)). A covered recipient physician is defined as any physician legally authorized to practice medicine by the state in which he performs such function or action (as defined by Section 1861(r) of the Act), except for a physician who is a bona fide employee of an applicable manufacturer or GPO that is reporting the payment (42 C.F.R. § 403.902). However, the term does not cover medical residents (*See* 78 FR 9467).

As further defined in the Open Payments final rule, covered recipients also include any teaching hospital, defined as an institution that received Indirect Medical Education (IME) or Graduate Medical Education (GME) payments under 1886(d)(5)(B), 1886(h), or 1886(s) of the Act, during the last calendar year for which such information is available.

In accordance with Section 1128G(c)(1)(C)(ix) of the Act, physicians and teaching hospitals can register in the Open Payments system to review data submitted by applicable manufacturers and GPOs prior to public posting, and dispute any information that may be inaccurate.

While not required to participate in Open Payments, CMS encourages physicians and teaching hospitals to actively engage in the program by registering, reviewing and disputing reported payments, transfers of value, and ownership and interest

information. Registration in the Open Payments system is voluntary for physicians and teaching hospitals, but if a physician or teaching hospital wants the opportunity to review and dispute data attributed to them for the reporting period, they must register in the Open Payments system.

CMS' role in the Open Payments program is to collect and publish information from applicable manufacturers and GPOs (Table 2). CMS also provides extensive outreach and education to the health care industry, physicians, teaching hospitals, and the general public to inform them about the Open Payments program. CMS will continue to provide technical assistance, guidance, and resources to all Open Payments stakeholders.

Table 2. Program Participants and Roles

Program Participants	Roles				
	Register in the Open Payments System	Submit Data	Review & Dispute Data	Address Disputes	Publish Data
CMS					✓
Manufacturers & GPOs <i>(Required)</i>	✓	✓		✓	
Physicians & Teaching Hospitals <i>(Voluntary)</i>	✓		✓		

Engagement and Outreach Efforts

In accordance with Section 1128G(c)(1)(C) of the Act, CMS solicited stakeholder assistance in the development of its public website. CMS met with multiple stakeholders and received feedback about context for the published information that would be useful to consumers. With the assistance of this feedback, CMS produced and published specific language for consumers to help them understand the various natures of payments and provided examples of such payments. A number of applicable manufacturers participated in user acceptance testing, by performing tasks such as registering, viewing records, and uploading data. Those involved in system testing provided valuable feedback that contributed to system improvements and better instructional documents for all system users.

Partner engagement and outreach efforts are a priority for CMS for the purpose of improving policies, operations and programs. Open Payments stakeholders, consisting of but not limited to, medical college faculty, teaching hospital employees, physicians, attorneys, and compliance professionals, received regular Open Payments outreach throughout the past year.

CMS undertook a robust outreach and education campaign to support this program year, using tools such as electronic listserv messaging, social media, webinars, stakeholder meetings and conference calls, blogs, CMS Regional Office engagements, and electronic news disseminations. CMS distributed 10 Medicare Learning Network (MLN) Connects messages on various Open Payments updates, including key deadlines

and background information. MLN Connects reached 140 provider partners representing more than 3.2 million members. More than 51,000 manufacturers, physicians and teaching hospitals signed up to receive electronic listserv messages from Open Payments and over 4.7 million emails were sent from the Open Payments electronic listserv. CMS reached an additional 175,000 physicians using other CMS listservs. CMS Regional Offices published articles on their websites and in e-newsletters, which reached more than 14,000 provider partners and approximately 750,000 providers.

Through the official CMS Twitter account, @CMSSGov, tweets shared regarding Open Payments developments had an approximate exposure to 3.5 million users. After the data release in June 2015, the public responded on social media with 346 posts. The general tone was positive. More than 9 million impressions (i.e., the number of times a digital ad was displayed on a web page) were tabulated through digital advertising avenues. This year saw increased response to the digital ads which lead viewers to the Open Payments website for more information.

CMS conducted a number of focus groups with different stakeholders including physicians and the general public, to get their impressions of the program and collect critical feedback. This helped to optimize CMS' messaging and outreach efforts, including the development of content for the Open Payments website.

CMS is also committed to working with states. In accordance with Section 1128G(d)(2) of the Act, CMS provided formal notification to states on June 30, 2015 that state-specific information was available through the public website. The website allows states to aggregate and filter state-specific data, as well as create state-specific visualizations.

Program Timeline

Applicable manufacturers and GPOs began data submissions on February 2, 2015 (Table 3). CMS provided quality control and review and dispute processes from April 6 through May 20, 2015, and industry corrections period extended May 21 through June 4, 2015. CMS published these data on June 30, 2015.

Table 3. Program Year Timeline

Program Activity	Start Date	End Date
Industry registered and submitted data in Open Payments system	February 2, 2015	March 31, 2015
Physicians and teaching hospitals registered	February 2, 2015	Ongoing*
Industry attestation to accuracy of submitted data	February 2, 2015	March 31, 2015
Physicians and teaching hospitals reviewed and disputed data	April 6, 2015	May 20, 2015
Industry made corrections to data as necessary	May 21, 2015	June 4, 2015
Data published by CMS	N/A	June 30, 2015**

Program Activity	Start Date	End Date
Report to states made available	N/A	June 30, 2015
Search tool released	Already In Place	N/A
* continuous enrollment made available		
** only attested data as of March 31, 2015 was considered for publication on June 30, 2015		

2. Data Submission and Data Integrity

Data Submission

Data submitted by applicable manufacturers and GPOs are categorized across three main payment types: general payments, research payments, and physician ownership information (Table 4).

Table 4. Open Payments Program Categories

General Payments	Research Payments	Physician Ownership Information
Payments or other transfers of value not made in connection with a research agreement or research protocol.	Payments or other transfers of value made in connection with a research agreement or research protocol.	Information about physicians or their immediate family members who have an ownership or investment interest in an applicable manufacturer or GPO.

The Act requires each applicable manufacturer to identify the nature of each payment or transfer of value that is reported. Natures of payment, as defined in the act, include consulting fees, research grants, travel reimbursements, and other gifts applicable manufacturers provide to physicians and teaching hospitals (Section 1128G(a)(1)(A)(vi)). CMS has information and examples on its website to help consumers understand the various natures of payments.

In accordance with the Open Payments final rule, certain research payments or other transfers of value made to a covered recipient by an applicable manufacturer under a product research or development agreement may be delayed from publication on the Open Payments website. Delayed publication of a payment or other transfer of value can be requested by an applicable manufacturer when made in connection with research on or development of (or clinical investigations regarding) a new drug, device, biological, or medical supply, or a new application of an existing drug, device, biological, or medical supply. CMS makes these payments available for physician review, and can delay publication for up to four years. Such optional delays in publication are part of the program, as required by statute, to help balance public interest in transparency with innovation in product design and research.

Data Integrity

CMS provided applicable manufacturers and GPOs with numerous aids and guides to assist with data submission. These support materials included the annually updated teaching hospital list, submission data mapping documents, sample submission files, the Open Payments System User Guide, step-by-step detailed instructions, and quick reference guides (Figure 2). With the assistance of these materials, applicable manufacturers and GPOs submitted attested data into the Open Payments system. After the data was collected and made available for review within the Open Payments system, registered physicians and teaching hospitals had the opportunity to review payments attributed to them and dispute information they believed to be inaccurate.

Figure 2. Example of Aids and Guides for Use With the Open Payments System

The figure displays several key resources for the Open Payments system:

- Open Payments Phase 2 CSV & XML Tutorial:** Preparing Data Files for Submission.
- Sample Error Report:** A screenshot of an error report window.
- Open Payments Quick Reference Guide – Physician Registration:** A document with instructions on how to register in EIDM and request access to the system.
- Data Mapping Table:** A table defining data elements for submission, including their names, descriptions, data types, formats, and validation rules.

ID #	Data Element Name	Definition / Description	Data Type	Format	Required?	Field Use	Validation	Publicly Displayed	XSD Element Name
1	Applicable Manufacturer or Applicable GPO Name	Default proper name of either the submitting Applicable Manufacturer or Submitting Applicable GPO (for teaching hospitals only). If this file contains a single Applicable Manufacturer/Applicable GPO's set of payment/transaction records, this Applicable Manufacturer/Applicable GPO name will be used for all records in the file. If this file contains a Consolidated Report, this Applicable Manufacturer/Applicable GPO Name will be used as the Consolidated Reporter, and the Applicable Manufacturer/Applicable GPO Name and Open Payments system ID of the submission related to the payment/transaction will be included with every payment or transaction record in the file.	Text	Free form text	Yes	1-100 Char	Match the name on file for registration (Registration ID)	Yes	ApplicableManufacturerID/ApplicableGPOName
2	Applicable Manufacturer or Applicable GPO Registration ID	Open Payments system generated identifier used to identify the Applicable Manufacturer or Applicable GPO (generated only with the CMS provided identifier). If this file contains a single Applicable Manufacturer/Applicable GPO's set of payment/transaction records, this Applicable Manufacturer/Applicable GPO name will be used for all records in the file. If this file contains a Consolidated Report, this Applicable Manufacturer/Applicable GPO Name will be used as the Consolidated Reporter, and the Applicable Manufacturer/Applicable GPO Name and Open Payments system ID of the submission related to the payment/transaction will be included with every payment or transaction record in the file.	Text	System generated	Yes	System generated Number (N/A)	Match the Registration ID on file	No	ApplicableManufacturerID/ApplicableGPOID
3	Consolidated Report Indicator	Indicator showing if this submission file contains a Consolidated Report.	Boolean	Y/N	Yes	1 Char	Limited to characters Y or N	No	ConsolidatedReportIndicator
4	Consolidated Report Identifier	Indicator showing if this submission file contains information that is considered a Consolidated Report of a Consolidated Report.	Boolean	Y/N	Yes	1 Char	Limited to characters Y or N	No	ConsolidatedReportIdentifier
5	Physician Identification Information	Default full name, as listed in the National Plan & Provider Enumeration System (NPPES), of the physician with the payment or transaction record being reported.	Text	Free form text	Yes	1-255 Char	Validation by CMS	Yes	PhysicianID/ApplicableGPOID/PhysicianName
6	Physician's First Name	Default middle initial or middle name, as listed in the National Plan & Provider Enumeration System (NPPES), of the physician with the payment or transaction record being reported.	Text	Free form text	Yes	1-255 Char	Validation by CMS	Yes	PhysicianID/ApplicableGPOID/PhysicianName
7	Physician's Middle Name	Default last name, as listed in the National Plan & Provider Enumeration System (NPPES), of the physician with the payment or transaction record being reported.	Text	Free form text	Yes	1-255 Char	Validation by CMS	Yes	PhysicianID/ApplicableGPOID/PhysicianName
8	Physician's Last Name	Default last name, as listed in the National Plan & Provider Enumeration System (NPPES), of the physician with the payment or transaction record being reported.	Text	Free form text	Yes	1-255 Char	Validation by CMS	Yes	PhysicianID/ApplicableGPOID/PhysicianName

Based on experiences in Program Year 2013, CMS made enhancements to the matching logic used in the Open Payments application for validating covered recipient identifiers. Part of these enhancements focused on ensuring that covered recipient profiles were constructed in the system based on fully vetted and reliable information extracted from two systems that CMS uses for identifying physicians: the National Plan & Provider Enumeration System (NPPES) and the Provider Enrollment, Chain and Ownership System (PECOS). Using these databases, CMS constructed a Validated Physician List composed of previously reported physician identifiers, and provided this tool to the applicable manufacturer industry to help ensure valid reporting. For all 2014 and 2013 data, CMS was able to validate that 98.8% of all records submitted in the Open Payments system

contained accurate identifying information about the associated covered recipient. All Open Payments data in 2013 and 2014 are now fully identified because of the enhancements in the matching process.

Data showed that covered recipients with higher counts of payment records or reports of ownership were more likely to be involved in the review and dispute process. Thirty percent (30%) of reported payment value is attributable to registered covered recipients, and registered covered recipients’ median total payment value is 4.5 times greater than that of unregistered covered recipients.

Approximately 28,000 physicians and over 450 teaching hospitals registered in the Open Payments system to review payments attributed to them. 30,000 payment disputes were initiated on 26,000 unique payment records (some records having multiple associated disputes) during the review and dispute period. These disputes were split fairly evenly among covered recipient type: teaching hospitals (38%), physicians (35%), and principal investigators (27%). Registered covered recipients disputed 2.7% of all payments or transfers of value. In comparison, registered covered recipients affirmed 3% of all payments or transfers of value. Disputes were evenly split between general and research payments with very few impacting ownership and investment interests. At the end of the review and dispute period, approximately 2,600 records pertaining to payments made in 2014 and 1,100 records pertaining to payments made in 2013 remained disputed.

Table 5: Review and Dispute Summary

Categories	Data Published*
Number of physicians that registered in Open Payments system to review and dispute	28,000
Number of teaching hospitals that registered Open Payments system to review and dispute	450
Number of records that were disputed	25,000**
Number of unresolved disputes at the end of review period	3,700
Number of records that were affirmed	27,000***
* Rounded ** Multiple disputes on the same record may occur. As a result, there were about 30,000 total disputes initiated during review and dispute associated with about 25,000 unique payment records. *** “Affirmed” indicator signifies that the covered recipient associated with the reported record has reviewed it and agreed with its accuracy.	

Reporting Compliance

The payments and transfers of value and ownership and investment interests displayed on the Open Payments website are self-reported by applicable manufacturers and

GPOs. CMS analysis of data to identify applicable manufacturers and GPOs that failed to report payment information as required by the Open Payments final rule is on-going.

Process for Enforcement Actions

For the 2013 Program Year, CMS implemented strategies to bolster compliance in the Open Payments Program using targeted outreach and education activities toward applicable manufacturers and GPOs (and more specifically PODs) that were potentially subject to the requirements in 42 CFR 403 Subpart I.

To that end, CMS identified applicable manufacturers, GPOs, and PODs based on various characteristics and attempted to connect directly with those entities and encourage reporting. These outreach activities educated entities about the Open Payments program in an effort to promote compliance with program requirements. Absent a national POD database or other system of record, special effort was taken to identify and educate PODs that were potentially non-compliant with Open Payments reporting requirements. Entities were mailed an initial notification, directing them to register and report in the Open Payments system prior to the submission deadline. Entities that took no action were sent a second notification. All CMS notices were sent via certified mail, return receipt requested. Responses to these notices were reviewed, documented and tracked.

As a result of CMS' outreach efforts, no civil monetary penalties were issued for 2013 program non-compliance. Using different environmental scanning methods, CMS has identified potential entity types, which due to their complex business models, require further investigation and research before civil monetary penalties can be imposed. Compliance activities will continue for subsequent program years. CMS continues to refine its methodology to identify potentially non-compliant applicable manufacturers and GPOs that may be subject to civil monetary penalties for failing to report in accordance with the requirements found at Section 1128G (b)(1) and (b)(2) of the Act and 42 CFR § 403.912.

3. Data Publication: Open Payments System, Public Website and Policy Changes

Open Payments System: Planned Improvements for Program Participants

A number of stakeholders are substantively engaged in the Open Payments program. CMS hosts regular meetings to share program updates and hear directly from stakeholders about their areas of concerns and challenges. CMS worked with multiple system users as pilot testers. In addition, CMS has hosted discussions and focus groups during the continued ongoing maintenance of the program.

CMS is making multiple system enhancements based on stakeholder feedback. In 2016, the following upgrades to the Open Payments system will be applied:

- Continue to make the Open Payments application more intuitive with user-friendly system screens, including just-in-time guidance via on-screen messages, which provide guidance directly at the point in the process where users require it.
- Enhancements to data download functionality including ability to download dispute data by reporting entities and ability for covered recipients to download data reported about them along with any outstanding disputes.
- Enhancements to better enable and facilitate review and dispute communication between disputing parties and applicable manufacturer and GPO entities.

CMS continuously analyzes user feedback received by the Open Payments Help Desk and through direct engagements with industry and the medical community. CMS will continue to use that feedback to guide future system enhancements.

Open Payments Website: Today

On June 30, 2015, CMS updated the Open Payments website to include both 2013 and 2014 program years' data and added a summary dashboard that displays high-level, aggregated data. The site continues to provide the necessary resources for all program participants, applicable manufacturers and GPOs that are required to report financial transactions and physicians and teaching hospitals that choose to register in the Open Payments system. On the website, visitors can find information explaining how the program works, why it was implemented, and how users can explore all the data CMS has published. CMS provided a field in the Open Payments system for applicable manufacturers and GPOs to voluntarily supply contextual information for each individual payment or transfer of value record submitted. This contextual information provided by applicable manufacturers and GPOs is now available to view on the public website. In addition to contextual information and resources for program participants, the site now displays both 2013 and 2014 reporting years' data. CMS developed the Open Payments website using a three-pronged data delivery approach:

1. **Search Tool:** Site visitors can get immediate results using this [standard search interface](#) to find information on individual physicians, teaching hospitals, or reporting entities. Site visitors can also view payment totals for an individual or entity, and select single records to see all the details associated with that particular piece of data, including any contextual information associated with that transaction (Figures 3 and 4).
2. **Data downloads:** Users can select a dataset and [download the data](#) in comma-separated values (.csv) format, which allows users to open and explore the data using their own software on their own computer. With this option, the user is not reliant upon an internet connection to view the data, but must have software that allows for downloading and viewing data in large datasets.
3. **Data Explorer:** Using the Data Explorer [web-based interface](#), users can select a dataset then customize the view using filters, sorts, and other actions to create their own, targeted views of the data. The Data Explorer interface allows users to create visualizations such as charts and graphs to interact with the data visually.

Figure 3. Example Company Making Payment Search: Summary Information (Search Tool)

For Illustrative Purposes Only





Figure 4. Detailed Transaction Information (Search Tool)



For Illustrative Purposes Only

From September 30, 2014 to August 1, 2015, CMS' website received over 1.1 million unique pageviews from visitors wanting to learn more about the Open Payments program or access resources for interacting with the Open Payments system. In that same timeframe, Open Payments data was accessed over 6.5 million times through the Search Tool or Data Explorer Tool, and Open Payments data has been downloaded close to 50,000 times. Major news outlets, such as the Wall Street Journal and the New York Times, professional journals, including the Journal of the American Medical Association, and special interest groups, like Pro Publica, have all published articles, blogs, and data visualizations based on the published Open Payments data.

Openpaymentsdata.cms.gov hit an all-time high for pageviews in direct response to an increase in social media attention. During the week of February 8, 2015, to February 14, 2015, the Open Payments Search Tool and Data Explorer Tool received approximately 2.5 million unique pageviews from site visitors.

Open Payments Website: Planned Enhancements

CMS continues to solicit stakeholder assistance to make enhancements to the public website. Using this feedback, CMS will provide more opportunities for all site visitors, from the advanced data user to the general public, to discover meaningful information in the Open Payments data published by CMS.

Open Payments Policy: Updates to the Final Rule

Since the Open Payments final rule was published in February 2013, implementing section 1128G of the Act, CMS received feedback from stakeholders regarding certain aspects of the reporting requirements. Responsive to this feedback, four revisions were published in the 2015 Medicare Physician Fee Schedule. These revisions were effective as of October 31, 2014. Data collection for the new requirements will begin on January 1, 2016, thus impacting reporting to CMS in 2017.

The following revisions were made:

- Deleted the definition of “covered device” because it was duplicative of the definition of “covered drug, device, biological or medical supply” already codified in the same section of the rule.
- Removed a Continuing Medical Education (CME) exclusion to ensure consistency in reporting.
- Required reporting of the marketed name for all covered drugs, devices, biologicals or medical supplies. Previously CMS provided applicable manufacturers the flexibility to report either marketed name, product category, or therapeutic area for devices and medical supplies.
- Required reporting by applicable manufacturers of distinct forms of payment: stocks, stock options, or any other ownership interests in order to collect more specified data regarding forms of payment.

The most significant of the revisions is the removal of the CME exclusion. The CME exclusion was redundant with the existing exclusion for indirect payments or transfers of value. With the removal of the CME exclusion, all payments or transfers of value will be subject to the same criteria to determine if a payment or transfer of value is reportable. This criteria includes:

- a direct payment and therefore reportable,
- an indirect payment and therefore reportable;
- an indirect payment subject to an exclusion, therefore not reportable; or
- a non-reportable event.

CMS will continue to revise and improve the rule to ensure greater consistency in reporting and in the data provided to the public.

Appendix A. Transparency Reports and Reporting of Physician Ownership or Investment Interests, Sec. 1128G. [42 U.S.C. 1320a-7h]

SEC. 1128G. [42 U.S.C. 1320a-7h]

(a) TRANSPARENCY REPORTS.—

(1) PAYMENTS OR OTHER TRANSFERS OF VALUE.—

(A) IN GENERAL.—On March 31, 2013, and on the 90th day of each calendar year beginning thereafter, any applicable manufacturer that provides a payment or other transfer of value to a covered recipient (or to an entity or individual at the request of or designated on behalf of a covered recipient), shall submit to the Secretary, in such electronic form as the Secretary shall require, the following information with respect to the preceding calendar year:

(i) The name of the covered recipient.

(ii) The business address of the covered recipient and, in the case of a covered recipient who is a physician, the specialty and National Provider Identifier of the covered recipient.

(iii) The amount of the payment or other transfer of value.

(iv) The dates on which the payment or other transfer of value was provided to the covered recipient.

(v) A description of the form of the payment or other transfer of value, indicated (as appropriate for all that apply) as—

(I) cash or a cash equivalent;

(II) in-kind items or services;

(III) stock, a stock option, or any other ownership interest, dividend, profit, or other return on investment; or

(IV) any other form of payment or other transfer of value (as defined by the Secretary).

(vi) A description of the nature of the payment or other transfer of value, indicated (as appropriate for all that apply) as—

(I) consulting fees;

(II) compensation for services other than consulting;

(III) honoraria;

(IV) gift;

(V) entertainment;

- (VI) food;
- (VII) travel (including the specified destinations);
- (VIII) education;
- (IX) research;
- (X) charitable contribution;
- (XI) royalty or license;
- (XII) current or prospective ownership or investment interest;
- (XIII) direct compensation for serving as faculty or as a speaker for a medical education program;
- (XIV) grant; or
- (XV) any other nature of the payment or other transfer of value (as defined by the Secretary).

(vii) If the payment or other transfer of value is related to marketing, education, or research specific to a covered drug, device, biological, or medical supply, the name of that covered drug, device, biological, or medical supply.

(viii) Any other categories of information regarding the payment or other transfer of value the Secretary determines appropriate.

(B) SPECIAL RULE FOR CERTAIN PAYMENTS OR OTHER TRANSFERS OF VALUE.—In the case where an applicable manufacturer provides a payment or other transfer of value to an entity or individual at the request of or designated on behalf of a covered recipient, the applicable manufacturer shall disclose that payment or other transfer of value under the name of the covered recipient.

(2) PHYSICIAN OWNERSHIP.—In addition to the requirement under paragraph (1)(A), on March 31, 2013, and on the 90th day of each calendar year beginning thereafter, any applicable manufacturer or applicable group purchasing organization shall submit to the Secretary, in such electronic form as the Secretary shall require, the following information regarding any ownership or investment interest (other than an ownership or investment interest in a publicly traded security and mutual fund, as described in section 1877(c)) held by a physician (or an immediate family member of such physician (as defined for purposes of section 1877(a))) in the applicable manufacturer or applicable group purchasing organization during the preceding year:

(A) The dollar amount invested by each physician holding such an ownership or investment interest.

(B) The value and terms of each such ownership or investment interest.

(C) Any payment or other transfer of value provided to a physician holding such an ownership or investment interest (or to an entity or individual at the request of or designated on behalf of a physician holding such an ownership or investment interest), including the information described in clauses (i) through (viii) of paragraph (1)(A),

except that in applying such clauses, ‘physician’ shall be substituted for ‘covered recipient’ each place it appears.

(D) Any other information regarding the ownership or investment interest the Secretary determines appropriate.

(b) PENALTIES FOR NONCOMPLIANCE.—

(1) FAILURE TO REPORT.—

(A) IN GENERAL.—Subject to subparagraph (B) except as provided in paragraph (2), any applicable manufacturer or applicable group purchasing organization that fails to submit information required under subsection (a) in a timely manner in accordance with rules or regulations promulgated to carry out such subsection, shall be subject to a civil money penalty of not less than \$1,000, but not more than \$10,000, for each payment or other transfer of value or ownership or investment interest not reported as required under such subsection. Such penalty shall be imposed and collected in the same manner as civil money penalties under subsection (a) of section 1128A are imposed and collected under that section.

(B) LIMITATION.—The total amount of civil money penalties imposed under subparagraph (A) with respect to each annual submission of information under subsection (a) by an applicable manufacturer or applicable group purchasing organization shall not exceed \$150,000.

(2) KNOWING FAILURE TO REPORT.—

(A) IN GENERAL.—Subject to subparagraph (B), any applicable manufacturer or applicable group purchasing organization that knowingly fails to submit information required under subsection (a) in a timely manner in accordance with rules or regulations promulgated to carry out such subsection, shall be subject to a civil money penalty of not less than \$10,000, but not more than \$100,000, for each payment or other transfer of value or ownership or investment interest not reported as required under such subsection. Such penalty shall be imposed and collected in the same manner as civil money penalties under subsection (a) of section 1128A are imposed and collected under that section.

(B) LIMITATION.—The total amount of civil money penalties imposed under subparagraph (A) with respect to each annual submission of information under subsection (a) by an applicable manufacturer or applicable group purchasing organization shall not exceed \$1,000,000.

(3) USE OF FUNDS.—Funds collected by the Secretary as a result of the imposition of a civil money penalty under this subsection shall be used to carry out this section.

(c) PROCEDURES FOR SUBMISSION OF INFORMATION AND PUBLIC AVAILABILITY.—

(1) IN GENERAL.—

(A) ESTABLISHMENT.—Not later than October 1, 2011, the Secretary shall establish procedures—

(i) for applicable manufacturers and applicable group purchasing organizations to submit information to the Secretary under subsection (a); and

(ii) for the Secretary to make such information submitted available to the public.

(B) DEFINITION OF TERMS.—The procedures established under subparagraph (A) shall provide for the definition of terms (other than those terms defined in subsection (e)), as appropriate, for purposes of this section.

(C) PUBLIC AVAILABILITY.—Except as provided in subparagraph (E), the procedures established under subparagraph (A)(ii) shall ensure that, not later than September 30, 2013, and on June 30 of each calendar year beginning thereafter, the information submitted under subsection (a) with respect to the preceding calendar year is made available through an Internet website that—

(i) is searchable and is in a format that is clear and understandable;

(ii) contains information that is presented by the name of the applicable manufacturer or applicable group purchasing organization, the name of the covered recipient, the business address of the covered recipient, the specialty of the covered recipient, the value of the payment or other transfer of value, the date on which the payment or other transfer of value was provided to the covered recipient, the form of the payment or other transfer of value, indicated (as appropriate) under subsection (a)(1)(A)(v), the nature of the payment or other transfer of value, indicated (as appropriate) under subsection (a)(1)(A)(vi), and the name of the covered drug, device, biological, or medical supply, as applicable;

(iii) contains information that is able to be easily aggregated and downloaded;

(iv) contains a description of any enforcement actions taken to carry out this section, including any penalties imposed under subsection (b), during the preceding year;

(v) contains background information on industry physician relationships;

(vi) in the case of information submitted with respect to a payment or other transfer of value described in subparagraph (E)(i), lists such information separately from the other information submitted under subsection (a) and designates such separately listed information as funding for clinical research;

(vii) contains any other information the Secretary determines would be helpful to the average consumer;

(viii) does not contain the National Provider Identifier of the covered recipient, and

(ix) subject to subparagraph (D), provides the applicable manufacturer, applicable group purchasing organization, or covered recipient an opportunity to review and submit corrections to the information submitted with respect to the applicable manufacturer, applicable group purchasing organization, or covered recipient, respectively, for a period of not less than 45 days prior to such information being made available to the public.

(D) CLARIFICATION OF TIME PERIOD FOR REVIEW AND CORRECTIONS.—In no case may the 45-day period for review and submission of corrections to information under subparagraph (C)(ix) prevent such information from being made available to the public in accordance with the dates described in the matter preceding clause (i) in subparagraph (C).

(E) DELAYED PUBLICATION FOR PAYMENTS MADE PURSUANT TO PRODUCT RESEARCH OR DEVELOPMENT AGREEMENTS AND CLINICAL INVESTIGATIONS.—

(i) IN GENERAL.—In the case of information submitted under subsection (a) with respect to a payment or other transfer of value made to a covered recipient by an applicable manufacturer pursuant to a product research or development agreement for services furnished in connection with research on a potential new medical technology or a new application of an existing medical technology or the development of a new drug, device, biological, or medical supply, or by an applicable manufacturer in connection with a clinical investigation regarding a new drug, device, biological, or medical supply, the procedures established under subparagraph (A)(ii) shall provide that such information is made available to the public on the first date described in the matter preceding clause (i) in subparagraph (C) after the earlier of the following:

(I) The date of the approval or clearance of the covered drug, device, biological, or medical supply by the Food and Drug Administration.

(II) Four calendar years after the date such payment or other transfer of value was made.

(ii) CONFIDENTIALITY OF INFORMATION PRIOR TO PUBLICATION.—Information described in clause (i) shall be considered confidential and shall not be subject to disclosure under section 552 of title 5, United States Code, or any other similar Federal, State, or local law, until on or after the date on which the information is made available to the public under such clause.

(2) CONSULTATION.—In establishing the procedures under paragraph (1), the Secretary shall consult with the Inspector General of the Department of Health and Human Services, affected industry, consumers, consumer advocates, and other interested parties in order to ensure that the information made available to the public under such paragraph is presented in the appropriate overall context.

(d) ANNUAL REPORTS AND RELATION TO STATE LAWS.—

(1) ANNUAL REPORT TO CONGRESS.—Not later than April 1 of each year beginning with 2013, the Secretary shall submit to Congress a report that includes the following:

(A) The information submitted under subsection (a) during the preceding year, aggregated for each applicable manufacturer and applicable group purchasing organization that submitted such information during such year (except, in the case of information submitted with respect to a payment or other transfer of value described in subsection (c)(1)(E)(i), such information shall be included in the first report submitted to

Congress after the date on which such information is made available to the public under such subsection).

(B) A description of any enforcement actions taken to carry out this section, including any penalties imposed under subsection (b), during the preceding year.

(2) ANNUAL REPORTS TO STATES.—Not later than September 30, 2013, and on June 30 of each calendar year thereafter, the Secretary shall submit to States a report that includes a summary of the information submitted under subsection (a) during the preceding year with respect to covered recipients in the State (except, in the case of information submitted with respect to a payment or other transfer of value described in subsection (c)(1)(E)(i), such information shall be included in the first report submitted to States after the date on which such information is made available to the public under such subsection).

(3) RELATION TO STATE LAWS.—

(A) IN GENERAL.—In the case of a payment or other transfer of value provided by an applicable manufacturer that is received by a covered recipient (as defined in subsection (e)) on or after January 1, 2012, subject to subparagraph (B), the provisions of this section shall preempt any statute or regulation of a State or of a political subdivision of a State that requires an applicable manufacturer (as so defined) to disclose or report, in any format, the type of information (as described in subsection (a)) regarding such payment or other transfer of value.

(B) NO PREEMPTION OF ADDITIONAL REQUIREMENTS.—Subparagraph (A) shall not preempt any statute or regulation of a State or of a political subdivision of a State that requires the disclosure or reporting of information—

(i) not of the type required to be disclosed or reported under this section;

(ii) described in subsection (e)(10)(B), except in the case of information described in clause (i) of such subsection;

(iii) by any person or entity other than an applicable manufacturer (as so defined) or a covered recipient (as defined in subsection (e)); or

(iv) to a Federal, State, or local governmental agency for public health surveillance, investigation, or other public health purposes or health oversight purposes.

(C) Nothing in subparagraph (A) shall be construed to limit the discovery or admissibility of information described in such subparagraph in a criminal, civil, or administrative proceeding.

(4) CONSULTATION.—The Secretary shall consult with the Inspector General of the Department of Health and Human Services on the implementation of this section.

(e) DEFINITIONS.—In this section:

(1) APPLICABLE GROUP PURCHASING ORGANIZATION.—The term “applicable group purchasing organization” means a group purchasing organization (as defined by the Secretary) that purchases, arranges for, or negotiates the purchase of a covered drug,

device, biological, or medical supply which is operating in the United States, or in a territory, possession, or commonwealth of the United States.

(2) APPLICABLE MANUFACTURER.—The term “applicable manufacturer” means a manufacturer of a covered drug, device, biological, or medical supply which is operating in the United States, or in a territory, possession, or commonwealth of the United States.

(3) CLINICAL INVESTIGATION.—The term “clinical investigation” means any experiment involving 1 or more human subjects, or materials derived from human subjects, in which a drug or device is administered, dispensed, or used.

(4) COVERED DEVICE.—The term “covered device” means any device for which payment is available under title XVIII or a State plan under title XIX or XXI (or a waiver of such a plan).

(5) COVERED DRUG, DEVICE, BIOLOGICAL, OR MEDICAL SUPPLY.—The term “covered drug, device, biological, or medical supply” means any drug, biological product, device, or medical supply for which payment is available under title XVIII or a State plan under title XIX or XXI (or a waiver of such a plan).

(6) COVERED RECIPIENT.—

(A) IN GENERAL.—Except as provided in subparagraph (B), the term “covered recipient” means the following:

(i) A physician.

(ii) A teaching hospital.

(B) EXCLUSION.—Such term does not include a physician who is an employee of the applicable manufacturer that is required to submit information under subsection (a).

(7) EMPLOYEE.—The term “employee” has the meaning given such term in section 1877(h)(2).

(8) KNOWINGLY.—The term “knowingly” has the meaning given such term in section 3729(b) of title 31, United States Code.

(9) MANUFACTURER OF A COVERED DRUG, DEVICE, BIOLOGICAL, OR MEDICAL SUPPLY.—The term “manufacturer of a covered drug, device, biological, or medical supply” means any entity which is engaged in the production, preparation, propagation, compounding, or conversion of a covered drug, device, biological, or medical supply (or any entity under common ownership with such entity which provides assistance or support to such entity with respect to the production, preparation, propagation, compounding, conversion, marketing, promotion, sale, or distribution of a covered drug, device, biological, or medical supply).

(10) PAYMENT OR OTHER TRANSFER OF VALUE.—

(A) IN GENERAL.—The term “payment or other transfer of value” means a transfer of anything of value. Such term does not include a transfer of anything of value that is

made indirectly to a covered recipient through a third party in connection with an activity or service in the case where the applicable manufacturer is unaware of the identity of the covered recipient.

(B) EXCLUSIONS.—An applicable manufacturer shall not be required to submit information under subsection (a) with respect to the following:

(i) A transfer of anything the value of which is less than \$10, unless the aggregate amount transferred to, requested by, or designated on behalf of the covered recipient by the applicable manufacturer during the calendar year exceeds \$100. For calendar years after 2012, the dollar amounts specified in the preceding sentence shall be increased by the same percentage as the percentage increase in the consumer price index for all urban consumers (all items; U.S. city average) for the 12-month period ending with June of the previous year.

(ii) Product samples that are not intended to be sold and are intended for patient use.

(iii) Educational materials that directly benefit patients or are intended for patient use.

(iv) The loan of a covered device for a short term trial period, not to exceed 90 days, to permit evaluation of the covered device by the covered recipient.

(v) Items or services provided under a contractual warranty, including the replacement of a covered device, where the terms of the warranty are set forth in the purchase or lease agreement for the covered device.

(vi) A transfer of anything of value to a covered recipient when the covered recipient is a patient and not acting in the professional capacity of a covered recipient.

(vii) Discounts (including rebates).

(viii) In-kind items used for the provision of charity care.

(ix) A dividend or other profit distribution from, or ownership or investment interest in, a publicly traded security and mutual fund (as described in section 1877(c)).

(x) In the case of an applicable manufacturer who offers a self-insured plan, payments for the provision of health care to employees under the plan.

(xi) In the case of a covered recipient who is a licensed non-medical professional, a transfer of anything of value to the covered recipient if the transfer is payment solely for the non-medical professional services of such licensed non-medical professional.

(xii) In the case of a covered recipient who is a physician, a transfer of anything of value to the covered recipient if the transfer is payment solely for the services of the covered recipient with respect to a civil or criminal action or an administrative proceeding.

(11) PHYSICIAN.—The term “physician” has the meaning given that term in section 1861(r).

Appendix B. Aggregate Data by Applicable Manufacturer/Group Purchasing Organization

The aggregated data included in this report (Appendix B) contains data from Program Years 2013 and 2014 currently on the public display site. This data set has been verified to have congruent identifying information about the covered recipient and has undergone review and dispute for 45-days as per the final rule. As a result, CMS has confidence in the accuracy of the data provided in this Report to Congress. Any data that was found to have inconsistencies regarding the covered recipient of the payment or other transfer of value were rejected at the time of data submission and returned to the industry for correction and resubmission.

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
180 Medical, Inc.	\$22,758	\$0	\$0	\$0	1,364	0	0	0	1,060	0
3D Systems	\$83,942	\$0	\$0	\$0	25	0	0	0	23	2
3M Company	\$1,256,137	\$103,195	\$0	\$0	7,669	22	0	0	5,233	7
Aastrom Biosciences, Inc	\$18,225	\$0	\$0	\$0	167	0	0	0	124	0
ABB Con-Cise Optical Group LLC	\$113,023	\$0	\$0	\$0	4,408	0	0	0	2,412	0
Abbott Laboratories	\$11,892,686	\$12,272,052	\$0	\$0	39,795	2,102	0	0	14,302	160
AbbVie, Inc.	\$40,563,182	\$47,389,681	\$0	\$0	289,457	5,485	0	0	63,369	170
ABEON MEDICAL CORPORATION	\$33,282	\$0	\$440,000	\$261,610	6	0	1	1	3	0
ABIOMED	\$1,412,387	\$137,048	\$0	\$0	7,444	49	0	0	3,120	3
ABL Medical, LLC	\$67,248	\$0	\$0	\$0	55	0	0	0	28	0
Ablative Solutions, Inc.	\$155	\$0	\$6,007,388	\$7,386,688	3	0	47	47	45	0
Abraxis BioScience, LLC	\$14,165	\$1,034,156	\$0	\$0	53	22	0	0	35	8
Accel SPINE, LLC	\$22,291	\$0	\$0	\$0	43	0	0	0	17	0
ACCELLENT INC.	\$129,892	\$0	\$0	\$0	23	0	0	0	2	0
Access Closure, Inc	\$35,331	\$0	\$0	\$0	931	0	0	0	634	0
Acclarent, Inc	\$1,137,494	\$1,118,223	\$0	\$0	11,871	142	0	0	3,989	10
ACCURAY INCORPORATED	\$252,499	\$336,817	\$0	\$0	495	36	0	0	243	16
ACE Surgical Supply Co., Inc.	\$45,666	\$0	\$0	\$0	167	0	0	0	91	0
ACell, Inc.	\$8,383,233	\$250,208	\$0	\$0	15,770	30	0	0	3,221	178
Acist Medical Systems, Inc.	\$14,509	\$0	\$0	\$0	394	0	0	0	244	0
Acorda Therapeutics, Inc	\$2,891,180	\$65,312	\$0	\$0	4,490	166	0	0	675	2
Actavis Pharma Inc	\$2,635,298	\$951,862	\$0	\$0	61,533	89	0	0	21,136	16
Actelion Clinical Research, Inc.	\$194,433	\$312,198	\$0	\$0	140	192	0	0	70	14
Actelion Pharmaceuticals US, Inc.	\$3,817,250	\$2,429,849	\$0	\$0	25,030	389	0	0	8,486	55
Actelion Pharmaceuticals, Ltd	\$673,902	\$1,153,207	\$0	\$0	603	153	0	0	114	20
Acteon Inc	\$22,512	\$0	\$0	\$0	168	0	0	0	158	0
Active Medical, LLC	\$14,212	\$0	\$0	\$0	59	0	0	0	39	0
Actuated Medical, Inc.	\$0	\$0	\$0	\$124,304	0	0	6	6	6	0
ACUMED LLC	\$4,186,160	\$240,505	\$0	\$0	1,374	8	0	0	614	26

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Acute Innovations, LLC	\$72,222	\$0	\$0	\$0	151	0	0	0	66	1
A-dec, Inc.	\$1,925,181	\$0	\$0	\$0	9,351	0	0	0	3,119	2
Admedus Corporation	\$31,821	\$0	\$0	\$0	10	0	0	0	3	0
Advanced Bionics, LLC	\$614,972	\$270,228	\$0	\$0	323	11	0	0	133	28
Advanced Biosolutions LLC	\$0	\$0	\$80,000	\$226,341	0	0	1	1	1	0
Advanced Circulatory Systems Inc.	\$35,731	\$22,061	\$2,633,861	\$5,272,202	36	3	16	16	33	6
Advanced Critical Devices, Inc.	\$407	\$0	\$0	\$0	5	0	0	0	5	0
Advanced Medical Partners Inc	\$57,735	\$0	\$0	\$0	55	0	0	0	50	0
Advanced Orthopaedic Solutions, Inc.	\$259,793	\$34,125	\$0	\$0	80	16	0	0	37	0
Advanced Respiratory, Inc	\$163,132	\$0	\$0	\$0	2,571	0	0	0	1,508	74
Advanced Vertebral Solutions LLC	\$90	\$0	\$2	\$645	1	0	2	2	2	0
Aegerion Pharmaceuticals, Inc.	\$880,869	\$839,457	\$0	\$0	7,190	12	0	0	4,078	15
Aerocrine, Inc	\$396,424	\$71,340	\$0	\$0	2,332	3	0	0	1,696	0
Aero-Med LTD	\$1,522	\$0	\$0	\$0	19	0	0	0	18	1
Aesculap AG	\$1,442,498	\$0	\$0	\$0	46	0	0	0	16	0
Aesculap Akademie GmbH	\$5,997	\$0	\$0	\$0	36	0	0	0	10	0
Aesculap Biologics, LLC	\$36,690	\$0	\$0	\$0	122	0	0	0	43	0
Aesculap Implant Systems, LLC	\$3,146,042	\$20,000	\$0	\$0	1,369	2	0	0	335	6
Aesculap, Inc.	\$379,593	\$195,677	\$0	\$0	732	10	0	0	406	32
Afaxys, Inc.	\$8,848	\$0	\$0	\$0	24	0	0	0	11	0
Affordable Pharmaceuticals, LLC	\$316,708	\$0	\$0	\$0	8	0	0	0	2	0
Agfa HealthCare Corporation	\$1,510,168	\$0	\$0	\$0	184	0	0	0	47	36
Akorn Inc.	\$10,308	\$12,413	\$0	\$0	135	1	0	0	104	0
AKRIMAX PHARMACEUTICALS, LLC	\$71,494	\$0	\$0	\$0	2,541	0	0	0	1,339	0
Alcon Grieshaber AG	\$320	\$0	\$0	\$0	3	0	0	0	1	0
Alcon Laboratories Inc	\$16,567,173	\$0	\$0	\$0	124,472	0	0	0	31,743	6
Alcon Pharmaceuticals Ltd	\$911,603	\$0	\$0	\$0	10	0	0	0	3	0
Alcon Puerto Rico Inc	\$23,009	\$0	\$0	\$0	113	0	0	0	71	0
Alcon Research Ltd	\$3,292,771	\$3,438,723	\$0	\$0	2,366	2,190	0	0	1,197	32
ALDEN OPTICAL LABORATORIES, INC	\$9,319	\$0	\$0	\$0	7	0	0	0	5	0
ALERE HOME MONITORING, INC.	\$76,500	\$0	\$0	\$0	12	0	0	0	2	0
Alere Inc.	\$48,864	\$0	\$0	\$0	5	0	0	0	1	0

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Alere North America, LLC	\$5,464	\$0	\$0	\$0	36	0	0	0	36	0
Alere San Diego, Inc.	\$200,399	\$216,393	\$0	\$0	41	24	0	0	11	4
ALERE SCARBOROUGH, INC.	\$1,945	\$650,836	\$0	\$0	2	39	0	0	0	7
Alexion Pharmaceuticals, Inc.	\$3,912,825	\$3,447,667	\$0	\$0	16,296	730	0	0	5,934	51
Alexza Pharmaceuticals, Inc.	\$14,255	\$29,225	\$0	\$40,735	7	2	2	2	4	1
Alkermes, Inc.	\$918,380	\$17,035,856	\$0	\$0	4,497	10,113	0	0	2,114	23
Allerderm Laboratories	\$10,882	\$90,923	\$0	\$0	30	7	0	0	14	0
Allergan Inc.	\$46,585,577	\$47,830,786	\$416,629	\$601,751	234,346	12,491	2	2	49,079	60
Alliance Partners LLC	\$197,644	\$0	\$0	\$0	40	0	0	0	4	0
Alliqua BioMedical, Inc.	\$99,598	\$0	\$118,300	\$118,300	753	0	1	1	362	0
AlloSource	\$250,350	\$0	\$0	\$0	32	0	0	0	21	0
Allotech, LLC	\$9,100	\$0	\$2	\$192,330	1	0	2	2	2	0
Almatica Pharma Inc.	\$183,637	\$0	\$0	\$0	379	0	0	0	113	0
Alpha Orthopedic Systems	\$26,696	\$0	\$0	\$0	135	0	0	0	82	0
Alpine Implant Alliance, LLC	\$227,000	\$0	\$302,309	\$283,325	9	0	17	17	16	0
Altatec GmbH	\$469,116	\$0	\$0	\$0	1,857	0	0	0	810	0
AMAG Pharmaceuticals, Inc.	\$129,751	\$729,616	\$0	\$0	2,360	33	0	0	1,432	4
Amarin Pharma Inc.	\$2,220,342	\$3,351,761	\$0	\$0	22,890	374	0	0	9,243	15
AMD GROUP LLC	\$31,467	\$0	\$0	\$0	19	0	0	0	11	0
AMD Lasers LLC	\$45,932	\$0	\$0	\$0	87	0	0	0	42	0
Amedica Corporation	\$1,221,515	\$0	\$4,588,307	\$178,291	375	0	42	42	144	0
Amendia, Inc.	\$4,441,503	\$0	\$1,925,000	\$1,925,000	1,236	0	12	12	159	0
American Medical Hospital Supply Company, Inc.	\$14,421	\$0	\$0	\$0	530	0	0	0	51	0
American Medical Systems Inc.	\$7,738,070	\$381,203	\$0	\$0	20,797	314	0	0	5,181	7
AMERICAN MEDICAL TECHNOLOGY INC	\$2,765	\$0	\$19,500	\$686,677	17	0	1	1	2	1
American Orthodontics Corporation	\$215,174	\$0	\$0	\$0	185	0	0	0	176	0
American Surgical Company, LLC	\$2,500	\$0	\$0	\$0	1	0	0	0	0	1
AmerisourceBergen Drug Corporation	\$43,646	\$0	\$0	\$0	8	0	0	0	1	5
Amgen Inc.	\$18,255,602	\$65,161,410	\$0	\$0	144,264	4,306	0	0	42,203	188
Amniox Medical	\$581,074	\$9,174	\$0	\$0	971	1	0	0	519	0
Amphastar Pharmaceuticals, Inc.	\$0	\$1,090,834	\$3,668,022	\$14,016,888	0	20	9	9	9	0
Anaeropahrma Science, Inc.	\$0	\$336,063	\$0	\$0	0	1	0	0	0	0

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Analogic Corporation	\$34,364	\$0	\$0	\$0	92	0	0	0	77	0
Anesthetic Gas Reclamation, LLC	\$0	\$0	\$565,001	\$540,000	0	0	3	3	3	0
AngioDynamics, Inc.	\$3,143,946	\$136,177	\$0	\$0	2,711	6	0	0	2,355	52
AngioScore, Inc.	\$277,057	\$0	\$0	\$0	2,349	0	0	0	1,024	0
Anika Therapeutics, Inc.	\$32,653	\$0	\$0	\$0	11	0	0	0	11	0
Animas Corporation	\$189,212	\$2,305	\$0	\$0	4,724	2	0	0	1,584	30
Ansell Healthcare Products LLC	\$37,511	\$381,426	\$0	\$0	2	1	0	0	2	0
Antares Pharma, Inc.	\$53,872	\$877,552	\$0	\$0	758	111	0	0	530	0
APOLLO ENDOSURGERY INC	\$621,709	\$309,116	\$0	\$399,733	4,484	27	7	7	2,314	12
Apollo Surgical Group, LLC	\$70,752	\$0	\$0	\$0	375	0	0	0	185	0
APO-PHARMA INC.	\$13,774	\$252,487	\$0	\$0	29	33	0	0	9	3
APO-PHARMA USA, INC.	\$41,688	\$0	\$0	\$0	127	0	0	0	48	0
Applied Medical Australia, Pty, Ltd.	\$1,820	\$0	\$0	\$0	2	0	0	0	2	0
Applied Medical Corporation	\$12,064	\$0	\$1,004,639	\$9,252,230	1	0	23	23	21	0
Applied Medical Europe BV	\$8,563	\$0	\$0	\$0	5	0	0	0	4	0
Applied Medical Resources Corporation	\$1,858,910	\$9,466	\$0	\$0	402	1	0	0	154	29
APPLIED MEDICAL TECHNOLOGY INC	\$357,377	\$0	\$193,955	\$511,594	71	0	1	1	22	35
Aptalis Pharma US, Inc	\$219,616	\$117,314	\$0	\$0	2,461	27	0	0	1,890	7
Aptis Medical, LLC	\$58,529	\$0	\$500,000	\$352,044	37	0	1	1	8	0
Aqua Pharmaceuticals	\$1,520,750	\$91,197	\$0	\$0	17,707	13	0	0	2,225	0
Aquesys, Inc.	\$0	\$0	\$13	\$4,875	0	0	2	2	2	0
Arbor Pharmaceuticals, Inc.	\$1,737,758	\$2,444,832	\$0	\$0	27,015	384	0	0	13,647	0
ARGON MEDICAL DEVICES, INC.	\$52,993	\$0	\$1,699,864	\$2,522,555	1,100	0	2	2	452	1
ARIAD Pharmaceuticals, Inc.	\$860,773	\$3,070,337	\$0	\$0	2,114	586	0	0	871	20
Aribex Inc.	\$9,795	\$0	\$0	\$0	2	0	0	0	2	0
Arizona Cryosurgical Partnership LP	\$156,499	\$0	\$394,557	\$315,426	154	0	15	15	15	0
ArjoHuntleigh, Inc.	\$19,537	\$0	\$0	\$0	138	0	0	0	85	0
ARKRAY USA, Inc.	\$41,617	\$22,085	\$0	\$0	4	2	0	0	2	2
Arrow International, Inc.	\$623,275	\$418,637	\$0	\$0	993	2	0	0	686	21
Arrow Interventional, Inc.	\$1,768	\$0	\$0	\$0	11	0	0	0	7	0
Art Optical Contact Lens Inc.	\$35,663	\$0	\$0	\$0	89	0	0	0	53	0
Arthrex, Inc.	\$40,009,729	\$966,298	\$0	\$0	10,202	102	0	0	2,141	12

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Arthrosurface Incorporated	\$646,673	\$58,388	\$3,427,798	\$7,952,205	1,569	8	30	30	980	2
ASAHI INTECC CO., LTD.	\$12,280	\$0	\$0	\$0	20	0	0	0	5	0
ASAHI INTECC USA, INC.	\$130,597	\$0	\$0	\$0	151	0	0	0	45	2
AsahiKasei Medical Co.,Ltd.	\$1,812	\$0	\$0	\$0	5	0	0	0	2	0
ASCEND Therapeutics US, LLC	\$125,629	\$0	\$0	\$0	4,713	0	0	0	1,518	0
Ascension Orthopedics, Inc.	\$506,486	\$0	\$0	\$0	413	0	0	0	87	1
ASD Specialty Healthcare, Inc.	\$4,781	\$0	\$0	\$0	77	0	0	0	45	0
Aseptico, Inc.	\$9,704	\$0	\$0	\$0	4	0	0	0	3	0
ASPEN SURGICAL PRODUCTS, INC.	\$678	\$0	\$0	\$0	4	0	0	0	2	2
Astellas Pharma Europe BV	\$29,553	\$5,653,451	\$0	\$0	8	233	0	0	8	7
Astellas Pharma Global Development	\$395,214	\$4,270,670	\$0	\$0	144	195	0	0	49	34
Astellas Pharma Inc	\$204,076	\$1,235,301	\$0	\$0	133	108	0	0	41	16
Astellas Pharma US Inc	\$9,818,115	\$0	\$0	\$0	173,449	0	0	0	48,699	114
Astellas Scientific and Medical Affairs	\$551,857	\$6,582,548	\$0	\$0	517	216	0	0	307	31
Astellas US Technologies	\$0	\$753,724	\$0	\$0	0	35	0	0	0	18
AstraZeneca AB	\$6,842	\$0	\$0	\$0	23	0	0	0	8	0
AstraZeneca Pharmaceuticals LP	\$72,535,014	\$85,664,028	\$0	\$0	761,766	2,479	0	0	115,131	283
AstraZeneca UK Limited	\$124,240	\$530,701	\$0	\$0	60	60	0	0	24	7
Asuragen, Inc.	\$1,196	\$0	\$0	\$0	3	0	0	0	1	0
Atlantic Coast Cryotherapy LP	\$255,114	\$0	\$0	\$0	378	0	0	0	33	0
Atlas Spine, Inc.	\$1,037	\$0	\$2,122,119	\$3,252,388	6	0	23	23	29	0
Atos Medical Inc	\$6,099	\$0	\$0	\$0	50	0	0	0	46	1
Atossa Genetics Inc	\$1,929	\$41,600	\$0	\$0	15	2	0	0	15	0
AtriCure, Inc.	\$3,582,835	\$850,150	\$0	\$0	5,104	189	0	0	1,549	60
Atritech, Inc.	\$0	\$712,997	\$0	\$0	0	236	0	0	0	11
Atrium Medical Corporation	\$48,213	\$120,425	\$0	\$0	50	44	0	0	29	5
Auxilium Pharmaceuticals, Inc.	\$2,941,812	\$4,595,414	\$0	\$0	44,362	493	0	0	14,456	9
Avanir Pharmaceuticals, Inc.	\$3,358,588	\$795,375	\$0	\$0	22,987	252	0	0	6,783	1
AVID RADIOPHARMACEUTICALS, INC.	\$316,833	\$5,623,686	\$0	\$0	70	177	0	0	79	17
Avinger Inc.	\$231,752	\$101,613	\$33,783,285	\$33,783,285	1,768	46	29	29	564	4
AXOGEN	\$627,630	\$216,302	\$458,886	\$989,002	1,682	89	4	4	676	5
B. Braun Aesculap Japan Co., Ltd.	\$1,446	\$0	\$0	\$0	6	0	0	0	1	0

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
B. Braun Avitum AG	\$13,500	\$0	\$0	\$0	5	0	0	0	2	0
B. Braun Interventional Systems Inc.	\$304,000	\$460,043	\$0	\$0	561	89	0	0	160	19
B. Braun Medical (Shanghai) International Trading Co., Ltd.	\$20,093	\$0	\$0	\$0	6	0	0	0	2	0
B. Braun Medical Inc.	\$519,097	\$345,403	\$0	\$0	471	19	0	0	244	52
B. Braun Medical OY	\$31,067	\$0	\$0	\$0	10	0	0	0	2	0
B. Braun Medical UK Ltd.	\$8,626	\$0	\$0	\$0	28	0	0	0	4	0
B. Braun Melsungen AG	\$448,101	\$0	\$0	\$0	4	0	0	0	3	0
B. Braun Surgical SA	\$4,931	\$0	\$0	\$0	3	0	0	0	2	0
b2d Marketing	\$1,635	\$0	\$0	\$0	41	0	0	0	36	0
Bacterin International Inc	\$368,866	\$96,494	\$509,172	\$155,763	370	1	27	27	255	0
Banyan International Corporation	\$105	\$0	\$0	\$0	1	0	0	0	1	0
Bard Access Systems, Inc.	\$186,644	\$67,468	\$0	\$0	405	8	0	0	251	32
Bard International, Inc.	\$91,185	\$0	\$0	\$0	92	0	0	0	36	0
Bard Peripheral Vascular, Inc.	\$4,034,425	\$533,366	\$0	\$0	9,522	293	0	0	3,507	73
Bausch and Lomb Inc.	\$11,713,736	\$4,723,490	\$0	\$0	23,956	647	0	0	8,895	6
Baxter Healthcare	\$6,989,791	\$6,224,416	\$0	\$0	28,716	1,151	0	0	13,670	52
Bayer HealthCare LLC	\$1,388,469	\$703,575	\$0	\$0	7,042	148	0	0	3,479	12
Bayer HealthCare Pharmaceuticals Inc.	\$9,561,931	\$10,470,863	\$0	\$0	53,623	1,242	0	0	23,712	54
Baylis Medical Company Inc	\$25,420	\$0	\$0	\$0	11	0	0	0	5	0
BD Rx Inc.	\$471	\$0	\$0	\$0	42	0	0	0	35	0
Beacon Endoscopic Corporation	\$4,127	\$0	\$158,326	\$318,802	5	0	4	4	9	0
Beaver-Visitec International, Inc.	\$124,461	\$0	\$181,592	\$181,592	88	0	1	1	73	0
Beckman Coulter, Inc.	\$102,271	\$100,000	\$0	\$0	219	1	0	0	21	58
Becton, Dickinson and Company	\$2,708,329	\$1,926,863	\$844,770	\$1,267,923	3,931	61	1	1	2,204	76
Belle Bonfils Memorial Blood Center	\$2,291	\$0	\$0	\$0	5	0	0	0	4	0
Belmont Instrument Corporation	\$12,000	\$0	\$0	\$0	1	0	0	0	1	0
Benco Dental Supply Co.	\$2,554,852	\$0	\$0	\$0	18,094	0	0	0	2,624	0
Benvenue Medical Inc	\$768,275	\$0	\$254,689	\$254,689	761	0	8	8	263	0
BG Medicine, Inc.	\$164,893	\$0	\$0	\$0	267	0	0	0	150	1
Bio Products Laboratory, Inc.	\$385,780	\$581,007	\$0	\$0	115	63	0	0	83	2
Biocompatibles UK Ltd	\$87,339	\$900,621	\$0	\$0	24	22	0	0	8	4
Biocompatibles, Inc.	\$539,365	\$0	\$0	\$0	1,560	0	0	0	681	3

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Biocomposites Inc	\$938,882	\$0	\$0	\$0	211	0	0	0	145	0
BioDelivery Sciences International, Inc.	\$460,271	\$0	\$0	\$0	2,062	0	0	0	1,016	0
BioFire Diagnostics, LLC	\$361,732	\$328,329	\$0	\$0	316	24	0	0	29	98
Biogen Idec Inc.	\$21,741,398	\$17,622,314	\$0	\$0	88,919	6,463	0	0	7,157	77
BioHorizons Implant Systems Inc.	\$4,552,615	\$0	\$2,341,845	\$3,548,250	13,524	0	32	32	5,980	3
BIOLASE, INC.	\$1,050,772	\$973,320	\$0	\$0	3,435	41	0	0	1,600	1
BioMarin Pharmaceutical Inc.	\$372,037	\$3,591,046	\$0	\$0	901	397	0	0	235	32
BioMedical Enterprises Inc	\$78,961	\$0	\$498,650	\$645,450	209	0	13	13	190	0
bioMerieux	\$264,098	\$856,059	\$0	\$0	194	30	0	0	120	29
Biomet 3i Australia Pty Ltd	\$1,984	\$0	\$0	\$0	3	0	0	0	1	0
Biomet 3i Canada Inc	\$888	\$0	\$0	\$0	15	0	0	0	7	0
Biomet 3i Deutschland GMBH	\$451	\$0	\$0	\$0	3	0	0	0	2	0
Biomet 3i Japan, Inc	\$504	\$0	\$0	\$0	10	0	0	0	2	0
Biomet 3i Mexico SA de CV	\$817	\$0	\$0	\$0	20	0	0	0	2	0
Biomet 3i UK Ltd	\$362	\$0	\$0	\$0	4	0	0	0	2	0
Blomet 3i, LLC	\$6,409,136	\$105,726	\$0	\$0	17,070	8	0	0	7,576	5
Biomet Biologics, LLC	\$351,526	\$822,597	\$0	\$0	345	144	0	0	251	15
Biomet Europe, Ltd	\$73,411	\$0	\$0	\$0	274	0	0	0	33	0
BIOMET INTERNATIONAL, LTD	\$51	\$0	\$0	\$0	2	0	0	0	1	0
Biomet Microfixation, LLC	\$2,114,904	\$495,680	\$0	\$0	2,376	53	0	0	1,076	17
Biomet Orthopedics, LLC	\$18,676,248	\$1,679,970	\$0	\$0	14,058	546	0	0	3,236	88
Biomet Spine, LLC	\$5,407,575	\$224,398	\$0	\$0	4,292	110	0	0	852	40
Biomet Sports Medicine, LLC	\$3,025,582	\$5,829	\$0	\$0	1,383	2	0	0	561	2
Biomet Trauma, LLC	\$3,586,509	\$0	\$0	\$0	2,610	0	0	0	936	3
Biom'Up SA	\$102,180	\$0	\$0	\$0	49	0	0	0	20	0
BIONESS INC	\$4,016	\$26,590	\$1,302	\$1,302	2	9	2	2	4	1
BioPro, Inc.	\$93,777	\$0	\$0	\$0	256	0	0	0	144	0
Bio-Rad Laboratories, Inc.	\$1,844,691	\$38,690	\$0	\$0	2,882	22	0	0	52	160
Biosense Webster, Inc.	\$2,998,328	\$3,185,839	\$0	\$0	10,382	431	0	0	2,057	94
Biotest Pharmaceuticals Corporation	\$1,621	\$0	\$0	\$0	39	0	0	0	35	0
BIOTRONIK INC.	\$3,765,412	\$6,091,651	\$0	\$0	26,524	27,537	0	0	4,856	82
Bioventus LLC	\$907,081	\$0	\$0	\$0	9,615	0	0	0	5,181	7

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Blockade Medical, LLC	\$24,129	\$63,492	\$1,214,732	\$1,214,732	208	5	24	24	90	2
Blood Bank of San Bernardino and Riverside Counties	\$60,755	\$0	\$0	\$0	3	0	0	0	2	0
Blood Systems, Inc.	\$563,744	\$0	\$0	\$0	28	0	0	0	16	0
Blue Belt Technologies, Inc.	\$344,355	\$0	\$290,598	\$1,955,442	318	0	10	10	144	0
Blue Sky Bio, LLC	\$0	\$0	\$50,000	\$50,000	0	0	2	2	2	0
Boehringer Ingelheim b.v.	\$288,320	\$2,144,063	\$0	\$0	231	1,679	0	0	75	7
Boehringer Ingelheim Canada Ltd.Ltee	\$34,585	\$247	\$0	\$0	95	5	0	0	22	1
Boehringer Ingelheim Danmark A/S	\$9,866	\$0	\$0	\$0	8	0	0	0	5	0
Boehringer Ingelheim Del Ecuador Cia. Ltda.	\$6,206	\$0	\$0	\$0	2	0	0	0	1	0
Boehringer Ingelheim Do Brasil Quimica e Farmaceutical Ltda.	\$18,401	\$0	\$0	\$0	9	0	0	0	2	0
Boehringer Ingelheim Espana S.A.	\$3,000	\$0	\$0	\$0	2	0	0	0	1	0
Boehringer Ingelheim Finland Ky	\$2,550	\$0	\$0	\$0	5	0	0	0	5	0
Boehringer Ingelheim France S.A.S.	\$43,162	\$7,180	\$0	\$0	31	12	0	0	6	1
Boehringer Ingelheim Hong Kong Ltd	\$27,093	\$0	\$0	\$0	6	0	0	0	2	0
Boehringer Ingelheim Ilac Ticaret A.S.	\$2,069	\$0	\$0	\$0	1	0	0	0	1	0
Boehringer Ingelheim International GmbH	\$492,210	\$1,462,756	\$0	\$0	210	195	0	0	78	7
Boehringer Ingelheim Int'l Trading (Shanghai) Co., Ltd.	\$16,040	\$0	\$0	\$0	5	0	0	0	1	0
Boehringer Ingelheim Ireland Limited	\$42,302	\$0	\$0	\$0	11	0	0	0	4	0
Boehringer Ingelheim Limited	\$4,225	\$501	\$0	\$0	3	6	0	0	2	2
Boehringer Ingelheim Ltda	\$14,079	\$0	\$0	\$0	6	0	0	0	2	0
Boehringer Ingelheim Malaysia Sdn. Bhd.	\$34,129	\$0	\$0	\$0	28	0	0	0	2	0
Boehringer Ingelheim MENA (Scientific Office) FZ-LLC	\$1,936	\$0	\$0	\$0	5	0	0	0	2	0
Boehringer Ingelheim Mexico SA de CV	\$98,608	\$0	\$0	\$0	30	0	0	0	7	0
Boehringer Ingelheim Norway KS	\$0	\$5,346	\$0	\$0	0	55	0	0	0	0
Boehringer Ingelheim Pharma GmbH & Co.KG	\$1,644,561	\$3,219,057	\$0	\$0	1,286	1,143	0	0	231	21
Boehringer Ingelheim Pharmaceuticals, Inc.	\$23,017,402	\$20,109,230	\$0	\$0	314,308	2,848	0	0	70,642	214
Boehringer Ingelheim Pty Ltd	\$17,636	\$0	\$0	\$0	4	0	0	0	1	0
Boehringer Ingelheim RCV GmbH & Co KG	\$22,600	\$120,974	\$0	\$0	2	4	0	0	1	3
Boehringer Ingelheim S.A.	\$23,370	\$0	\$0	\$0	4	0	0	0	3	0
Boehringer Ingelheim Singapore Pte. Ltd.	\$16,506	\$0	\$0	\$0	4	0	0	0	2	0
Boehringer Ingelheim Taiwan Ltd.	\$22,096	\$0	\$0	\$0	6	0	0	0	2	0

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Bolton Medical Inc	\$247,749	\$0	\$0	\$0	864	0	0	0	251	0
Boost Information Systems, Inc.	\$1,021	\$0	\$0	\$0	3	0	0	0	3	0
Boston Scientific Corporation	\$26,269,132	\$18,405,660	\$0	\$0	101,560	4,743	0	0	29,279	200
Bovie Medical Corporation	\$113,200	\$0	\$0	\$0	105	0	0	0	44	0
BRACCO DIAGNOSTICS INC.	\$184,485	\$259,397	\$0	\$0	296	32	0	0	163	10
Braemar Manufacturing, LLC	\$555,036	\$0	\$180,836	\$180,836	2,526	0	3	3	2,367	0
Brahms GmbH	\$38,050	\$679,039	\$0	\$0	13	55	0	0	6	11
Brainlab, Inc.	\$517,626	\$932,000	\$0	\$0	1,391	1	0	0	640	26
Braintree Laboratories, Inc.	\$1,585,390	\$653,918	\$24,120	\$27,338,650	6,698	14	2	2	3,228	0
Breckenridge Pharmaceutical, Inc.	\$5,764	\$0	\$0	\$0	1	0	0	0	1	0
Bristol-Myers Squibb Company	\$480,908	\$0	\$0	\$0	75	0	0	0	3	0
BSD Medical Corporation	\$88,724	\$0	\$0	\$0	15	0	0	0	6	0
BTG International Canada Inc.	\$423,027	\$758,981	\$0	\$0	561	198	0	0	133	12
BTG International, Inc.	\$583,234	\$266,204	\$0	\$0	678	22	0	0	493	9
Buffalo Filter, LLC	\$300	\$0	\$0	\$0	2	0	0	0	2	0
C. R. Bard Foundation, Inc.	\$61,834	\$0	\$0	\$0	5	0	0	0	0	4
C. R. Bard, Inc. & Subsidiaries	\$2,175,029	\$175,032	\$0	\$0	1,293	21	0	0	740	89
C2 Therapeutics, Inc	\$1,300	\$81,231	\$0	\$0	2	3	0	0	2	3
Cadence Pharmaceuticals, Inc.	\$1,252,006	\$495,597	\$0	\$0	9,364	70	0	0	6,357	61
Cadwell Industries, INC	\$46,489	\$0	\$0	\$0	53	0	0	0	21	4
Caldera Medical, Inc	\$78,899	\$0	\$0	\$0	69	0	0	0	55	0
Calvary Spine Products, LLC	\$68,250	\$0	\$105,750	\$216,788	1	0	2	2	1	0
Calvary Spine, LLC	\$750,000	\$0	\$467,168	\$247,009	1	0	1	1	1	0
Canon U.S.A., Inc.	\$3,050	\$13,600	\$0	\$0	7	1	0	0	3	0
Cantel Medical Corp.	\$25,510	\$51,965	\$0	\$0	4	3	0	0	2	1
Capitol Cryotherapy LP	\$252,487	\$0	\$250,613	\$306,365	110	0	10	10	10	0
Capnia, Inc.	\$5,132	\$34,960	\$0	\$0	123	3	0	0	119	2
Captiva Spine Inc	\$268,733	\$0	\$0	\$0	64	0	0	0	37	0
CARDICA, INC.	\$15,898	\$31,240	\$0	\$0	89	3	0	0	42	3
Cardinal Health 108, LLC	\$268,860	\$0	\$0	\$0	813	0	0	0	123	0
Cardinal Health 110, LLC	\$7,705	\$0	\$0	\$0	13	0	0	0	6	1
Cardinal Health 200, LLC	\$367,661	\$0	\$0	\$0	289	0	0	0	86	17

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Cardinal Health 414, LLC	\$315,485	\$0	\$0	\$0	146	0	0	0	91	3
Cardinal Health P.R. 120, Inc.	\$1,919	\$0	\$0	\$0	7	0	0	0	7	0
Cardiosolutions, Inc.	\$59,552	\$0	\$1,084,718	\$1,195,345	9	0	27	27	27	1
Cardiovascular Systems Inc.	\$3,962,856	\$2,097,737	\$0	\$0	18,540	482	0	0	5,244	52
Cardiox Corporation	\$207	\$16,441	\$10,254	\$20,244	2	3	2	2	4	3
CARDIVA MEDICAL, INC.	\$25,550	\$0	\$0	\$0	271	0	0	0	268	0
CareFusion Corporation	\$1,897,252	\$520,845	\$0	\$2,023,672	3,230	12	1	1	963	476
Carestream Dental, LLC	\$1,545,318	\$0	\$0	\$0	3,991	0	0	0	2,420	1
Carestream Health, Inc.	\$165,596	\$134,500	\$0	\$0	50	3	0	0	25	8
Carl Zeiss Meditec AG	\$103,059	\$6,435	\$0	\$0	24	2	0	0	13	0
Carl Zeiss Meditec, Inc.	\$1,609,375	\$0	\$0	\$0	2,887	0	0	0	1,391	21
CARTER BLOODCARE	\$30,024	\$0	\$0	\$0	111	0	0	0	5	7
CAS Medical Systems Inc.	\$172,161	\$232,713	\$0	\$0	214	17	0	0	154	9
Catheter Robotics Inc.	\$399,165	\$0	\$0	\$0	24	0	0	0	1	12
CBA Associates, LLC	\$350,000	\$0	\$196,757	\$196,757	1	0	1	1	1	0
CCPA Purchasing Partners, L.P.	\$0	\$0	\$42,406	\$101,427	0	0	1,171	1,171	1,166	0
CDC Medical LLC	\$55,764	\$0	\$0	\$0	186	0	0	0	91	0
Celera Corporation	\$25,000	\$0	\$0	\$0	1	0	0	0	0	1
Celgene Corporation	\$18,317,861	\$31,732,981	\$0	\$0	76,576	2,437	0	0	14,932	170
Celleration_Inc	\$39,534	\$41,148	\$0	\$0	252	9	0	0	155	3
CeloNova BioSciences, Inc.	\$170,193	\$0	\$10	\$10	144	0	10	10	113	0
Centinel Spine, Inc.	\$317,156	\$2,100	\$0	\$309,825	400	2	10	10	206	2
Central Admixture Pharmacy Services Inc.	\$1,500	\$0	\$0	\$0	1	0	0	0	0	1
Central Blood Bank	\$135,185	\$0	\$0	\$0	38	0	0	0	0	2
Central California Surgical Distributors, LLC	\$133,500	\$0	\$177,912	\$232,907	4	0	13	13	12	0
Central Dallas Surgical Supply, LLC	\$710,000	\$0	\$125,000	\$125,000	5	0	5	5	5	0
Central Florida Cryo Partners LP	\$47,629	\$0	\$0	\$0	231	0	0	0	21	0
Centrix Inc	\$793	\$0	\$0	\$0	13	0	0	0	13	0
Ceptaris Therapeutics, Inc.	\$14,939	\$0	\$0	\$0	15	0	0	0	5	0
Ceterix Orthopaedics, Inc.	\$188,004	\$19,750	\$0	\$0	457	3	0	0	197	3
Cheetah Medical, Inc.	\$35,479	\$22,225	\$0	\$0	52	1	0	0	43	2
Chek-Med Systems, Inc.	\$29,185	\$50,000	\$4,061,975	\$4,061,975	3	1	2	2	2	2

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Chiesi USA, Inc.	\$700,019	\$0	\$0	\$0	3,211	0	0	0	1,643	53
Choice Spine, LP	\$2,784	\$20,823	\$0	\$0	31	8	0	0	22	0
Chugai Pharmaceutical Co., Ltd.	\$427,586	\$625,213	\$0	\$0	221	9	0	0	65	4
Cianna Medical, Inc	\$117,707	\$7,800	\$0	\$0	539	5	0	0	350	0
CIVCO Medical Instruments	\$6,738	\$142,265	\$0	\$0	9	4	0	0	5	2
Clariance SAS	\$582	\$0	\$0	\$0	4	0	0	0	3	0
Clariance, Inc.	\$54,254	\$0	\$0	\$0	56	0	0	0	4	0
CLARITY MEDICAL SYSTEM	\$76,092	\$0	\$0	\$0	58	0	0	0	17	0
Clinical Innovations, LLC	\$78,656	\$0	\$0	\$0	19	0	0	0	10	0
Clinical Technology, Inc	\$25,067	\$0	\$0	\$0	5	0	0	0	5	0
Clinician's Choice Dental Products Inc.	\$45,074	\$0	\$0	\$0	37	0	0	0	11	0
Cochlear AG	\$5,766	\$0	\$0	\$0	11	0	0	0	2	0
Cochlear Americas	\$671,035	\$971,860	\$0	\$0	1,518	312	0	0	554	95
Cochlear Bone Anchored Solutions AB	\$0	\$6,380	\$0	\$0	0	1	0	0	0	0
Cochlear Ltd	\$12,833	\$0	\$0	\$0	6	0	0	0	6	0
Cochlear Medical Device Company India Pvt Ltd	\$12,946	\$0	\$0	\$0	6	0	0	0	2	0
Codman & Shurtleff Inc.	\$63	\$0	\$0	\$0	2	0	0	0	2	0
COGENT THERAPEUTICS LLC	\$0	\$0	\$1,378,100	\$677,761	0	0	29	29	29	0
Collagen Matrix, Inc	\$38	\$0	\$0	\$0	1	0	0	0	1	0
Coloplast Corp	\$4,054,962	\$264,057	\$0	\$0	11,862	116	0	0	3,355	10
Coltene Whaledent Inc.	\$249,218	\$0	\$0	\$0	126	0	0	0	67	1
Community Blood Center	\$1,418	\$0	\$0	\$0	17	0	0	0	17	0
Community Blood Center of Greater Kansas City, Inc.	\$24,814	\$0	\$0	\$0	14	0	0	0	5	5
COMSORT, Inc	\$620,025	\$0	\$0	\$0	4,756	0	0	0	4,630	0
Concordia Laboratories Inc.	\$17,992	\$0	\$0	\$0	50	0	0	0	13	0
ConforMIS, Inc.	\$2,229,449	\$334,798	\$1,095,950	\$15,581,199	2,203	69	15	15	832	11
CONMED Corporation	\$1,602,819	\$9,618	\$0	\$0	835	4	0	0	575	13
Consensus Orthopedics, Inc.	\$310,731	\$0	\$257,279	\$202,273	355	0	6	6	39	0
Convatec Inc.	\$145,855	\$9,095	\$0	\$0	1,160	1	0	0	930	40
Convergent Dental Inc.	\$440,244	\$90,612	\$4,597,440	\$5,990,048	392	2	19	19	221	1
Cook Biotech Incorporated	\$331,926	\$0	\$0	\$0	89	0	0	0	48	0
Cook Incorporated	\$24,687,831	\$0	\$0	\$0	19,977	0	0	0	7,717	65

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Cook Medical LLC	\$152,700	\$0	\$0	\$0	406	0	0	0	266	2
Cook Medical Technologies LLC	\$356,537	\$0	\$0	\$0	22	0	0	0	15	0
CooperSurgical, Inc.	\$1,852,608	\$0	\$0	\$0	897	0	0	0	621	2
CooperVision Inc.	\$1,154,191	\$1,101,763	\$0	\$0	16,504	43	0	0	8,304	1
Corcept Therapeutics	\$260,891	\$0	\$0	\$0	1,480	0	0	0	866	7
Cordis Corporation	\$580,915	\$6,881,021	\$0	\$0	4,990	14,931	0	0	1,531	99
CorMatrix Cardiovascular Inc.	\$430,972	\$272,503	\$523,872	\$1,988,731	2,345	68	7	7	939	9
Corventis, Inc.	\$156,228	\$0	\$0	\$0	57	0	0	0	4	0
Cosmedent, Inc.	\$136,433	\$0	\$40,500	\$15,100,000	79	0	2	2	13	0
COTHERA, LLC	\$0	\$96,635	\$0	\$0	0	1	0	0	0	1
Covidien Caribbean, Inc.	\$65,539	\$0	\$0	\$0	299	0	0	0	180	2
Covidien LP	\$43,709,948	\$6,508,438	\$0	\$0	15,454	1,375	0	0	6,148	224
Covidien Sales LLC	\$39,383,375	\$0	\$0	\$0	43,306	0	0	0	17,336	234
Covis Pharmaceuticals, Inc.	\$323,553	\$159,500	\$0	\$0	1,164	1	0	0	478	0
Cranial Technologies, Inc	\$45,040	\$0	\$0	\$0	2,323	0	0	0	2,322	0
Crealta Pharmaceuticals LLC	\$249,303	\$361,746	\$0	\$0	1,164	220	0	0	643	0
Creative Testing Solutions	\$253,752	\$0	\$0	\$0	2	0	0	0	2	0
Crosstex International Inc.	\$26,889	\$0	\$0	\$0	51	0	0	0	43	1
Cryo Specialty Medical, LLC	\$384,375	\$0	\$457,859	\$658,286	17	0	12	12	17	0
CryoLife, Inc.	\$1,538,423	\$91,674	\$0	\$0	2,202	28	0	0	1,040	44
CSL Behring	\$4,952,722	\$0	\$0	\$0	13,188	0	0	0	4,763	17
Cubist Pharmaceuticals Inc	\$5,750,270	\$9,586,841	\$0	\$0	7,491	4,249	0	0	3,013	55
Cumberland Pharmaceuticals, Inc.	\$248,046	\$488,845	\$0	\$0	4,399	75	0	0	2,715	14
Curax Scientific LLC	\$0	\$0	\$611,250	\$611,250	0	0	14	14	14	0
Custom Spine, Inc.	\$46,253	\$0	\$0	\$0	10	0	0	0	10	0
CVRx, Inc.	\$321,280	\$0	\$214,127	\$171,987	211	0	5	5	32	0
Cyberonics, Inc.	\$1,921,372	\$342,225	\$0	\$0	10,915	47	0	0	2,871	16
D4D Technologies, LLC	\$92,080	\$0	\$0	\$0	236	0	0	0	220	0
Daiichi Sankyo Company LTD	\$223,976	\$0	\$0	\$0	103	0	0	0	29	5
Daiichi Sankyo Europe GmbH	\$74,552	\$0	\$0	\$0	28	0	0	0	6	0
Daiichi Sankyo Inc.	\$3,289,457	\$4,594,072	\$0	\$0	241,022	2,315	0	0	39,505	38
Dako North America, Inc	\$903,179	\$0	\$0	\$0	34	0	0	0	2	12

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Dakota Sciences, LLC	\$3,850	\$0	\$0	\$0	1	0	0	0	1	0
DARA Biosciences, Inc.	\$24,939	\$0	\$0	\$0	624	0	474	474	440	0
Darby Dental Supply, LLC	\$613,542	\$0	\$0	\$0	2	0	0	0	2	0
DASH MEDICAL GLOVES INC	\$51,105	\$0	\$0	\$0	1,629	0	0	0	1,621	0
Datascope Corp.	\$38,596	\$387,217	\$0	\$0	20	4	0	0	7	1
Davol Inc.	\$7,284,506	\$646,383	\$0	\$0	8,308	89	0	0	3,076	23
DeGen Medical, Inc.	\$70,760	\$0	\$0	\$0	68	0	0	0	7	0
Den-Mat Holdings, LLC	\$528,630	\$0	\$0	\$0	687	0	0	0	308	0
Dental Equipment LLC	\$99,949	\$236	\$0	\$0	310	4	0	0	137	0
Dental Imaging Technologies Corp.	\$277,056	\$30	\$0	\$0	342	2	0	0	133	0
Dental Material Gesellschaft mbH	\$6,520	\$0	\$0	\$0	31	0	0	0	12	0
DentalEZ Alabama, Inc.	\$995	\$0	\$0	\$0	12	0	0	0	9	1
DentalEZ, Inc.	\$178,676	\$0	\$0	\$0	250	0	0	0	186	1
DENTPSLY IH AB	\$220,702	\$1,178,962	\$0	\$0	80	72	0	0	20	5
DENTSPLY Australia Pty Limited	\$2,733	\$0	\$0	\$0	8	0	0	0	1	0
DENTSPLY Canada Ltd	\$50,615	\$0	\$0	\$0	35	0	0	0	10	0
DENTSPLY IH Inc.	\$2,039,505	\$0	\$0	\$0	15,256	0	0	0	7,113	7
Dentsply International	\$6,223,017	\$0	\$0	\$0	6,737	0	0	0	5,480	11
DENTSPLY LLC	\$1,251,173	\$20,558	\$0	\$0	1,151	2	0	0	466	4
DENTSPLY Ltd	\$14,228	\$0	\$0	\$0	28	0	0	0	3	0
DENTSPLY Mexico SA de CV	\$629	\$0	\$0	\$0	2	0	0	0	1	0
DENTSPLY NZ Limited	\$27,915	\$0	\$0	\$0	56	0	0	0	13	0
Dentsply US Prosthetics LLC	\$41,782	\$0	\$0	\$0	64	0	0	0	38	1
Depomed, Inc.	\$3,041,459	\$11,800	\$0	\$0	23,908	1	0	0	7,038	1
DePuy Institute, LLC	\$6,400	\$0	\$0	\$0	10	0	0	0	5	1
DePuy Mitek LLC	\$6,980,839	\$31,308	\$0	\$0	117	4	0	0	48	3
DePuy Orthopaedics Inc.	\$17,131,560	\$4,649,583	\$0	\$0	6,935	720	0	0	1,710	157
DePuy Products Inc.	\$2,315	\$6,450	\$0	\$0	2	1	0	0	2	0
DePuy Spine, LLC	\$19,964	\$4,905	\$0	\$0	3	5	0	0	3	0
DePuy Synthes Products LLC	\$58,602,961	\$293,610	\$0	\$0	1,675	14	0	0	290	9
DePuy Synthes Sales Inc.	\$3,780,569	\$0	\$0	\$0	44,864	0	0	0	12,466	29
Derma Sciences, Inc.	\$459,935	\$0	\$0	\$0	2,250	0	0	0	1,405	0

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
DermaRite Industries, LLC	\$100	\$0	\$0	\$0	3	0	0	0	3	0
Desert Mountain Medical	\$78,016	\$0	\$0	\$0	444	0	0	0	189	0
DETNSPLY DeTrey GmbH	\$149	\$7,498	\$0	\$0	2	2	0	0	3	0
Devicor Medical Products, Inc.	\$196,698	\$0	\$1	\$133,291	604	0	1	1	378	2
Dexcom, Inc.	\$611,584	\$802,725	\$0	\$0	2,429	27	0	0	1,100	4
DFINE, Inc	\$445,461	\$35,917	\$33,435	\$5,070	2,547	8	2	2	1,102	6
diaDexus, Inc.	\$193,169	\$0	\$0	\$0	2,727	0	0	0	1,799	0
Diagnosoft, Inc.	\$2,628	\$0	\$0	\$0	3	0	0	0	3	0
Diagnostica Stago SAS	\$0	\$26,611	\$0	\$0	0	6	0	0	1	2
Diagnostica Stago, Inc	\$2,611	\$195,838	\$0	\$0	13	15	0	0	5	9
Digestive Care, Inc.	\$6,403	\$0	\$0	\$0	75	0	0	0	75	0
Digirad Corporation	\$4,570	\$0	\$0	\$0	125	0	0	0	102	0
DISCOVERY LABORATORIES, INC.	\$124,800	\$0	\$0	\$0	597	0	0	0	292	12
DMG AMERICA LLC	\$214,631	\$0	\$0	\$0	345	0	0	0	236	0
DNE LLC	\$151,314	\$0	\$150,000	\$42,020	10	0	1	1	11	0
Dohmen Life Science Services, LLC	\$337,039	\$0	\$0	\$0	20	0	0	0	3	0
Domain Surgical, Inc.	\$125,752	\$0	\$0	\$0	4	0	4	4	5	0
Dornier MedTech America, Inc	\$26,705	\$0	\$0	\$0	139	0	0	0	96	5
Dr.Reddy's Laboratories, Inc.	\$242,554	\$5,696,241	\$0	\$0	143	338	0	0	22	0
Draeger Medical GmbH	\$49,313	\$58,150	\$0	\$0	7	5	0	0	3	7
Draeger Medical Systems, Inc	\$500	\$0	\$0	\$0	1	0	0	0	0	1
Draeger Medical, Inc	\$48,252	\$0	\$0	\$0	70	0	0	0	35	11
Drake Precision Dental Lab	\$32	\$0	\$0	\$0	3	0	0	0	3	0
DS Healthcare Inc	\$9,047	\$0	\$0	\$0	488	0	0	0	468	0
Duchesnay USA Incorporated	\$762,376	\$75,141	\$0	\$0	9,006	19	0	0	4,112	0
Dune Medical Devices, Inc.	\$20,241	\$0	\$0	\$0	81	0	0	0	66	0
Durata Therapeutics Inc.	\$542,293	\$3,273,889	\$0	\$0	1,959	492	0	0	1,158	29
Dux Industries Inc	\$21,928	\$0	\$0	\$0	23	0	0	0	12	0
Dyax Corp	\$200,509	\$501,786	\$0	\$0	932	23	0	0	417	5
Dynasplint Systems Inc.	\$3,640	\$0	\$0	\$0	170	0	0	0	126	0
DySIS Medical, Inc.	\$9,325	\$0	\$0	\$0	143	0	0	0	126	0
E.R. Squibb & Sons, L.L.C.	\$22,827,002	\$220,746,55	\$0	\$0	184,062	5,037	0	0	57,319	262

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
		9								
Eagle Pharmaceuticals, Inc.	\$1,158	\$0	\$0	\$0	13	0	0	0	6	0
Eagle Vision, Inc.	\$11,564	\$0	\$1,048,992	\$1,167,122	5	0	1	1	5	0
EBI Medical Systems, LLC	\$94,141	\$0	\$0	\$0	2,570	0	0	0	1,890	0
eCardio Diagnostics, LLC	\$128,512	\$80,000	\$0	\$0	62	1	0	0	50	4
Eckert & Ziegler, BEBIG	\$5,614	\$0	\$0	\$0	64	0	0	0	38	0
EDAP TECHNOMED INC	\$66,873	\$52,415	\$0	\$0	23	6	0	0	10	3
Edgemont Pharmaceuticals LLC	\$74,600	\$0	\$0	\$0	47	0	0	0	42	0
Edwards Lifesciences Corporation	\$6,846,746	\$44,028,352	\$0	\$0	23,588	895	0	0	6,691	192
Eisai Co., Ltd.	\$178,760	\$1,723,939	\$0	\$0	79	1,995	0	0	8	15
Eisai Inc.	\$12,205,885	\$44,654,251	\$0	\$0	93,935	27,606	0	0	39,778	105
EKOS Corporation	\$222,915	\$378,688	\$71,212	\$71,212	2,693	52	22	22	1,634	18
Electrical Geodesics, Inc	\$66,703	\$15,024	\$0	\$0	4	1	0	0	2	1
Electromed, Inc.	\$55,761	\$0	\$0	\$0	1,381	0	0	0	928	32
Electronic Waveform Lab, Inc.	\$49,442	\$0	\$0	\$0	1,834	0	0	0	490	0
Elekta Instrument AB	\$114,306	\$0	\$0	\$0	17	0	0	0	1	1
Elekta Instrument Shanghai Ltd	\$48,000	\$0	\$0	\$0	1	0	0	0	0	1
Elekta K.K.	\$2,537	\$0	\$0	\$0	3	0	0	0	1	0
Elekta LTD	\$219	\$0	\$0	\$0	7	0	0	0	2	0
Elekta Pty Ltd	\$15,892	\$0	\$0	\$0	3	0	0	0	1	0
Elekta, Inc.	\$38,017	\$0	\$0	\$0	561	0	0	0	341	0
Elevate Oral Care	\$961	\$0	\$0	\$0	70	0	0	0	69	0
ELI LILLY AND COMPANY	\$8,770,250	\$137,380,377	\$0	\$0	3,701	6,417	0	0	1,221	151
ELI LILLY EXPORT S.A. PUERTO RICO BRANCH	\$66,176	\$2,310,937	\$0	\$0	1,398	86	0	0	602	1
Ellex, Inc	\$42,847	\$0	\$0	\$0	81	0	0	0	56	1
Ellipse Technologies, Inc.	\$331,066	\$65,414	\$3,599,234	\$3,599,234	219	9	21	21	99	4
ELLMAN INTERNATIONAL	\$283,058	\$0	\$0	\$0	97	0	0	0	77	0
EMD Millipore Corporation	\$2,768,313	\$0	\$0	\$0	3,671	0	0	0	8	118
EMD Serono, Inc.	\$3,307,096	\$17,359,065	\$0	\$0	32,509	8,863	0	0	5,222	37
Emerge Medical, INC	\$7,225	\$0	\$0	\$0	5	0	0	0	3	0
Emergent Biosolutions Inc.	\$268,842	\$1,028,585	\$0	\$0	851	751	0	0	500	11

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
EMPI, INC.	\$111,498	\$84,000	\$0	\$0	4,542	4	0	0	2,856	0
Encision Inc	\$429	\$0	\$0	\$0	16	0	0	0	13	3
ENCORE MEDICAL, LP	\$7,003,618	\$386,101	\$0	\$0	3,575	106	0	0	720	6
End Product Results LLC	\$59,900	\$0	\$0	\$0	9	0	0	0	4	0
Endo Pharmaceuticals Inc.	\$2,878,052	\$190,382	\$0	\$0	25,645	40	0	0	12,141	8
Endocare, Inc.	\$194,079	\$0	\$0	\$0	938	0	0	0	428	0
EndoChoice, Inc.	\$97,028	\$0	\$249,825	\$1,910,057	710	0	15	15	462	0
ENDOCO Inc dba Ultimate Dental	\$113,346	\$0	\$0	\$0	325	0	0	0	120	0
EndoEvolution, LLC	\$12,500	\$0	\$72	\$72	4	0	2	2	6	0
Endogastric Solutions, Inc	\$138,215	\$760,215	\$127,498	\$15,422	611	105	3	3	278	4
Endologix, Inc.	\$1,930,000	\$0	\$1,029,450	\$1,029,450	8,369	0	4	4	2,115	4
Entellus Medical, Inc.	\$999,904	\$81,069	\$21,661	\$658,814	7,788	28	6	6	2,229	1
Epimed International, Inc	\$444,235	\$0	\$0	\$0	157	0	0	0	104	0
ERBE USA Inc	\$15,259	\$0	\$0	\$0	136	0	0	0	122	2
ERMI Inc.	\$15,268	\$0	\$0	\$0	586	0	0	0	572	0
Esaoite North America, Inc.	\$192,396	\$0	\$0	\$0	106	0	0	0	24	3
ESSA Pharmaceuticals Corp.	\$6,000	\$0	\$0	\$0	4	0	0	0	4	0
ESSENTIAL DENTAL SYSTEMS INCORPORATED	\$1,509,221	\$0	\$3,096,942	\$3,096,942	817	0	2	2	319	0
Ethicon Endo-Surgery Inc.	\$1,875,120	\$4,420,362	\$0	\$0	428	77	0	0	157	47
Ethicon Inc.	\$1,066,188	\$888,067	\$0	\$0	1,251	80	0	0	319	27
Ethicon US, LLC	\$4,964,966	\$0	\$0	\$0	29,444	0	0	0	11,153	52
Evergreen Orthopedic Research Lab LLC	\$45,832	\$0	\$164,462	\$48,752	51	0	1	1	15	0
Evofem Inc.	\$0	\$478,204	\$0	\$0	0	71	0	0	34	0
Exactech, Inc.	\$8,246,836	\$341,398	\$0	\$0	2,020	52	0	0	521	2
Exalenz Bioscience Ltd.	\$3,714	\$0	\$0	\$0	36	0	0	0	35	0
Exelixis Inc.	\$938,613	\$8,791,670	\$0	\$0	836	2,436	0	0	546	35
Extremity Medical	\$388,514	\$0	\$0	\$621,019	270	0	4	4	151	0
F. Hoffmann-La Roche AG	\$1,951,230	\$8,614,116	\$0	\$0	1,461	703	0	0	503	30
Farallon Surgical, LLC	\$1,564,361	\$0	\$130,000	\$551,553	22	0	3	3	3	0
FCI Ophthalmics, Inc.	\$393	\$0	\$0	\$0	3	0	0	0	3	0
FERA PHARMACEUTICALS, LLC	\$250	\$0	\$0	\$0	1	0	0	0	1	0
Ferring Inc.	\$1,000	\$0	\$0	\$0	1	0	0	0	1	0

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Ferring International Center SA	\$45,446	\$0	\$0	\$0	41	0	0	0	10	0
Ferring International Pharmascience Center US	\$57,854	\$97,173	\$0	\$0	62	35	0	0	11	2
Ferring Pharmaceuticals (Asia) Co. Ltd.	\$15,492	\$0	\$0	\$0	20	0	0	0	1	0
Ferring Pharmaceuticals AS	\$80,620	\$657,917	\$0	\$0	60	10	0	0	9	0
Ferring Pharmaceuticals Co. Ltd.	\$7,253	\$0	\$0	\$0	7	0	0	0	1	0
Ferring Pharmaceuticals Inc.	\$2,674,513	\$1,605,824	\$0	\$0	35,388	31	0	0	10,810	5
Ferring Pharmaceuticals LLC	\$34,850	\$0	\$0	\$0	17	0	0	0	2	0
Ferring Pharmaceuticals LTD	\$2,025	\$0	\$0	\$0	2	0	0	0	1	0
Ferring Pharmaceuticals Ltd (UK)	\$3,499	\$0	\$0	\$0	2	0	0	0	1	0
Ferring Pharmaceuticals Pty Ltd	\$35,603	\$0	\$0	\$0	24	0	0	0	2	0
Ferring Pharmaceuticals SA Rep Office Middle East	\$15,062	\$0	\$0	\$0	12	0	0	0	1	0
Ferring Production Inc.	\$2,327	\$0	\$0	\$0	1	0	0	0	0	1
Ferring Research Institute Inc.	\$50,957	\$100,000	\$0	\$0	32	2	0	0	14	0
Ferring SA de CV	\$3,452	\$0	\$0	\$0	7	0	0	0	1	0
FFF Enterprises, Inc.	\$3,807	\$0	\$0	\$0	10	0	0	0	3	2
FHC, Inc.	\$6,500	\$0	\$0	\$0	3	0	0	0	1	2
Fidia Pharma USA Inc	\$43,515	\$29,447	\$0	\$0	1,146	20	0	0	839	0
Fisher & Paykel Healthcare Inc	\$54,590	\$0	\$0	\$0	887	0	0	0	632	0
Fisher & Paykel Healthcare Limited	\$258,200	\$496,688	\$0	\$0	79	7	0	0	26	1
Fisher Scientific Company L.L.C.	\$82,907	\$0	\$0	\$0	195	0	0	0	119	8
Flexuspine, Inc	\$1,580	\$0	\$0	\$0	8	0	0	0	4	0
Flowonix Medical Incorporated	\$223,776	\$0	\$187,600	\$121,720	474	0	3	3	474	0
Focus Diagnostics Inc	\$91,186	\$33,595	\$0	\$0	7	2	0	0	0	5
FOREST LABORATORIES, INC.	\$952,851	\$0	\$0	\$0	108	0	0	0	16	0
FOREST PHARMACEUTICALS, INC.	\$16,409,803	\$0	\$0	\$0	397,594	0	0	0	66,494	50
FOREST RESEARCH INSTITUTE, INC.	\$581,791	\$34,531,825	\$0	\$0	370	5,032	0	0	163	50
Fort Worth Surgical Supply, LLC	\$159,200	\$0	\$50,000	\$50,000	1	0	1	1	1	0
Fresenius Kabi USA, LLC	\$513,211	\$0	\$0	\$0	151	0	0	0	28	4
Fresenius USA Inc.	\$500	\$0	\$0	\$0	1	0	0	0	1	0
Fresenius USA Manufacturing, Inc.	\$590	\$0	\$0	\$0	4	0	0	0	1	0
Fresenius USA Marketing, Inc.	\$98,704	\$449,368	\$0	\$0	2,681	7	0	0	1,598	3
FSC Laboratories, Inc.	\$7,322	\$0	\$0	\$0	518	0	0	0	509	0

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
FUJIFILM Medical Systems USA, Inc.	\$1,256,236	\$101,797	\$0	\$0	594	3	0	0	181	50
FUJIFILM SonoSite, Inc.	\$1,199,716	\$3,040	\$0	\$0	1,209	1	0	0	891	39
Fujirebio Diagnostics, Incorporated	\$1,847,099	\$459,272	\$0	\$0	29	9	0	0	25	11
FUKUDA DENSHI Co., Ltd.	\$153,821	\$147,337	\$0	\$0	11	5	0	0	11	0
Functional Neuromodulation Inc	\$343	\$1,436,988	\$0	\$0	3	18	0	0	14	2
GAC International LLC	\$1,744,561	\$0	\$0	\$0	2,106	0	0	0	909	7
Galderma Laboratories, L.P.	\$4,659,194	\$388,944	\$0	\$0	36,975	39	0	0	10,175	0
Galderma Research & Development, LLC	\$29,361	\$163,607	\$0	\$0	19	47	0	0	7	0
Galen US Inc	\$1,409	\$0	\$0	\$0	67	0	0	0	54	0
Galena Biopharma, Inc.	\$132,372	\$81,150	\$0	\$0	893	20	0	0	897	0
Galil Medical Inc.	\$198,640	\$64,266	\$0	\$0	238	84	0	0	158	27
Galt Medical	\$5,725	\$0	\$0	\$0	23	0	0	0	20	0
Gamma Medica, Inc.	\$71,253	\$0	\$0	\$0	28	0	0	0	22	1
Gauss Surgical Inc.	\$7,187	\$0	\$0	\$0	18	0	0	0	6	0
GC America Inc.	\$508,116	\$0	\$0	\$0	1,677	0	0	0	1,216	0
GE Global Research an unincorporated business unit of General Electric Company	\$0	\$583,440	\$0	\$0	0	7	0	0	0	4
GE Healthcare	\$5,749,336	\$4,630,828	\$0	\$0	6,481	244	0	0	2,803	170
GEBAUER COMPANY	\$57,979	\$316,428	\$0	\$0	42	8	0	0	19	3
Geistlich Pharma, North America, Inc.	\$172,639	\$487,708	\$0	\$0	178	16	0	0	106	2
Gemini Medical LLC	\$40,065	\$0	\$0	\$0	208	0	0	0	131	0
Genentech USA, Inc.	\$18,207,823	\$0	\$0	\$0	106,838	0	0	0	26,450	153
Genentech, Inc.	\$274,204,029	\$99,218,412	\$0	\$0	4,219	12,612	0	0	1,340	181
Genesys Orthopedics Systems, L.L.C.	\$863,437	\$44,700	\$0	\$0	27	2	0	0	20	0
Genetics Institute LLC	\$500	\$0	\$0	\$0	1	0	0	0	0	1
GenMark Diagnostics, Inc.	\$7,922	\$0	\$0	\$0	3	0	0	0	1	2
Gentleman Orthopedic Solutions	\$8,567	\$0	\$0	\$0	60	0	0	0	35	0
GENZYME CORPORATION	\$18,340,823	\$3,458,181	\$0	\$0	39,790	430	0	0	7,928	60
Georgia Cryotherapy LP	\$130,234	\$0	\$0	\$0	516	0	0	0	49	0
Gilead Sciences Inc	\$31,392,562	\$39,977,290	\$0	\$0	156,400	5,822	0	0	27,298	140
Given Imaging Ltd.	\$0	\$1,536,075	\$0	\$0	0	192	0	0	6	9
Given Imaging, Inc.	\$180,111	\$0	\$0	\$0	601	0	0	0	470	2

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
GLAUKOS CORPORATION	\$897,639	\$382,073	\$765,916	\$3,423,151	1,815	113	9	9	1,286	5
GlaxoSmithKline, LLC.	\$36,036,629	\$177,109,198	\$0	\$0	265,798	24,479	0	0	78,213	35
Globus Medical, Inc.	\$10,240,540	\$277,393	\$0	\$0	7,502	92	0	0	1,657	17
GLYCOMARK, INC.	\$12,427	\$0	\$0	\$0	293	0	0	0	250	0
GM Pharmaceuticals, Inc.	\$717	\$0	\$0	\$0	4	0	0	0	4	0
Goetze-Niemer Co	\$11,373	\$0	\$0	\$0	65	0	0	0	57	0
Goode Surgical Inc	\$18,129	\$0	\$0	\$0	91	0	0	0	35	0
Gotham Surgical Solutions & Devices, Inc.	\$13,105	\$0	\$0	\$0	120	0	0	0	71	0
Grace Medical, Inc.	\$30,171	\$0	\$1,048,992	\$1,167,122	43	0	1	1	38	0
Great Lakes Medical Services, LLC	\$49,872	\$0	\$90,000	\$81,000	30	0	9	9	11	0
Great Plains Surgical Distributors, LLC	\$0	\$0	\$94,500	\$94,500	0	0	9	9	9	0
Greatbatch, Inc.	\$213,018	\$0	\$0	\$0	46	0	0	0	12	0
Greer Laboratories, Inc.	\$85,812	\$0	\$0	\$0	246	0	0	0	193	2
Grifols Biologicals, Inc.	\$147	\$952,723	\$0	\$0	2	73	0	0	1	3
Grifols Diagnostic Solutions Inc.	\$13,179	\$0	\$0	\$0	46	0	0	0	30	0
Grifols Shared Services North America, Inc.	\$379,761	\$513,147	\$0	\$0	461	14	0	0	141	9
Grifols Therapeutics Inc.	\$52,435	\$1,259,433	\$0	\$0	134	115	0	0	27	13
Grifols, S.A.	\$119,973	\$0	\$0	\$0	73	0	0	0	28	0
Grunenthal USA Inc	\$26,618	\$0	\$0	\$0	10	0	0	0	6	0
GUERBET LLC	\$1,092,552	\$772,391	\$0	\$0	1,055	54	0	0	324	10
Gulf Coast Regional Blood Center	\$2,080	\$0	\$0	\$0	3	0	0	0	3	0
Gulf States Cryotherapy LP	\$58,254	\$0	\$248,004	\$0	9	0	9	9	9	0
Gyrus ACMI, Inc.	\$298,458	\$0	\$0	\$0	131	0	0	0	40	4
Gyrus ACMI, L.P.	\$24,263	\$0	\$0	\$0	9	0	0	0	4	1
Gyrus ENT, L.L.C.	\$24,671	\$0	\$0	\$0	19	0	0	0	12	1
Gyrus Medical GmbH	\$50,922	\$0	\$0	\$0	6	0	0	0	0	1
Gyrus Medical, Inc.	\$17,824	\$0	\$0	\$0	2	0	0	0	2	0
H. Lundbeck A S	\$761,338	\$498,741	\$0	\$0	376	48	0	0	69	3
Haag-Streit USA, Inc.	\$195,202	\$7,053	\$0	\$0	38	1	0	0	11	1
Haemonetics Corporation	\$980,426	\$911,671	\$0	\$0	536	49	0	0	267	56
Halozyme Inc	\$324,375	\$3,228	\$0	\$0	410	1	0	0	323	0

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Halt Medical, INC	\$683,322	\$864,297	\$250,500	\$251,536	522	53	7	7	36	5
HALYARD HEALTH, INC.	\$1,071,459	\$229,736	\$0	\$0	7,840	55	0	0	4,241	1
Hand Biomechanics Laboratory	\$25,711	\$0	\$48,033	\$219,613	1	0	1	1	1	0
Hansen Medical, Inc.	\$103,140	\$373,210	\$0	\$0	537	28	0	0	309	4
HeartWare, Inc.	\$1,561,116	\$1,664,084	\$0	\$0	2,424	92	0	0	619	56
Heidelberg Engineering, Inc.	\$749,127	\$0	\$0	\$0	641	0	0	0	486	24
Helena Laboratories Corporation	\$19,518	\$35,763	\$0	\$0	88	30	0	0	12	27
Helix Medical, LLC	\$148,048	\$0	\$0	\$0	31	0	0	0	15	0
Helsinn Healthcare SA	\$447,339	\$0	\$0	\$0	52	0	0	0	10	0
Henry Schein Medical Systems, Inc.	\$13	\$0	\$0	\$0	1	0	0	0	1	0
Henry Schein Practice Solutions Inc.	\$39,968	\$0	\$0	\$0	74	0	0	0	35	0
Henry Schein, Inc.	\$3,425,413	\$0	\$0	\$0	15,162	0	0	0	8,404	7
Heraeus Kulzer, LLC	\$302,997	\$0	\$0	\$0	4,143	0	0	0	3,334	2
HET Systems LLC	\$0	\$0	\$0	\$24,802,856	0	0	4	4	4	0
Hexal AG	\$1,655	\$0	\$0	\$0	1	0	0	0	1	0
HF Acquisition Co. LLC	\$2,103	\$0	\$0	\$0	34	0	0	0	33	0
Highline Surgical Solutions, LLC	\$0	\$0	\$48,000	\$315,257	0	0	5	5	5	0
Hill-Rom Company, Inc	\$384,893	\$35,450	\$0	\$0	218	4	0	0	13	101
HILL-ROM HOLDINGS, INC	\$82,524	\$6,900	\$0	\$0	52	1	0	0	3	2
Hill-Rom Services PTE, LTD	\$24,000	\$57,018	\$0	\$0	3	5	0	0	2	3
HILL-ROM SERVICES, INC	\$113,317	\$0	\$0	\$0	81	0	0	0	4	27
HILL-ROM, INC	\$2,997	\$0	\$0	\$0	12	0	0	0	3	1
Hiossen, Inc.	\$1,067,700	\$0	\$0	\$0	63	0	0	0	63	0
Hitachi Aloka Medical America Inc.	\$54,604	\$0	\$0	\$0	91	0	0	0	65	1
Hitachi Aloka Medical, Ltd.	\$1,728	\$0	\$0	\$0	10	0	0	0	8	1
Hitachi Medical Systems America, Inc.	\$14,104	\$0	\$0	\$0	183	0	0	0	105	0
Hi-Tech Pharmacal Co., Inc.	\$236,549	\$0	\$0	\$0	14	0	0	0	2	1
Hoffmann-La Roche Inc.	\$22,117	\$1,075,508	\$0	\$0	2	152	0	0	8	5
Hoffmann-La Roche Limited	\$46,535	\$553,944	\$0	\$0	57	143	0	0	16	7
Hollister Incorporated	\$404,417	\$61,268	\$0	\$0	877	9	0	0	412	127
HOLOGIC INC	\$4,135,307	\$4,408,533	\$0	\$0	11,130	216	0	0	5,938	292
Horizon Pharma Ireland Limited	\$0	\$512,042	\$0	\$0	0	13	0	0	0	5

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Horizon Pharma USA, Inc.	\$965,474	\$209,120	\$0	\$0	70,312	156	0	0	14,136	5
Hospira Worldwide, Inc.	\$830,707	\$828,035	\$0	\$0	4,504	50	0	0	2,510	41
Hotspur Technologies, Inc.	\$3,948	\$0	\$0	\$0	2	0	0	0	2	0
HOYA Medical Singapore PTE LTD	\$40,625	\$0	\$0	\$0	3	0	0	0	2	1
Hoya Surgical Optics GmbH	\$564	\$0	\$0	\$0	5	0	0	0	5	0
Hoya Surgical Optics, Inc	\$46,121	\$7,500	\$0	\$0	213	1	0	0	117	0
Hu-Friedy Mfg. Co., LLC	\$323,519	\$0	\$0	\$0	1,948	0	0	0	1,462	5
Hutchinson Technology Inc.	\$23,213	\$0	\$0	\$0	9	0	0	0	5	4
Hydrogel Vision Corporation	\$13,050	\$0	\$0	\$0	61	0	0	0	55	0
Hyperion Therapeutics Inc.	\$73,449	\$701,163	\$0	\$0	198	147	0	0	65	24
HZNP USA Inc.	\$227,459	\$0	\$0	\$0	341	0	0	0	215	4
IBSA Institut Biochimique SA	\$0	\$18,290	\$0	\$0	0	7	0	0	7	0
iCAD, Inc	\$324,364	\$0	\$606,821	\$1,030,247	301	0	3	3	124	0
Icare USA	\$42,000	\$0	\$0	\$0	4	0	0	0	4	0
ICU Medical Inc	\$0	\$0	\$170,544,848	\$170,544,848	0	0	4	4	4	0
Ikaria, Inc.	\$39,186	\$0	\$0	\$0	41	0	0	0	17	0
Illinois Cryotherapy LP	\$178,197	\$0	\$0	\$0	240	0	0	0	20	0
Illumina, Inc.	\$1,993	\$0	\$0	\$0	41	0	0	0	37	1
IMCLONE SYSTEMS, LLC	\$653	\$5,487,485	\$0	\$0	12	230	0	0	15	37
Immucor, Inc.	\$751,050	\$162,307	\$0	\$0	20	4	0	0	12	3
Impax Laboratories, Inc.	\$53,520	\$0	\$0	\$0	2,586	0	0	0	1,509	0
ImpediMed, Inc.	\$162,247	\$20,000	\$0	\$0	53	1	0	0	47	1
Implant Direct International LLC	\$839,102	\$0	\$0	\$0	4,406	0	0	0	2,831	0
IMRIS INC.	\$44,683	\$0	\$0	\$0	57	0	0	0	31	2
Incisive Surgical, Inc.	\$2,477	\$0	\$0	\$0	106	0	0	0	106	0
InControl Medical, LLC	\$105,305	\$0	\$50,004	\$250,000	39	0	5	5	32	0
Incyte Corporation	\$3,809,332	\$141,140,505	\$0	\$0	11,034	11,152	0	0	3,732	74
Inland Surgical Products, LLC	\$845,000	\$0	\$1,381,811	\$1,217,478	5	0	5	5	5	0
InnerSpace Neuro Solutions, Inc.	\$906	\$0	\$0	\$0	45	0	0	0	40	0
INNOCUTIS Holdings LLC	\$249,465	\$0	\$0	\$0	1,834	0	0	0	850	0
Innovasis Inc	\$1,024,010	\$0	\$0	\$0	117	0	0	0	43	0

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Innovative Cryosurgery, LLC	\$67	\$0	\$0	\$0	3	0	0	0	3	0
Innovative Medical Devices, Inc.	\$463	\$0	\$0	\$0	10	0	0	0	7	0
Innovative Medical Technologies, LLC	\$3,839	\$0	\$66,214	\$0	147	0	215	215	208	0
Innovative Ophthalmic Products, Inc.	\$155,375	\$0	\$0	\$0	21	0	0	0	21	0
Innovative Therapies Inc.	\$6,169	\$0	\$0	\$0	22	0	0	0	16	0
InnoVision Incorporated	\$188,731	\$0	\$0	\$0	66	0	0	0	5	0
INO Therapeutics LLC	\$821,054	\$542,447	\$0	\$0	567	59	0	0	222	32
Inogen, Inc.	\$1,183	\$0	\$0	\$0	75	0	0	0	66	0
Inova Diagnostics, Inc.	\$3,279	\$147,926	\$0	\$0	22	1	0	0	12	4
Inova Labs Inc	\$1,035	\$0	\$0	\$0	89	0	0	0	89	0
Insight Instruments, Inc.	\$70,875	\$0	\$0	\$0	21	0	0	0	9	0
Inspire Medical Systems, Inc.	\$33,919	\$0	\$0	\$0	213	0	0	0	154	3
Institute for Transfusion Medicine	\$1,609,532	\$758,442	\$0	\$0	53	67	0	0	8	6
Instradent USA Inc	\$31,770	\$0	\$0	\$0	533	0	0	0	384	0
Instrumentation Laboratory Company	\$124,252	\$326,253	\$0	\$0	89	13	0	0	22	6
INSULET CORPORATION	\$528,430	\$0	\$0	\$0	3,975	0	0	0	1,775	27
INSYS Therapeutics Inc	\$7,390,872	\$722,470	\$0	\$0	10,007	17	0	0	2,114	0
Integra LifeSciences Sales LLC	\$10,163	\$0	\$0	\$0	278	0	0	0	236	0
Integra LifeSciences Corporation	\$4,063,990	\$1,695,742	\$0	\$0	9,004	188	0	0	3,781	32
Integra LifeSciences France LLC	\$7,097	\$0	\$0	\$0	7	0	0	0	1	0
Integra Sales, Inc.	\$3,205	\$0	\$0	\$0	29	0	0	0	29	0
Integra York PA, Inc.	\$2,287	\$0	\$0	\$0	10	0	0	0	6	0
integrated dental systems	\$27,402	\$0	\$0	\$0	240	0	0	0	134	0
Integrated Medical Systems International, Inc.	\$20,875	\$0	\$0	\$0	7	0	0	0	0	5
Intercell USA, Inc.	\$75,638	\$0	\$0	\$0	31	0	0	0	4	0
Intermune, Inc.	\$210,850	\$2,851,633	\$0	\$0	15	105	0	0	8	30
INTERNATIONAL REHABILITATIVE SCIENCES, INC	\$101	\$0	\$0	\$0	10	0	0	0	10	0
Intersect ENT, Inc.	\$857,318	\$56,582	\$1,548,718	\$6,039,050	8,079	27	3	3	3,200	1
InterValve, Inc.	\$1,985	\$24,950	\$1,725,645	\$2,653,620	4	4	4	4	5	3
Interventional Spine, Inc.	\$107,460	\$0	\$2,324,687	\$2,324,687	19	0	19	19	31	0
Intuitive Surgical Operations, Inc.	\$1,083,578	\$377,273	\$0	\$0	512	26	0	0	115	13
Intuitive Surgical, Inc.	\$28,023,508	\$0	\$0	\$0	71,693	0	0	0	10,437	151

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Invacare Corporation	\$98,107	\$0	\$0	\$0	13	0	0	0	1	0
Ipsen Biopharm Limited	\$3,632	\$0	\$0	\$0	13	0	0	0	13	0
Ipsen Biopharmaceuticals, Inc	\$433,562	\$143,622	\$0	\$0	2,140	84	0	0	954	16
Ipsen Bioscience Inc	\$21,378	\$129,252	\$0	\$0	8	4	0	0	2	4
Ipsen Innovation	\$214,713	\$44,758	\$0	\$0	156	6	0	0	33	3
Ipsen Pharma SAS	\$36,334	\$48,415	\$0	\$0	15	7	0	0	4	3
IQuum, Inc.	\$0	\$270,772	\$0	\$0	0	6	0	0	0	1
iRhythm Technologies, Inc.	\$241,337	\$536,305	\$366,829	\$3,730,517	138	2	5	5	129	2
Iroko Pharmaceuticals, LLC	\$2,645,355	\$2,480,054	\$0	\$0	26,255	545	0	0	12,505	0
Ironwood Pharmaceuticals, Inc	\$539,081	\$477,475	\$7,800	\$60,450	20,564	15	1	1	8,911	2
iScreen Vision Inc.	\$758	\$0	\$0	\$0	12	0	0	0	12	0
IsoTis OrthoBiologics, Inc.	\$23,482	\$0	\$0	\$0	53	0	0	0	46	0
ISTO TECHNOLOGIES, INC.	\$150,742	\$29,738	\$1,585,370	\$2,653,149	336	10	23	23	243	4
ITxM Clinical Services	\$139,900	\$0	\$0	\$0	93	0	0	0	4	6
ITxM Diagnostics	\$35,321	\$0	\$0	\$0	32	0	0	0	1	3
Ivoclar Vivadent, Inc.	\$781,041	\$49,617	\$0	\$0	3,360	22	0	0	1,986	5
iWalk, Inc.	\$0	\$64,000	\$0	\$0	0	1	0	0	0	1
J. Morita USA, Inc.	\$139,176	\$76,316	\$0	\$0	70	39	0	0	13	6
Janssen Biotech, Inc.	\$2,965,564	\$2,007,514	\$0	\$0	109,762	3	0	0	21,686	53
Janssen Diagnostics, LLC	\$213,237	\$604,876	\$0	\$0	92	63	0	0	67	8
Janssen Global Services, LLC	\$249,660	\$0	\$0	\$0	160	0	0	0	60	0
Janssen Pharmaceuticals, Inc	\$40,138,187	\$0	\$0	\$0	503,541	0	0	0	92,696	157
Janssen Products, LP	\$4,035,936	\$0	\$0	\$0	7,617	0	0	0	2,770	0
Janssen Research & Development, LLC	\$4,312,856	\$94,571,320	\$0	\$0	1,849	13,715	0	0	458	161
Janssen Scientific Affairs, LLC	\$9,980,344	\$200,750	\$0	\$0	12,983	3	0	0	5,403	20
Jazz Pharmaceuticals Inc.	\$3,276,764	\$1,378,286	\$0	\$0	18,007	100	0	0	6,664	51
Johnson & Johnson Health Care Systems Inc.	\$27,861	\$0	\$0	\$0	194	0	0	0	138	6
Johnson & Johnson Medical Devices & Diagnostics Group - Latin America, L.L.C.	\$51,443	\$0	\$0	\$0	62	0	0	0	18	0
Johnson & Johnson Vision Care, Inc.	\$2,336,819	\$11,171,678	\$0	\$0	26,614	668	0	0	10,345	1
Johnson and Johnson International	\$154,250	\$0	\$0	\$0	990	0	0	0	364	1
Joint Active Systems, Inc.	\$0	\$0	\$634,941	\$634,941	0	0	4	4	1	0

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Jumar Corporation	\$3,885	\$0	\$0	\$0	4	0	0	0	4	0
JustRight Surgical LLC	\$7,500	\$0	\$1,718,409	\$4,717,000	2	0	7	7	6	2
K2M, Inc.	\$3,640,867	\$100,572	\$0	\$0	3,349	18	0	0	650	12
Kadmon Corporation LLC	\$115,439	\$1,135,125	\$0	\$0	76	34	0	0	43	6
KADMON PHARMACEUTICALS LLC	\$93,388	\$0	\$0	\$0	2,009	0	0	0	1,258	1
Kairos Surgical Inc	\$37,090	\$0	\$0	\$0	213	0	0	0	138	0
Kaleo, Inc.	\$40,581	\$0	\$0	\$0	312	0	0	0	258	0
Kansas Cryosurgery Associates LLC	\$102,507	\$0	\$0	\$0	176	0	0	0	16	0
KARL STORZ Endoscopia Mexico, S.A.	\$582	\$0	\$0	\$0	5	0	0	0	1	0
KARL STORZ ENDOVISION, INC.	\$224,758	\$0	\$0	\$0	6	0	0	0	2	1
KARL STORZ IMAGING, INC.	\$39,995	\$0	\$0	\$0	10	0	0	0	1	1
KARL STORZ Lithotripsy-America, Inc.	\$1,036	\$0	\$0	\$0	15	0	0	0	15	0
KARLSTORZ Endoscopy-America	\$7,119,073	\$829,164	\$0	\$0	6,330	109	0	0	1,346	353
Katena Products, Inc.	\$23,851	\$0	\$0	\$0	68	0	0	0	68	0
KaVo Technologies LLC	\$317	\$0	\$0	\$0	7	0	0	0	7	0
KCI USA, Inc	\$1,442,984	\$2,121,002	\$0	\$0	6,392	78	0	0	4,190	39
Kensey Nash	\$10,909	\$0	\$0	\$0	7	0	0	0	4	0
Kerr Corporation	\$1,587,065	\$3,050	\$0	\$0	2,516	1	0	0	1,927	0
Keystone Dental Inc.	\$442,513	\$27,460	\$948,131	\$948,131	56	7	1	1	59	0
Keystone Surgical Systems, Inc.	\$26,169	\$0	\$0	\$0	339	0	0	0	165	2
Kinamed, Inc.	\$18,368	\$8,000	\$0	\$0	22	1	0	0	22	0
KLS Martin L.P.	\$1,242,185	\$0	\$0	\$0	1,481	0	0	0	807	37
KONAN MEDICAL USA, INC.	\$70,670	\$0	\$0	\$0	20	0	0	0	4	2
Konica Minolta Medical Imaging USA, Inc.	\$5,000	\$0	\$0	\$0	4	0	0	0	4	0
Koven Technology, Inc.	\$528	\$0	\$0	\$0	3	0	0	0	1	1
Kowa Company, Ltd.	\$14,165	\$0	\$0	\$0	16	0	0	0	7	0
KOWA RESEARCH INSTITUTE, INC.	\$110,797	\$0	\$0	\$0	175	0	0	0	39	0
Kuraray America Inc.	\$220,625	\$4,095	\$0	\$0	112	1	0	0	52	0
LAAx, Inc.	\$0	\$15,350	\$0	\$0	0	1	0	0	0	0
Laboratorios Ferring Ltda.	\$7,412	\$0	\$0	\$0	2	0	0	0	1	0
Laboratorios Pfizer Lda.	\$8,901	\$0	\$0	\$0	1	0	0	0	1	0
Laboratory Supply Company	\$67	\$0	\$0	\$0	1	0	0	0	1	0

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
LAKE REGION MANUFACTURING, INC. D.B.A. LAKE REGION MEDICAL	\$134,671	\$0	\$0	\$0	78	0	0	0	22	0
Lannett Company Inc	\$28,529	\$0	\$0	\$0	618	0	0	0	332	0
Lantheus Medical Imaging, Inc.	\$1,191,227	\$8,208	\$0	\$0	5,240	5	0	0	2,070	20
Laser Specialty Medical, LLC	\$131,400	\$0	\$148,497	\$244,029	18	0	13	13	18	0
LDR HOLDING CORPORATION	\$0	\$0	\$19,099	\$256,554	0	0	2	2	2	0
LDR SPINE USA, INC	\$1,655,852	\$720,391	\$0	\$0	5,643	58	0	0	1,582	14
LEICA MICROSYSTEMS INC.	\$241,811	\$83	\$0	\$0	31	1	0	0	19	4
LeMaitre Vascular, Inc.	\$369,725	\$24,158	\$0	\$0	1,319	4	0	0	656	15
LENSAR, Inc.	\$404,165	\$0	\$3,880,130	\$4,440,228	760	0	16	16	380	0
LEO Pharma AS	\$169,325	\$1,993,053	\$0	\$0	311	326	0	0	53	2
LEO Pharma Inc.	\$761,458	\$67,305	\$0	\$0	12,499	37	0	0	3,797	3
Liberty Surgical, Inc	\$15,393	\$0	\$0	\$0	85	0	0	0	48	0
Life Spine, Inc.	\$768,539	\$0	\$0	\$0	405	0	0	0	106	0
Life Technologies Corporation	\$21,385	\$0	\$0	\$0	137	0	0	0	100	0
LifeCell Corporation	\$5,529,237	\$270,760	\$0	\$0	17,700	21	0	0	5,413	61
LifeNet Health Inc.	\$89,791	\$54,009	\$0	\$0	77	4	0	0	29	2
LifeScan, Inc.	\$92,203	\$107,541	\$0	\$0	89	9	0	0	26	3
LifeSource	\$175,500	\$0	\$0	\$0	11	0	0	0	1	1
LifeWatch Services Inc	\$312,798	\$0	\$0	\$0	1,078	0	0	0	880	28
Lightsscalpel LLC	\$208,559	\$0	\$0	\$0	34	0	0	0	11	0
LILLY USA, LLC	\$10,030,185	\$4,550,202	\$0	\$0	187,783	425	0	0	58,800	182
Linde Gas North America, LLC	\$0	\$15,285	\$0	\$0	0	10	0	0	0	10
Lineage Therapeutics Inc.	\$4,593	\$0	\$0	\$0	161	0	0	0	134	0
Linvatec Corporation	\$1,961,002	\$0	\$0	\$0	1,302	0	0	0	437	5
LIPOSCIENCE, INC.	\$750,192	\$137,416	\$0	\$0	8,669	4	0	0	4,921	1
Liventa Biosciences Inc.	\$0	\$1,000	\$0	\$0	0	1	0	0	1	0
Lombard Medical Technologies Inc.	\$153,201	\$28,328	\$0	\$0	1,353	8	0	0	734	7
LSI SOLUTIONS INC	\$337,587	\$0	\$0	\$0	165	0	0	0	161	1
Luitpold Pharmaceuticals Inc	\$608,387	\$2,208,290	\$0	\$0	8,731	587	0	0	4,444	26
LUMARA HEALTH INC.	\$123,294	\$434,613	\$0	\$0	6,448	95	0	0	4,358	3
Lumenis, Inc	\$430,698	\$0	\$0	\$0	121	0	0	0	119	0

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Luminex Corporation	\$32,062	\$0	\$0	\$0	19	0	0	0	0	19
Luminex Molecular Diagnostics	\$61,790	\$0	\$0	\$0	7	0	0	0	0	7
Lundbeck LLC	\$7,633,708	\$1,455,083	\$0	\$0	50,828	121	0	0	11,742	62
Lung Biotechnology Corp	\$248,195	\$0	\$0	\$0	5,158	0	0	0	1,919	0
Lutonix, Inc.	\$762,247	\$124,000	\$0	\$0	621	37	0	0	160	19
LVB Acquisition, Inc.	\$0	\$0	\$4,452,870	\$5,552,685	0	0	19	19	19	0
M2S, Inc	\$368,164	\$0	\$0	\$0	24	0	0	0	14	0
MacuLogix, Inc.	\$70,680	\$0	\$0	\$0	122	0	0	0	62	1
Magellan Diagnostics Inc	\$20,790	\$0	\$0	\$0	46	0	0	0	45	0
Maillefer Instruments Holding Sarl	\$2,031,631	\$0	\$0	\$0	49	0	0	0	11	1
Mallinckrodt LLC	\$3,477,302	\$2,408,532	\$0	\$0	49,347	64	0	0	21,691	49
Maquet Cardiopulmonary AG	\$421,146	\$0	\$0	\$0	18	0	0	0	3	1
Maquet Cardiovascular L.L.C.	\$38,780	\$4,729	\$0	\$0	58	1	0	0	41	1
Maquet Cardiovascular U.S. Sales, L.L.C.	\$544,511	\$27,061	\$0	\$0	5,478	4	0	0	3,251	51
Maquet Critical Care AB	\$152	\$0	\$0	\$0	1	0	0	0	1	0
Maquet GmbH	\$56	\$0	\$0	\$0	1	0	0	0	1	0
Mar Cor Purification, Inc.	\$1,120	\$0	\$0	\$0	1	0	0	0	1	0
Marathon Pharmaceuticals, LLC	\$90,426	\$0	\$0	\$0	120	0	0	0	87	0
Marine Polymer Technologies, Inc.	\$48,000	\$0	\$0	\$0	1	0	0	0	1	0
Masimo Corporation	\$2,433,149	\$0	\$0	\$0	1,691	0	0	0	769	110
Materialise USA LLC	\$46,873	\$0	\$0	\$0	10	0	0	0	10	0
Maxx Orthopedics, Inc.	\$284,638	\$22,300	\$0	\$0	110	13	0	0	40	0
McKesson Corporation	\$204	\$0	\$0	\$0	2	0	0	0	0	1
McKesson Medical-Surgical, Inc.	\$2,387	\$0	\$0	\$0	24	0	0	0	15	1
McKesson Specialty Care Distribution Corp.	\$414,487	\$0	\$0	\$0	843	0	0	0	727	1
McKesson Technologies, Inc.	\$141,916	\$0	\$0	\$0	57	0	0	0	8	9
Meda Pharmaceuticals, Inc.	\$1,573,413	\$1,268,018	\$0	\$0	22,678	291	0	0	11,734	0
MEDAC PHARMA, INC.	\$64,411	\$0	\$0	\$0	553	0	0	0	458	0
MEDACTA USA	\$3,077,577	\$133,077	\$0	\$0	2,358	11	0	0	225	0
Medafor, Inc.	\$164,410	\$0	\$0	\$0	229	0	0	0	99	0
MED-EL Corporation	\$286,404	\$50,480	\$0	\$0	924	7	0	0	189	12
MEDELA INC.	\$55,397	\$74,541	\$0	\$0	61	1	0	0	25	28

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Mederi Therapeutics Inc	\$357,422	\$0	\$0	\$0	134	0	0	0	57	0
Medical Action Industries Inc	\$7,541	\$0	\$0	\$0	4	0	0	0	3	1
Medical Engineering and Development Institute, Inc.	\$716,833	\$377,702	\$0	\$0	511	117	0	0	53	28
Medical Graphics Corporation	\$4,995	\$0	\$0	\$0	18	0	0	0	13	2
MEDICAL INVESTMENT ADVISORS LLC	\$80,031	\$0	\$0	\$0	25	0	0	0	8	0
Medical Modeling Inc.	\$35,364	\$0	\$0	\$0	14	0	0	0	10	2
MEDICAL POSITIONING INC	\$21,477	\$0	\$0	\$0	2	0	0	0	2	0
Medicomp Inc	\$16,072	\$0	\$0	\$0	343	0	0	0	218	0
Medicrea International	\$1,443	\$0	\$0	\$0	8	0	0	0	5	0
Medicrea USA, Corp.	\$367,991	\$26,128	\$0	\$0	507	9	0	0	163	3
Medigus Ltd.	\$47,247	\$31,005	\$0	\$0	18	2	0	0	16	2
Medimetriks Pharmaceuticals, Inc.	\$770,646	\$0	\$261,092	\$790,264	1,689	0	11	11	1,462	0
MedImmune, LLC	\$1,656,740	\$24,377,530	\$0	\$0	8,720	489	0	0	5,186	59
Medinc of Texas	\$48,042	\$0	\$0	\$0	319	0	0	0	213	1
Medistim USA, Inc.	\$6,655	\$0	\$0	\$0	104	0	0	0	74	0
Medivance, Inc.	\$3,080	\$0	\$0	\$0	58	0	0	0	54	0
Medivation Inc.	\$1,431,751	\$8,453,921	\$0	\$0	12,025	1,426	0	0	5,089	29
Medivators Inc.	\$123,558	\$0	\$0	\$0	482	0	0	0	252	57
Medline Industries, Inc.	\$1,158,687	\$117,575	\$10,880,223	\$23,893,986	940	12	11	11	586	194
MedOne Surgical Inc	\$6,000	\$0	\$0	\$0	1	0	0	0	1	0
MedShape, Inc.	\$148,377	\$0	\$0	\$0	53	0	0	0	38	0
Medspira, LLC	\$94,678	\$14,552	\$0	\$0	4	2	0	0	1	2
MEDTEC, Inc.	\$1,445	\$0	\$0	\$0	18	0	0	0	15	0
Medtronic MiniMed, Inc.	\$1,215,926	\$460,636	\$0	\$0	14,093	200	0	0	3,479	32
Medtronic Sofamor Danek USA, Inc.	\$68,513,138	\$2,774,867	\$0	\$0	32,234	1,070	0	0	7,522	32
Medtronic USA, Inc.	\$34,539,119	\$8,035,029	\$0	\$0	66,299	1,055	0	0	14,931	44
Medtronic Vascular, Inc.	\$24,528,384	\$41,206,757	\$0	\$0	117,935	6,614	0	0	18,109	160
Medtronic Xomed, Inc.	\$4,423,099	\$186,241	\$0	\$0	10,830	17	0	0	5,017	29
Medtronic, Inc.	\$215,874	\$3,842,012	\$0	\$0	1,848	984	0	0	541	18
Medventure Technology Corporation	\$1,250	\$0	\$0	\$0	1	0	0	0	1	0
Medwest Associates	\$37,322	\$0	\$0	\$0	97	0	0	0	70	0
Medyssey USA, Inc	\$76,206	\$20,000	\$0	\$0	14	1	0	0	14	1

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Megadyne Medical Products Inc	\$6,000	\$0	\$0	\$0	4	0	0	0	4	0
Meisinger USA, LLC	\$125,710	\$0	\$0	\$0	183	0	0	0	46	0
Memphis Cryo Associates LP	\$44,000	\$0	\$107,823	\$110,400	110	0	10	10	10	0
Menicon America, Inc.	\$3,208	\$0	\$0	\$0	81	0	0	0	75	0
Mentor Worldwide LLC	\$1,695,777	\$816,334	\$0	\$0	7,900	525	0	0	2,670	17
Mercator MedSystems, Inc.	\$5,324	\$176,383	\$868,263	\$864,758	30	50	3	3	31	15
Mercedes Medical, LLC	\$6,523	\$0	\$0	\$0	686	0	0	0	132	0
Merck Sharp & Dohme Corporation	\$26,889,780	\$97,674,149	\$0	\$0	317,906	6,456	0	0	91,639	242
Mercury Enterprises, Inc.	\$926	\$0	\$0	\$0	32	0	0	0	22	0
Meridian Bioscience Inc.	\$60,422	\$183,508	\$0	\$0	306	26	0	0	211	55
Meridian Medical Technologies, Inc.	\$0	\$464,102	\$0	\$0	0	33	0	0	0	2
Merit Medical Systems Inc	\$1,158,216	\$371,029	\$837,126	\$905,719	921	60	2	2	465	23
Merz North America, Inc.	\$2,707,323	\$0	\$0	\$0	23,120	0	0	0	7,969	10
Merz Pharmaceuticals GmbH	\$765,889	\$551,492	\$0	\$0	203	53	0	0	84	16
Merz Pharmaceuticals, LLC	\$0	\$2,802,055	\$0	\$0	0	94	0	0	8	14
Merz, Inc.	\$2,964	\$0	\$0	\$0	45	0	0	0	23	0
Metrex Research, LLC	\$6,030	\$0	\$0	\$0	87	0	0	0	84	0
Metric Medical Devices, Inc.	\$2,392	\$0	\$25,000	\$25,000	37	0	1	1	36	0
Mevion_Medical_Systems_Inc	\$2,531	\$0	\$0	\$0	27	0	0	0	21	0
Michigan Mobile Urology Services LLC	\$273,372	\$0	\$0	\$0	591	0	0	0	53	0
MicroAire Surgical Instruments LLC	\$350,795	\$0	\$0	\$0	409	0	0	0	92	7
Microgenics Corporation	\$327,473	\$0	\$0	\$0	170	0	0	0	6	19
MicrolineSurgical Inc	\$38,306	\$0	\$0	\$0	15	0	0	0	6	0
Micromed Inc	\$7,711	\$0	\$0	\$0	47	0	0	0	42	0
MicroPort Orthopedics Inc	\$7,706,041	\$9,840	\$0	\$0	1,965	2	0	0	237	6
Mid America Management, LLC	\$1,052,725	\$0	\$0	\$0	5	0	0	0	5	0
Mid-Atlantic Surgical Systems, LLC	\$61,173	\$0	\$0	\$0	305	0	0	0	140	0
Midmark Corporation	\$63,311	\$0	\$0	\$0	91	0	0	0	90	0
Midsouth Orthopedics	\$3,570	\$0	\$0	\$0	28	0	0	0	21	0
Midwest Cryotherapy LP	\$305,108	\$0	\$8,259	\$11,842	324	0	1	1	27	0
Midwest Surgical Alliance, LLC	\$235,000	\$0	\$1,057,590	\$1,346,803	2	0	18	18	17	0
Millennium Pharmaceuticals, Inc.	\$8,348,599	\$51,055,513	\$0	\$0	13,421	2,283	0	0	4,406	150

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Millennium Spine, LLC	\$1,430,000	\$0	\$1,011,923	\$1,108,927	4	0	3	3	3	0
Milliken Healthcare Products, LLC	\$615	\$165,591	\$0	\$0	32	4	0	0	32	0
Mindray DS USA, Inc.	\$32,493	\$2,125	\$0	\$0	165	36	0	0	140	8
Minimally Invasive Devices Inc.	\$314	\$0	\$0	\$0	3	0	0	0	2	0
MIPRO US, Inc.	\$488	\$15,650	\$0	\$0	6	8	0	0	8	0
Miromatrix Medical Inc.	\$28,516	\$214,773	\$56,980	\$110,940	16	10	2	2	14	1
MIS Implants Technologies, Inc.	\$66,807	\$10,000	\$0	\$0	94	1	0	0	67	0
Misonix Inc	\$12,461	\$0	\$0	\$0	69	0	0	0	57	0
Mission Pharmacal Company	\$225,800	\$0	\$0	\$0	11,840	0	0	0	7,336	0
Mist Pharmaceuticals, LLC	\$2,574	\$0	\$0	\$0	90	0	0	0	58	0
MLH-RX, LLC	\$19,600	\$0	\$0	\$0	5	0	0	0	5	0
Mobile Cryosurgical Partners LP	\$200,932	\$0	\$319,341	\$64,360	14	0	15	15	15	0
Mobius Therapeutics, LLC	\$14,537	\$0	\$0	\$0	58	0	0	0	50	0
Modern Orthopedic Consultants	\$7,171	\$0	\$0	\$0	98	0	0	0	67	0
Mohawk Hospital Equipment, Inc.	\$70,225	\$0	\$0	\$0	4	0	0	0	0	4
Molnlycke Health Care AB	\$22,054	\$0	\$0	\$0	5	0	0	0	3	0
Molnlycke Health Care US, LLC	\$191,068	\$0	\$0	\$0	615	0	0	0	399	35
Monaghan Medical Corporation	\$24,900	\$0	\$0	\$0	81	0	0	0	48	30
Monteris Medical Corporation	\$259,781	\$30,900	\$0	\$0	210	3	0	0	65	11
Moore Medical LLC	\$28	\$0	\$0	\$0	1	0	0	0	1	0
MORTARA INSTRUMENT INC	\$133,334	\$50,605	\$0	\$0	1	1	0	0	1	1
MRI Interventions, Inc.	\$390,491	\$199,944	\$4,702,409	\$4,726,987	203	3	104	104	157	19
Musculoskeletal Transplant Foundation Inc.	\$1,393,931	\$3,039,406	\$0	\$0	1,456	133	0	0	639	33
Mydent International, Inc.	\$2,851	\$0	\$0	\$0	27	0	0	0	27	0
Mylan Institutional Inc.	\$28,538	\$5,490	\$0	\$0	30	1	0	0	4	0
Mylan Pharmaceuticals Inc.	\$230,203	\$51,439	\$0	\$0	538	10	0	0	420	8
Mylan Specialty L.P.	\$2,111,001	\$2,849,194	\$0	\$0	35,343	655	0	0	17,820	3
Nanosphere, Inc.	\$48,709	\$0	\$0	\$0	25	0	0	0	13	6
Nanovis LLC	\$8,942	\$0	\$592,248	\$1,518,367	7	0	6	6	8	0
National Dentex Corporation	\$30,833	\$0	\$0	\$0	892	0	0	0	750	0
Navidea Biopharmaceuticals, Inc.	\$21,445	\$40,579	\$0	\$0	59	18	0	0	22	4
NDI Medical, LLC	\$109,902	\$7,177	\$1,476,141	\$292,037	233	1	13	13	136	2

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
NeedleTech Products, Inc.	\$1,406	\$0	\$0	\$0	9	0	0	0	9	0
NeoMedix Corporation	\$257,671	\$0	\$0	\$0	45	0	0	0	14	2
Neomend, Inc.	\$284,702	\$2,083,905	\$0	\$0	2,045	208	0	0	1,469	30
NeoTract Inc.	\$97,242	\$24,525	\$151,469	\$169,299	440	18	3	3	296	0
Neovanta Medical, Inc.	\$18,000	\$583	\$0	\$0	12	7	0	0	1	6
Nestle HealthCare Nutrition Inc.	\$193	\$0	\$0	\$0	9	0	0	0	9	0
Neurohabilitation Corporation	\$12,000	\$0	\$0	\$0	4	0	0	0	4	0
NeuroLogica Corporation, A Subsidiary of Samsung Electronics	\$3,873	\$0	\$0	\$0	57	0	0	0	22	5
NeuroMetrix Inc	\$102,569	\$35,740	\$0	\$0	7	4	0	0	6	3
Neuronetics, Inc.	\$269,311	\$101,042	\$0	\$0	1,810	51	0	0	851	7
NeuroPace, Inc.	\$81,901	\$1,781,771	\$688,509	\$2,389,668	201	252	6	6	65	26
Neurotech NA, Inc.	\$2,000	\$0	\$0	\$0	1	0	0	0	1	0
NeuroTherm, Inc.	\$62,008	\$0	\$0	\$0	432	0	0	0	282	0
NeuWave Medical, Inc.	\$1,289,221	\$0	\$0	\$0	480	0	0	0	211	53
New England Cryotherapy LP	\$49,384	\$0	\$124,237	\$53,347	97	0	9	9	9	0
New Wave Surgical Corp.	\$3,000	\$0	\$77,000	\$3,316,617	5	0	17	17	19	0
NEW WORLD MEDICAL, INC.	\$34,114	\$15,000	\$0	\$0	19	1	0	0	11	4
New York Blood Center, Inc.	\$801,472	\$454,916	\$0	\$0	30	4	0	0	13	13
Nexus-Dx, inc	\$3,000	\$13,416	\$0	\$0	1	6	0	0	1	2
Nexxt Spine, LLC	\$469,103	\$0	\$0	\$0	147	0	0	0	50	0
NICO Corporation	\$385,297	\$0	\$0	\$0	289	0	0	0	95	0
NIDEK CO., LTD.	\$623,992	\$0	\$0	\$0	75	0	0	0	6	1
Nidek Incorporated	\$56,290	\$0	\$0	\$0	8	0	0	0	8	0
Nihon Cochlear Co Ltd	\$11,372	\$0	\$0	\$0	3	0	0	0	1	0
Nihon Kohden America, Inc.	\$25,677	\$20,222	\$0	\$0	22	1	0	0	17	0
NinePoint Medical, Inc.	\$332,114	\$22,313	\$0	\$0	321	3	0	0	120	11
Nippon Boehringer Ingelheim Co., Ltd.	\$253,474	\$0	\$0	\$0	93	0	0	0	10	0
Niveus Medical, Inc	\$0	\$4,000	\$122,020	\$255,607	0	1	6	6	6	1
Nobel Biocare USA	\$4,762,327	\$0	\$0	\$0	17,748	0	0	0	5,592	0
Nonin Medical, Inc.	\$95,176	\$384,382	\$0	\$0	66	28	0	0	38	0
Norgenix Pharmaceuticals, LLC	\$5,026	\$0	\$0	\$0	200	0	0	0	193	0

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
NormaTec Industries, LP	\$166	\$0	\$0	\$0	2	0	0	0	2	0
North Alabama Surgical Services GP, LLC	\$240,000	\$0	\$30,000	\$30,000	3	0	3	3	3	0
North Alabama Surgical Services, LLC	\$720,000	\$0	\$120,000	\$120,000	3	0	3	3	3	0
North Idaho Surgical Cooperative, LLC	\$0	\$0	\$287,383	\$287,383	0	0	11	11	10	0
North Shore Surgical Services, LLC	\$0	\$0	\$30,000	\$30,000	0	0	1	1	1	0
North Texas Surgical Services, LLC	\$123,080	\$0	\$320,000	\$320,000	10	0	10	10	10	0
Northeast Cryotherapy LP	\$81,257	\$0	\$0	\$0	524	0	0	0	43	0
Nova Biomedical Corporation	\$4,542	\$0	\$0	\$0	7	0	0	0	7	0
Novabone Products	\$62,772	\$0	\$119,997	\$119,997	32	0	1	1	7	0
Novadaq Technologies Inc.	\$1,272,493	\$1,402,384	\$0	\$0	2,128	94	0	0	1,704	45
Novartis Consumer Health Inc.	\$175,049	\$0	\$0	\$0	35	0	0	0	14	0
Novartis Pharma AG	\$977,245	\$42,114,667	\$0	\$0	390	1,132	0	0	129	62
Novartis Pharmaceuticals Corporation	\$18,969,638	\$235,922,540	\$0	\$0	154,758	5,369	0	0	38,898	128
Novartis Vaccines and Diagnostics Inc	\$1,304,435	\$3,469,877	\$0	\$0	7,394	151	0	0	4,511	10
Novartis Vaccines and Diagnostics S.r.l.	\$9,433	\$0	\$0	\$0	4	0	0	0	3	0
Noven Pharmaceuticals, Inc.	\$1,742,801	\$331,180	\$0	\$0	27,388	53	0	0	12,259	5
Novian Health Inc.	\$36,638	\$31,996	\$0	\$0	6	5	0	0	3	0
Novo Nordisk AS	\$2,946,814	\$17,525,012	\$0	\$0	3,836	16,723	0	0	526	42
Novo Nordisk Health Care AG	\$332,284	\$0	\$0	\$0	150	0	0	0	22	0
Novo Nordisk Inc	\$23,117,565	\$4,341,304	\$0	\$0	593,222	457	0	0	68,967	117
Novocure Inc.	\$1,074,427	\$898,512	\$0	\$0	1,193	173	0	0	315	25
Novocure Israel Ltd	\$0	\$351,714	\$0	\$0	0	6	0	0	0	1
NovoCure Limited	\$0	\$263,175	\$16,251,903	\$16,251,903	0	2	16	16	16	1
NovoSource, Inc.	\$10,245	\$0	\$3,294,050	\$2,193,882	9	0	66	66	50	0
NPS Pharmaceuticals, Inc.	\$734,518	\$2,144,182	\$0	\$0	2,996	660	0	0	1,863	46
NSK AMERICA CORPORATION	\$17,328	\$0	\$0	\$0	7	0	0	0	5	0
Nucletron Operations B.V.	\$4,968	\$0	\$0	\$0	16	0	0	0	11	0
NuMED for Children, LLC	\$90,000	\$0	\$0	\$0	3	0	0	0	3	0
Nuo Therapeutics	\$110,375	\$0	\$0	\$0	175	0	0	0	74	1
NuTech Plus, Inc.	\$3,826	\$0	\$0	\$0	12	0	0	0	3	0
Nutech Spine, Inc.	\$307,221	\$0	\$703,250	\$3,510,669	97	0	23	23	43	0

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
NuVasive, Inc.	\$22,175,132	\$484,018	\$0	\$0	16,700	199	0	0	2,077	19
NxStage Medical, Inc.	\$461,153	\$82,360	\$0	\$0	1,145	25	0	0	757	6
Oasis Medical, Inc.	\$116,952	\$0	\$0	\$0	61	0	0	0	19	0
OBI Biologics, Inc	\$0	\$0	\$2	\$32,198	0	0	2	2	1	0
Octapharma USA, Inc.	\$130,793	\$392,843	\$0	\$0	560	64	0	0	399	6
Ocular Therapeutix, Inc.	\$82,804	\$1,598,959	\$0	\$0	120	224	0	0	59	0
Oklahoma Urologic Therapies LP	\$406,623	\$0	\$616,515	\$584,850	167	0	14	14	13	0
Olea Medical	\$72,242	\$0	\$0	\$0	45	0	0	0	4	0
Olive Medical Corporation	\$81	\$0	\$342,508	\$354,786	2	0	7	7	8	0
Olympus Biotech Corporation	\$14,472	\$0	\$0	\$0	58	0	0	0	52	0
Olympus Corporation	\$32,553	\$0	\$0	\$0	7	0	0	0	0	1
Olympus Corporation of the Americas	\$3,668,744	\$0	\$0	\$0	4,282	0	0	0	639	34
Olympus Latin America, Inc.	\$11,341	\$0	\$0	\$0	14	0	0	0	6	0
Olympus Medical Systems Corporation	\$289,567	\$1,262,611	\$0	\$0	102	47	0	0	47	4
Olympus Winter & Ibe GmbH	\$8,287	\$0	\$0	\$0	2	0	0	0	1	0
OMNI SURGICAL LLC	\$361,591	\$0	\$0	\$0	27	0	0	0	8	0
OmniGuide, Inc.	\$263,240	\$0	\$2,250	\$1,350	626	0	1	1	447	7
OMNIlife science, Inc	\$4,076,532	\$151,086	\$3,682,622	\$28	384	13	28	28	100	1
Omnyx LLC	\$25,952	\$26,069	\$0	\$0	6	1	0	0	4	2
One Lambda, Inc.	\$69,368	\$2,969	\$0	\$0	13	3	0	0	6	4
OneBlood, Inc.	\$140,658	\$0	\$0	\$0	1	0	0	0	1	0
Onset Dermatology, Inc	\$50,592	\$0	\$0	\$0	985	0	0	0	497	0
On-x Life Technologies, Inc	\$133,225	\$619,688	\$0	\$0	539	118	0	0	246	13
ONY, Inc.	\$8,646	\$10,000	\$0	\$0	60	1	0	0	54	0
Onyx Pharmaceuticals, Inc., an Amgen subsidiary	\$4,718,319	\$51,671,993	\$0	\$0	11,999	395	0	0	3,526	64
OPHTEC USA, Inc.	\$0	\$34,225	\$0	\$0	0	35	0	0	33	0
OptiMedica Corporation	\$1,652,708	\$0	\$0	\$0	29	0	0	0	29	0
OPTOS PLC	\$366,482	\$0	\$0	\$0	968	0	0	0	191	0
Optos, Inc.	\$338,459	\$0	\$0	\$0	2,970	0	0	0	1,841	0
OPTOVUE, INC.	\$193,894	\$36,836	\$0	\$0	610	4	0	0	465	1
OraSure Technologies Inc.	\$10,747	\$203,583	\$0	\$0	43	3	0	0	5	16
Orexo US, Inc.	\$205,609	\$0	\$0	\$0	2,004	0	0	0	1,209	0

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Origio Inc.	\$38,277	\$0	\$0	\$0	22	0	0	0	6	1
Ormco Corporation	\$4,196,741	\$10,080	\$0	\$0	5,670	5	0	0	2,008	1
ORTHO DEVELOPMENT CORPORATION	\$3,038,300	\$0	\$0	\$0	840	0	0	0	89	1
Ortho Kinematics, Inc.	\$1,276	\$0	\$0	\$0	28	0	0	0	28	0
Ortho Organizers, Inc.	\$946,751	\$0	\$0	\$0	2,276	0	0	0	718	3
Ortho Restore, LLC	\$320,000	\$0	\$604,429	\$491,479	1	0	12	12	10	0
Ortho Technology, Inc	\$23,687	\$0	\$0	\$0	477	0	0	0	74	0
Orthofix International N.V.	\$4,093,068	\$398,724	\$0	\$0	2,798	91	0	0	947	0
OrthoPediatrics Corp.	\$669,692	\$0	\$14,343,864	\$4,236,683	590	0	90	90	248	1
Orthopedic Sciences, Inc.	\$245,666	\$0	\$1,800	\$275,400	4	0	2	2	3	0
OrthoSensor Inc.	\$177,277	\$18,775	\$7,033,346	\$6,348,923	247	14	21	21	130	1
Ortho-Stat Caribbean, Corp.	\$8,890	\$0	\$0	\$0	8	0	0	0	4	0
Osmotica Pharmaceutical Corp.	\$0	\$767,390	\$0	\$0	0	162	0	0	43	0
Osprey Medical Inc	\$101,245	\$65,671	\$0	\$0	21	7	0	0	8	7
Osseus Fusion Systems, LLC	\$243,207	\$0	\$0	\$0	12	0	0	0	6	0
Ossur Americas., Inc	\$60	\$0	\$0	\$0	2	0	0	0	1	0
Osteogenics Biomedical Inc.	\$144,899	\$0	\$2	\$2,313,764	30	0	2	2	12	8
Osteomed LLC	\$836,049	\$0	\$0	\$0	3,101	0	0	0	1,290	0
OsteoReady LLC	\$1,776,072	\$0	\$890,000	\$890,000	690	0	1	1	397	0
Oticon Medical, LLC	\$138,512	\$50,149	\$0	\$0	102	3	0	0	55	31
Otsuka America Pharmaceutical, Inc.	\$23,613,355	\$206,460	\$0	\$0	152,069	4	0	0	38,269	95
Otsuka Pharmaceutical Co., Ltd.	\$4,037,315	\$10,000	\$0	\$0	429	1	0	0	57	2
Otsuka Pharmaceutical Development & Commercialization, Inc.	\$663,467	\$16,799,443	\$0	\$0	172	629	0	0	87	49
Owens & Minor Distribution, Inc.	\$397,637	\$0	\$0	\$0	78	0	0	0	4	61
Oxford Immunotec Inc.	\$309,387	\$0	\$0	\$0	658	0	0	0	403	0
Ozark Cryosurgery, LLC	\$112,000	\$0	\$70,600	\$224,000	7	0	7	7	7	0
Pacific Medical, Inc	\$84,343	\$0	\$0	\$0	609	0	0	0	264	0
Pacira Pharmaceuticals Incorporated	\$2,492,684	\$2,596,291	\$0	\$0	9,568	181	0	0	5,266	16
Pajunk Medical Systems, LP	\$102,940	\$0	\$0	\$0	26	0	0	0	10	0
Panasonic Corporation of North America	\$300	\$0	\$0	\$0	1	0	0	0	0	1
Panasonic Healthcare Corporation of North America	\$71	\$0	\$0	\$0	1	0	0	0	1	0

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Panoramic Rental Corp.	\$40,445	\$0	\$0	\$0	86	0	0	0	85	0
Par Pharmaceutical, Inc.	\$220,600	\$626,674	\$0	\$0	16,357	13	0	0	3,059	0
Paradigm Spine, LLC	\$228,338	\$0	\$21,095,339	\$36,472,148	775	0	66	66	439	0
Paragon 28, Inc.	\$102,477	\$0	\$3,239,800	\$3,026,467	222	0	28	28	198	0
ParaPRO, LLC	\$8,098	\$0	\$0	\$0	6	0	0	0	4	0
PARI RESPIRATORY EQUIPMENT, INC.	\$69,057	\$0	\$0	\$0	15	0	0	0	1	0
Parkedale Pharmaceuticals, Inc.	\$103	\$0	\$0	\$0	2	0	0	0	0	1
PBM Pharmaceuticals	\$452	\$0	\$0	\$0	37	0	0	0	37	0
Peerless Surgical Inc.	\$20,149	\$0	\$0	\$0	206	0	0	0	86	0
PENTAX of America, Inc.	\$458,994	\$38,588	\$0	\$0	360	5	0	0	105	34
Penumbra, Inc.	\$5,073,920	\$1,760,384	\$1,983,325	\$7,576,957	3,170	331	16	16	1,197	74
Pernix Therapeutics Holdings, Inc.	\$374,630	\$381,303	\$0	\$0	1,887	11	0	0	1,413	0
Perrigo Company plc	\$187,098	\$10,821,946	\$0	\$0	67	33	0	0	52	2
Peter Brasseler Holdings, LLC	\$1,464,560	\$0	\$0	\$0	670	0	0	0	439	2
Pfizer AG	\$18,035	\$0	\$0	\$0	1	0	0	0	1	0
Pfizer Canada Inc	\$7,671	\$0	\$0	\$0	4	0	0	0	1	0
Pfizer Corporation Hong Kong Limited	\$21,232	\$0	\$0	\$0	4	0	0	0	3	0
Pfizer Inc.	\$53,263,218	\$234,173,044	\$0	\$0	561,424	134,792	0	0	110,889	371
Pfizer International LLC	\$1,073,254	\$487,192	\$0	\$0	669	7	0	0	179	4
Pfizer International Operations (S.A.S.)	\$7,828	\$0	\$0	\$0	1	0	0	0	1	0
Pfizer Japan Inc.	\$113,498	\$0	\$0	\$0	19	0	0	0	17	0
Pfizer Limited	\$27,256	\$0	\$0	\$0	15	0	0	0	11	0
Pfizer Pharma GmbH	\$5,851	\$0	\$0	\$0	3	0	0	0	2	0
Pfizer Pharmaceuticals Korea Limited	\$7,932	\$0	\$0	\$0	2	0	0	0	2	0
Pfizer Pharmaceuticals LLC	\$187,024	\$0	\$0	\$0	2,624	0	0	0	1,333	3
Pfizer, S.L.	\$32,172	\$0	\$0	\$0	3	0	0	0	2	1
Phadia AB	\$17,660	\$16,082	\$0	\$0	11	8	0	0	4	4
Phadia US Inc.	\$714,716	\$0	\$0	\$0	15,519	0	0	0	11,041	0
Pharmacia & Upjohn Company LLC	\$10,114	\$39,648	\$0	\$0	10	3	0	0	0	6
Pharmacyclics, Inc	\$530,263	\$7,577,746	\$0	\$0	2,853	759	0	0	1,550	36
Philips Electronics North America Corporation	\$3,975,923	\$2,134,861	\$0	\$0	3,869	89	0	0	1,736	57

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Photocure Inc	\$82,195	\$0	\$0	\$0	427	0	0	0	271	1
Physician Discoveries, LLC	\$214,161	\$0	\$554,920	\$468,652	123	0	99	99	99	0
Pinnacle Biologics, Inc	\$157,431	\$19,350	\$0	\$0	377	2	0	0	120	12
Pinnacle, Inc	\$20,028	\$0	\$0	\$0	298	0	0	0	121	0
Planmeca USA, Inc.	\$227,721	\$0	\$0	\$0	498	0	0	0	452	3
Plasma Surgical, Inc.	\$154,368	\$0	\$0	\$0	778	0	0	0	472	0
Plexikon Inc.	\$0	\$1,697,540	\$0	\$0	0	134	0	0	22	19
Precision Eye Services	\$35,467	\$0	\$0	\$0	2	0	0	0	2	0
Precision Spine, Inc.	\$1,609,521	\$0	\$0	\$0	217	0	0	0	70	0
Premier Dental Products Company	\$31,052	\$0	\$0	\$0	195	0	0	0	55	0
PRN Medical Services, LLC	\$3,111	\$0	\$0	\$0	200	0	0	0	178	0
Procedural Orthopedics Inc	\$8,009	\$0	\$0	\$0	44	0	0	0	29	0
Prodigy Surgical Distribution, Inc.	\$61,923	\$0	\$0	\$0	135	0	0	0	65	0
Professional Hospital Supply, Inc.	\$47,440	\$0	\$0	\$0	9	0	0	0	0	9
Prometheus Laboratories Inc.	\$727,907	\$2,294,601	\$0	\$0	11,846	870	0	0	5,133	20
Promius Pharma LLC	\$478,659	\$0	\$0	\$0	6,358	0	0	0	1,979	0
Pronova Corporation	\$410	\$0	\$0	\$0	30	0	0	0	30	0
Prosidyan, Inc	\$309	\$0	\$1,490,001	\$3,150,002	6	0	9	9	12	0
ProStrakan, Inc.	\$60,915	\$130,054	\$0	\$0	2,335	3	0	0	1,302	3
PruGen, Inc. Pharmaceuticals	\$3,443	\$0	\$0	\$0	62	0	0	0	60	0
PSS World Medical Inc.	\$4,635	\$0	\$0	\$0	10	0	0	0	8	2
Pulmonx Corporation	\$0	\$0	\$1,583,401	\$96,790	0	0	17	17	16	0
PULPDENT CORPORATION	\$78,363	\$68,800	\$0	\$0	64	2	0	0	61	0
Purdue Pharma	\$151,710	\$0	\$0	\$0	11	0	0	0	2	0
Purdue Pharma L.P.	\$6,100,435	\$5,888,865	\$0	\$0	62,141	559	0	0	23,386	12
Purdue Pharma of Puerto Rico	\$937	\$0	\$0	\$0	52	0	0	0	18	0
Purdue Transdermal Technologies L.P.	\$1,559,656	\$0	\$0	\$0	2,677	0	0	0	1,379	19
Pursuit Vascular, Inc.	\$0	\$0	\$297,400	\$405,400	0	0	5	5	5	0
Pylant Medical	\$8,431	\$0	\$0	\$0	114	0	0	0	82	0
QIAGEN Sciences, LLC	\$764,608	\$195,078	\$0	\$0	1,380	7	0	0	720	83
QOL Medical, LLC	\$209,508	\$323,533	\$0	\$0	687	58	0	0	288	12
Quest Medical Inc.	\$60,366	\$0	\$0	\$0	25	0	0	0	15	0

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Quest Medical LLC	\$14,558	\$0	\$0	\$0	116	0	0	0	52	0
Questcor Pharmaceuticals	\$8,608,099	\$2,215,128	\$0	\$0	50,617	98	0	0	8,696	18
Quidel Corporation	\$535,039	\$587,346	\$0	\$0	282	48	0	0	200	5
R&M Distributing, LLC	\$24,882	\$0	\$0	\$0	147	0	0	0	71	0
Radlink, Inc	\$8,157	\$0	\$1,490,388	\$1,954,670	5	0	7	7	8	0
Raintree Essix Inc	\$213,416	\$0	\$0	\$0	1,366	0	0	0	1,169	0
Ramsay Medical, Inc	\$6,340	\$0	\$0	\$0	76	0	0	0	49	0
Ranbaxy Inc.	\$1,867,779	\$163,421	\$0	\$0	12,925	3	0	0	2,152	0
Rapid PAtrogen Screening, Inc.	\$11,446	\$392,579	\$7,483,775	\$16,784,900	267	45	67	67	286	8
Raptor Pharmaceuticals	\$197,545	\$607,201	\$0	\$0	1,550	30	0	0	62	5
RARE DISEASE THERAPEUTICS, INC.	\$111	\$0	\$0	\$0	6	0	0	0	6	0
RECORDATI_RARE_DISEASES_INC.	\$30,345	\$0	\$0	\$0	49	0	0	0	11	0
RedMedical, LLC	\$8,344	\$0	\$0	\$0	54	0	0	0	45	0
Regeneron Pharmaceuticals, Inc.	\$6,242,720	\$38,812,754	\$0	\$0	7,852	8,085	0	0	2,383	44
Reichert, Inc.	\$180,556	\$0	\$0	\$0	51	0	0	0	21	0
Reliance Medical Products, Inc.	\$152	\$7,053	\$0	\$0	5	1	0	0	5	1
Remel, Inc.	\$47,972	\$20,000	\$0	\$0	36	1	0	0	2	7
Renaissance Pharma, Inc.	\$17,782	\$0	\$0	\$0	700	0	0	0	532	0
ResMed Corp	\$99,271	\$319,076	\$0	\$0	1,564	49	0	0	980	4
Respiratory Technologies, Inc.	\$57,627	\$0	\$0	\$0	2,567	0	0	0	1,780	0
Response Biomedical Corp.	\$4,326	\$51,049	\$0	\$0	1	14	0	0	0	3
Retrophin, Inc.	\$59,560	\$1,138,121	\$0	\$0	187	66	0	0	160	11
Reverse Medical Corporation	\$19,050	\$0	\$0	\$487,827	4	0	7	7	9	0
ReVision Optics, Inc.	\$314,180	\$28	\$0	\$0	89	2	0	0	35	0
rEVO Biologics, Inc.	\$20,827	\$138,235	\$0	\$0	74	9	0	0	44	7
RF Surgical Systems, Inc.	\$7,941	\$0	\$0	\$0	3	0	0	0	3	0
Rhodes Pharmaceuticals L.P.	\$964	\$140,824	\$0	\$0	8	6	0	0	5	0
Richard Wolf Medical Instruments Corp.	\$101,460	\$0	\$0	\$0	191	0	0	0	112	3
Richard-Allan Scientific Company	\$46,229	\$0	\$0	\$0	28	0	0	0	1	19
RIKCO INTERNATIONAL, LLC	\$144,056	\$0	\$0	\$0	1,343	0	0	0	381	0
Rinat Neuroscience Corp.	\$2,837	\$0	\$0	\$0	2	0	0	0	0	1
Roanoke Area Surgical Lasers, LLC	\$124,066	\$0	\$70,000	\$210,000	12	0	7	7	8	0

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Roche Diagnostics Corporation	\$1,502,431	\$1,130,277	\$0	\$0	8,662	23	0	0	5,277	56
Roche Diagnostics GmbH	\$69,632	\$751,072	\$0	\$0	14	22	0	0	5	1
Roche Diagnostics International Ltd	\$139,354	\$0	\$0	\$0	60	0	0	0	13	0
Roche Diagnostics Operations, Inc.	\$34,689	\$6,280,874	\$0	\$0	38	371	0	0	9	12
Roche Health Solutions Inc.	\$109,200	\$0	\$0	\$0	22	0	0	0	3	0
Roche Molecular Systems, Inc.	\$94,815	\$3,448,285	\$0	\$0	64	15	0	0	20	4
Roche Products Limited	\$204,165	\$15,085,027	\$0	\$0	334	2,349	0	0	101	57
Roche TCRC, Inc.	\$151,876	\$1,618,272	\$0	\$0	55	105	0	0	35	18
Rochester Medical Corporation	\$27,299	\$0	\$0	\$0	1,357	0	0	0	941	0
Rocky Mountain Cryotherapy LP	\$30,100	\$0	\$203,655	\$0	45	0	5	5	5	0
Roho, Inc.	\$575	\$0	\$0	\$0	6	0	0	0	0	6
Romark Laboratories, LC	\$317,844	\$0	\$2,561,458	\$3,508,300	5,094	0	23	23	2,194	0
Rotation Medical, Inc.	\$50,543	\$0	\$0	\$0	82	0	0	0	49	0
Roxane Laboratories, Inc.	\$467,824	\$0	\$0	\$0	30	0	0	0	5	1
RSB Spine, LLC	\$0	\$0	\$621,934	\$306,615	0	0	5	5	5	0
RSW Medical Company, Inc.	\$18,414	\$0	\$0	\$0	76	0	0	0	65	0
RT Oncology Services Corporation	\$25,572	\$0	\$8,724,464	\$12,884,772	82	0	312	312	295	0
RTI Surgical, Inc.	\$1,211,992	\$53,466	\$0	\$0	1,076	7	0	0	518	2
Safco Dental Supply Co.	\$7,596	\$0	\$0	\$0	57	0	0	0	57	0
Safe Orthopaedics, LLC	\$8,724	\$0	\$0	\$0	43	0	0	0	25	0
SafeRay Spine, LLC	\$490	\$0	\$0	\$0	14	0	0	0	14	0
Safewire, LLC	\$1,629	\$0	\$728,297	\$728,297	22	0	12	12	24	0
Sagent Pharmaceuticals, Inc.	\$3,832	\$0	\$0	\$0	55	0	0	0	55	0
Salix Pharmaceuticals, Ltd	\$9,848,751	\$79,450	\$0	\$0	98,119	6	0	0	29,449	36
Samsung Electronics America, Inc.	\$258	\$0	\$0	\$0	3	0	0	0	2	0
San Francisco Surgical Services, LLC	\$83,083	\$0	\$60,000	\$60,000	3	0	2	2	2	0
Sandoz Inc.	\$170,440	\$446,130	\$0	\$0	4,627	8	0	0	2,295	0
Sanofi Pasteur Inc.	\$2,149,410	\$10,434,521	\$0	\$0	33,509	6,603	0	0	20,732	47
SANOFI US SERVICES INC.	\$4,696,583	\$153,182,917	\$0	\$0	896	49,676	0	0	393	244
SANOFI-AVENTIS U.S. LLC	\$17,532,023	\$6,861,414	\$0	\$0	168,199	434	0	0	58,184	186
Saphena Medical, Inc.	\$0	\$0	\$560,000	\$560,000	0	0	10	10	10	0

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Sauflon Pharmaceuticals Inc	\$5,828	\$0	\$0	\$0	65	0	0	0	64	0
Scanlan International Inc	\$128,305	\$0	\$0	\$0	87	0	0	0	72	0
SciCan Inc	\$25,397	\$0	\$0	\$0	31	0	0	0	31	0
Scioderm	\$533,799	\$0	\$0	\$0	82	0	0	0	9	0
SCS Boehringer Ingelheim Comm.V	\$2,996	\$0	\$0	\$0	7	0	0	0	3	0
SeaPearl Inc	\$10,905	\$0	\$0	\$0	69	0	0	0	44	0
SeaSpine, Inc.	\$1,496,864	\$0	\$0	\$0	147	0	0	0	40	0
Seattle Genetics, Inc.	\$1,290,016	\$41,288,895	\$0	\$0	4,873	2,065	0	0	1,857	27
Sebela Pharmaceuticals Inc.	\$6,909	\$0	\$0	\$0	330	0	0	0	267	0
Second Sight Medical Products, Inc.	\$84,585	\$0	\$0	\$0	25	0	0	0	11	4
SEFL Cryo Associates LLC	\$29,205	\$0	\$61,543	\$30,571	50	0	5	5	5	0
Sekisui Diagnostics LLC	\$3,688	\$187,711	\$0	\$0	1	5	0	0	1	2
Semprus Biosciences Corp.	\$17	\$0	\$0	\$0	1	0	0	0	1	0
Senate Surgical Distribution, LLC	\$0	\$0	\$160,132	\$273,295	0	0	26	26	25	0
Seneca Medical, Inc.	\$57,983	\$0	\$0	\$0	45	0	0	0	0	17
Septodont Inc.	\$243,616	\$116,240	\$0	\$0	1,365	5	0	0	396	0
Sequent Medical, Inc.	\$34,736	\$0	\$255,297	\$255,297	99	0	6	6	28	0
Sequoia Surgical Distributors, LLC	\$469,200	\$0	\$198,576	\$499,419	3	0	12	12	11	0
Shimadzu Precision Instruments, Inc.	\$19,529	\$0	\$0	\$0	61	0	0	0	15	26
Shionogi Inc	\$2,093,509	\$46,343	\$0	\$0	25,875	5	0	0	11,552	5
Shire North American Group Inc	\$4,782,491	\$19,979,414	\$0	\$0	77,747	2,584	0	0	25,107	44
Shofu Dental corp	\$157,846	\$0	\$0	\$0	140	0	0	0	129	0
Shoulder Options, Inc.	\$246	\$0	\$0	\$0	3	0	0	0	3	0
SI-BONE, Inc.	\$1,081,948	\$3,940,603	\$6,542,918	\$45,247,147	4,712	827	63	63	2,059	15
Siemens Hearing Instruments, Inc.	\$4,580	\$0	\$0	\$0	104	0	0	0	48	1
Siemens Medical Solutions USA, Inc.	\$11,393,047	\$1,492,400	\$0	\$0	7,660	68	0	0	2,434	101
Siesta Medical, Inc.	\$0	\$0	\$85,618	\$95,995	0	0	7	7	7	0
Sigma-Tau Pharmaceuticals, Inc.	\$503,177	\$1,135,082	\$0	\$0	610	26	0	0	320	29
SIGN Fracture Care International	\$9,456	\$0	\$0	\$0	15	0	0	0	12	0
Silk Road Medical, Inc.	\$87,525	\$852,338	\$0	\$0	7	13	0	0	7	11
Silvergate Pharmaceuticals, Inc.	\$13,057	\$32,897	\$0	\$0	22	1	0	0	6	0
Sintea Plustek, LLC	\$22,373	\$0	\$0	\$0	4	0	0	0	2	0

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Sirona Dental Systems Inc.	\$1,144,190	\$0	\$0	\$0	1,357	0	0	0	555	0
Sirtex Medical Inc	\$2,223,552	\$0	\$0	\$0	4,853	0	0	0	1,415	0
Skeletal Dynamics LLC	\$166,087	\$66,415	\$0	\$0	570	18	0	0	249	1
Skeletal Kinetics LLC	\$11,766	\$0	\$0	\$0	54	0	0	0	49	1
Skyline Medical Inc.	\$135,574	\$0	\$50,000	\$57,192	4	0	1	1	3	0
Small Bone Innovations Inc.	\$840,112	\$173,115	\$0	\$0	676	12	0	0	263	41
SmartHealth Inc	\$33,204	\$0	\$0	\$0	497	0	0	0	105	0
SMG Pharmaceuticals, LLC	\$384	\$0	\$0	\$0	3	0	0	0	3	0
Smith & Nephew, Inc.	\$41,802,547	\$2,462,420	\$0	\$0	68,767	436	0	0	19,808	91
Smiths Medical ASD, Inc.	\$71,956	\$0	\$0	\$0	57	0	0	0	56	0
SNAP Diagnostics LLC	\$264,287	\$0	\$442,951	\$357,305	3	0	2	2	3	0
Sobi, Inc	\$40,702	\$123,125	\$0	\$0	641	2	0	0	465	3
Somersault Orthopedics, Inc	\$0	\$0	\$65,000	\$65,000	0	0	2	2	2	0
SonaCare Medical, LLC	\$165,349	\$29,447	\$189,183	\$189,183	175	5	21	21	87	1
Sonendo Inc	\$713,197	\$0	\$0	\$0	161	0	0	0	83	0
SONOCINE, INC.	\$30,633	\$0	\$3,933,087	\$3,933,087	23	0	27	27	33	3
Sony Electronics Inc.	\$10,501	\$0	\$0	\$0	10	0	0	0	4	1
Sorin Crm Usa, Inc.	\$356,789	\$868,544	\$0	\$0	1,291	213	0	0	468	19
Sorin Group USA Inc.	\$505,871	\$2,369,758	\$0	\$0	2,103	221	0	0	573	65
Sotera Wireless, Inc.	\$45,091	\$0	\$0	\$0	70	0	0	0	21	17
Southeast Cryotherapy LP	\$31,400	\$0	\$43,808	\$42,351	12	0	1	1	1	0
Southern Surgical Solutions, LLC	\$385,000	\$0	\$290,350	\$2,295,906	1	0	11	11	10	0
SouthTech Orthopedics	\$17,452	\$0	\$0	\$0	75	0	0	0	45	0
SPACELABS HEALTHCARE INC	\$103,506	\$0	\$0	\$0	22	0	0	0	0	21
Specialty Surgical Instrumentation	\$384,519	\$0	\$0	\$0	28	0	0	0	8	0
Specialty Surgical Products, Inc.	\$139,285	\$0	\$0	\$0	1	0	0	0	1	0
Spectrum Pharmaceuticals Inc.	\$0	\$2,715,725	\$0	\$0	0	257	0	0	0	20
Spectrum Surgical Instruments Corp.	\$47,689	\$0	\$0	\$0	48	0	0	0	1	27
Spinal Elements, Inc.	\$45,740	\$0	\$0	\$0	59	0	0	0	26	0
Spinal Modulation Inc.	\$259,945	\$23,840	\$8,625	\$28,031	222	2	1	1	71	0
Spine View, Inc.	\$28,334	\$0	\$289,323	\$373,270	36	0	10	10	33	0
Spine Wave, Inc.	\$1,033,820	\$0	\$1,125,186	\$1,515,120	1,462	0	20	20	352	0

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Spineart USA Inc	\$500,413	\$0	\$0	\$0	243	0	0	0	56	1
SpineGuard, Inc.	\$174,381	\$0	\$0	\$0	189	0	0	0	84	0
Spineology Inc.	\$93,444	\$146,935	\$3,548,535	\$2,709,527	357	46	43	43	376	0
SpineSelect, LLC	\$107,143	\$0	\$97,874	\$320,000	15	0	2	2	3	0
SpineSmith Holdings, LLC	\$17,014	\$128	\$0	\$0	109	1	0	0	73	0
Spineworks LLC	\$6,280	\$0	\$0	\$0	2	0	0	0	1	0
Spiracur Inc.	\$190,123	\$0	\$0	\$0	770	0	0	0	411	0
Spiration, Inc.	\$395,056	\$859,002	\$0	\$0	742	234	0	0	203	21
Spirus Medical LLC	\$24,064	\$0	\$0	\$0	8	0	0	0	4	0
SportsTek Medical, Inc	\$7,150	\$0	\$0	\$0	56	0	0	0	34	0
Spring Bioscience Corporation	\$9,076	\$0	\$0	\$0	4	0	0	0	0	1
SPS Medical Supply Corp.	\$2,416	\$0	\$0	\$0	34	0	0	0	13	16
SRS Medical Systems, Inc.	\$890	\$0	\$0	\$0	11	0	0	0	10	0
SS White Burs, Inc.	\$191,024	\$0	\$0	\$0	228	0	0	0	127	0
St. Jude Medical, Inc.	\$46,314,531	\$7,298,312	\$0	\$0	95,005	2,268	0	0	20,338	209
Stability Inc.	\$15,026	\$0	\$0	\$0	41	0	0	0	39	0
STANDARD DIAGNOSTICS, INC.	\$13,387	\$2,000	\$0	\$0	8	1	0	0	1	0
Stanmore, Inc.	\$13,268	\$0	\$0	\$0	30	0	0	0	15	0
Steelhead Surgical Inc	\$1,609	\$0	\$0	\$0	24	0	0	0	21	0
Stereotaxis Inc	\$107,749	\$38,360	\$0	\$0	182	1	0	0	93	0
Sterilmed, Inc.	\$5,614	\$0	\$0	\$0	12	0	0	0	5	0
STERIS Corporation	\$610,848	\$0	\$0	\$0	105	0	0	0	26	7
Strategic Dentistry LLC	\$436,001	\$0	\$275,000	\$275,000	227	0	1	1	61	0
Streck, Inc.	\$43,723	\$0	\$0	\$0	41	0	0	0	2	39
Stryker Corporation	\$73,135,901	\$5,689,436	\$0	\$0	85,338	881	0	0	19,058	427
Sucampo Pharma Americas, LLC	\$0	\$981,008	\$0	\$0	0	168	0	0	0	26
Sumitomo Dainippon Pharma Co., Ltd.	\$19,127	\$0	\$0	\$0	79	0	0	0	23	0
Summit Medical	\$58,493	\$0	\$283,042	\$283,042	20	0	3	3	7	0
Summit Surgical Corp.	\$2,561	\$0	\$0	\$0	20	0	0	0	12	0
SUN PHARMACEUTICAL INDUSTRIES LIMITED	\$11,175	\$51,249	\$0	\$0	33	12	0	0	10	5
Sunovion Pharmaceuticals Inc.	\$17,227,360	\$23,990,642	\$0	\$0	162,001	12,527	0	0	26,889	27
Sunquest Information Systems, Inc.	\$17,360	\$0	\$0	\$0	28	0	0	0	19	1

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Sunstar Americas, Inc.	\$56,334	\$0	\$0	\$0	183	0	0	0	175	0
Supernus Pharmaceuticals, Inc.	\$874,032	\$0	\$0	\$0	30,626	0	0	0	6,801	0
Supreme Orthopedic Systems, LLC	\$81,906	\$0	\$0	\$0	349	0	0	0	171	0
Surefire Medical, Inc.	\$194,779	\$0	\$0	\$0	134	0	0	0	88	0
Surgi-Care, Inc.	\$54,620	\$0	\$0	\$0	31	0	0	0	25	4
SurgiQuest, Inc.	\$44,796	\$43,936	\$0	\$0	641	11	0	0	543	7
Swedish Orphan Biovitrum AB	\$85,966	\$957,608	\$0	\$0	14	45	0	0	7	14
Synapse Biomedical Inc	\$258,583	\$109,538	\$205,976	\$249,453	69	18	6	6	4	8
SYNCARDIA SYSTEMS, INC	\$139,046	\$704,961	\$9,578,932	\$4,442,579	400	81	31	31	105	25
Synergetics USA, Inc	\$593,698	\$0	\$0	\$0	231	0	0	0	131	0
Synergeyes, Inc.	\$131,726	\$0	\$0	\$0	1,031	0	0	0	630	0
Synergy Medical Systems LLC	\$212	\$0	\$0	\$0	11	0	0	0	6	0
Synthes USA Products LLC	\$255,132	\$1,216,638	\$0	\$0	89	48	0	0	63	6
Systemex America, Inc.	\$98,419	\$194,150	\$0	\$0	293	8	0	0	73	57
Systemex Inostics Inc	\$82,927	\$0	\$0	\$0	155	0	0	0	98	2
Tactile Systems Technology Inc	\$197,974	\$104,313	\$186,361	\$192,321	1,240	19	3	3	836	8
Takeda California, Inc.	\$45,308	\$0	\$0	\$0	9	0	0	0	4	2
Takeda Development Center Americas, Inc.	\$299,439	\$55,832,368	\$0	\$0	84	16,166	0	0	84	71
Takeda Pharmaceutical Company, Limited	\$130,547	\$4,194,251	\$0	\$0	73	13	0	0	16	3
Takeda Pharmaceuticals America, Inc.	\$24,744,651	\$0	\$0	\$0	290,036	0	0	0	59,362	1
Takeda Pharmaceuticals International, Inc.	\$1,453,370	\$3,483,377	\$0	\$0	779	541	0	0	276	19
Takeda Pharmaceuticals Puerto Rico LLC	\$12,102	\$0	\$0	\$0	796	0	0	0	310	0
Takeda Pharmaceuticals U.S.A., Inc.	\$5,268,991	\$0	\$0	\$0	17,638	0	0	0	7,554	34
Takeda Vaccines, Inc.	\$263,969	\$241,246	\$0	\$0	51	18	0	0	7	3
Tandem Diabetes Care, Inc.	\$962,277	\$0	\$0	\$0	2,715	0	0	0	1,035	56
Team 1 Orthopaedics Inc	\$8,280	\$0	\$0	\$0	36	0	0	0	16	0
Team_Makena_LL_C	\$22,950	\$0	\$0	\$0	417	0	0	0	210	0
TearLab Corp	\$63,004	\$0	\$0	\$0	1,525	0	0	0	1,093	0
TEI Biosciences Inc	\$335,276	\$0	\$0	\$0	2,541	0	0	0	1,305	0
TEI Medical Inc.	\$291,215	\$0	\$0	\$0	4,646	0	0	0	1,814	0
Teleflex Incorporated	\$193,876	\$0	\$0	\$0	26	0	0	0	1	1
Teleflex Medical Incorporated	\$1,242,332	\$3,233	\$0	\$0	1,592	1	0	0	928	195

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Tem Systems, Inc.	\$71,992	\$0	\$0	\$0	255	0	0	0	140	0
Tenex Health Inc.	\$196,212	\$0	\$0	\$0	1,359	0	0	0	690	0
Terumo BCT, Inc.	\$304,310	\$0	\$0	\$0	517	0	0	0	167	6
Teva Pharmaceuticals USA, Inc.	\$27,059,925	\$45,936,155	\$0	\$0	178,472	13,306	0	0	40,110	45
The Atlanta Dental Supply Co.	\$2,674	\$0	\$0	\$0	37	0	0	0	32	0
The Binding Site Inc.	\$441	\$0	\$0	\$0	17	0	0	0	14	0
The Burkhart Dental Supply Company	\$2,501	\$0	\$0	\$0	20	0	0	0	18	0
The Cameron-Ehlen Group, Inc.	\$50,261	\$0	\$0	\$0	323	0	0	0	196	0
The Medicines Company	\$1,330,124	\$1,685,492	\$0	\$0	11,328	362	0	0	5,510	85
The North Carolina Mutual Wholesale Drug Company Inc	\$0	\$0	\$1,941,282	\$3,857,032	0	0	55	55	54	0
The Orthopaedic Implant Company	\$0	\$0	\$1,215,882	\$2,425,882	0	0	29	29	28	0
The Res. Rep. Office of Ferring Pharmaceuticals Ltd. in HCMC	\$5,221	\$0	\$0	\$0	7	0	0	0	5	0
The Spectranetics Corporation	\$3,406,415	\$315,734	\$0	\$0	9,088	82	0	0	3,078	7
The Walman Optical Company	\$36,759	\$0	\$0	\$0	119	0	0	0	104	0
Theken Spine, LLC	\$2,499	\$0	\$0	\$0	35	0	0	0	32	0
Theragenics Corporation	\$110,531	\$50,000	\$0	\$0	19	7	0	0	3	1
Therakos, Inc.	\$100,963	\$0	\$0	\$0	73	0	0	0	57	10
Theratechnologies Inc.	\$11,531	\$77,015	\$0	\$0	114	75	0	0	75	9
Theravance Biopharma Inc.	\$1,324,484	\$13,764,095	\$0	\$0	1,920	666	0	0	695	7
Thermo Fisher Scientific Asheville LLC	\$21,708	\$0	\$0	\$0	25	0	0	0	0	17
Think Surgical, Inc.	\$196,979	\$0	\$0	\$0	28	0	0	0	5	0
Thoratec Europe Limited	\$52,385	\$0	\$0	\$0	23	0	0	0	8	0
Tokuyama Dental America Inc.	\$59,835	\$0	\$0	\$0	121	0	0	0	118	0
TOLMAR Pharmaceuticals, Inc.	\$48,513	\$0	\$0	\$0	2,379	0	0	0	1,628	0
TOLMAR, INC.	\$15,029	\$2,874,534	\$0	\$0	9	353	0	0	9	2
TomoTherapy Incorporated	\$33,000	\$0	\$0	\$0	5	0	0	0	0	2
TOPCON CORPORATION	\$111,993	\$672,824	\$0	\$0	23	23	0	0	16	0
TOPCON MEDICAL SYSTEMS, INC.	\$170,212	\$0	\$0	\$0	47	0	0	0	26	0
Topera, Inc.	\$92,663,838	\$0	\$3,081,604	\$0	234	0	19	19	125	0
Torax Medical, Inc.	\$739,999	\$163,167	\$0	\$0	1,157	40	0	0	454	12
Toray International America Inc.	\$487	\$0	\$0	\$0	5	0	0	0	5	0

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
Tornier, Inc.	\$5,466,971	\$0	\$0	\$0	4,039	0	0	0	892	4
Toshiba America Medical Systems, Inc.	\$605,197	\$105,870	\$0	\$0	931	13	0	0	408	18
TOSHIBA MEDICAL RESEARCH INSTITUTE USA INC.	\$7,290	\$201,898	\$0	\$0	8	7	0	0	8	2
Toshiba Medical Systems Corporation	\$7,279	\$93,395	\$0	\$0	4	4	0	0	2	4
Tosoh Bioscience, Inc.	\$175,764	\$0	\$0	\$0	379	0	0	0	303	2
Total Joint Orthopedics, Inc.	\$29,740	\$0	\$0	\$0	85	0	0	0	31	0
Transcend Medical, Inc.	\$269,984	\$380,671	\$1,417	\$297,500	61	24	2	2	37	3
Transenterix, Inc.	\$77,344	\$0	\$0	\$0	137	0	0	0	25	0
Trasonic Systems Inc.	\$119,326	\$0	\$19,716	\$19,716	5	0	2	2	4	1
Traslational Cancer Drugs Pharma S.L.	\$0	\$130,562	\$0	\$0	0	2	0	0	0	1
Trice Medical, Inc.	\$157	\$0	\$0	\$0	9	0	0	0	8	0
Trilliant Surgical Ltd.	\$105,921	\$0	\$0	\$0	271	0	0	0	198	0
TriReme Medical LLC	\$23,742	\$0	\$380,660	\$323,183	354	0	2	2	182	0
Tri-State Cryosurgical Partnerships LP	\$350,777	\$0	\$0	\$0	457	0	0	0	39	0
TriVascular, Inc.	\$989,046	\$163,553	\$0	\$0	4,323	77	0	0	1,393	18
Tru-Form Optics, Inc	\$1,500	\$0	\$0	\$0	1	0	0	0	1	0
TRUMPF MEDICAL SYSTEMS, INC.	\$42,999	\$0	\$0	\$0	35	0	0	0	8	10
Tulsa Dental Products LLC	\$6,651,750	\$474	\$0	\$0	10,471	5	0	0	5,426	4
Turn-Key Medical, Inc.	\$2,478	\$0	\$0	\$0	17	0	0	0	16	0
UCB Biosciences Inc.	\$40,101	\$8,878,037	\$0	\$0	31	1,984	0	0	51	13
UHS Surgical Services, Inc.	\$9,515	\$0	\$0	\$0	230	0	0	0	205	0
Ultradent Products Inc	\$1,822,985	\$0	\$1,000	\$1,000	5,357	0	2	2	771	0
United Therapeutics Corporation	\$2,484,110	\$58,679,664	\$0	\$0	7,171	5,890	0	0	2,426	23
Universal Hospital Services, Inc.	\$19,035	\$0	\$0	\$0	18	0	0	0	8	0
Universal Instrumentation LLC	\$244,123	\$0	\$81,892	\$1,000,000	18	0	1	1	2	0
Universal Medical, Inc.	\$49,954	\$0	\$45,554	\$45,554	3	0	3	3	6	0
Unix Japan Group Inc	\$2,753	\$0	\$0	\$0	2	0	0	0	1	0
UOC USA, Inc.	\$93,349	\$0	\$0	\$0	34	0	0	0	16	0
Upsher-Smith Laboratories Inc.	\$1,416,605	\$97,893	\$0	\$0	6,797	5	0	0	3,116	1
UroGPO LLC	\$51,534	\$0	\$336,250	\$0	48	0	154	154	154	0
Urologix, Inc.	\$30,964	\$0	\$0	\$0	1,213	0	0	0	612	0
Uroplasty, Inc.	\$618,529	\$3,000	\$0	\$0	5,157	1	0	0	2,537	0

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
US Endoscopy	\$1,316,488	\$0	\$0	\$0	483	0	0	0	291	21
US Implant Solutions, LLC	\$3,481	\$0	\$0	\$0	19	0	0	0	16	0
US WorldMeds, LLC	\$1,378,141	\$0	\$1,096,811	\$512,340	7,606	0	9	9	1,728	0
Valeant Pharmaceuticals North America LLC	\$4,029,064	\$1,236,008	\$0	\$0	22,222	117	0	0	9,870	6
Valeritas, Inc.	\$190,993	\$126,550	\$0	\$0	8,613	291	0	0	3,742	1
Validus Pharmaceuticals LLC	\$122,623	\$0	\$0	\$0	2,118	0	0	0	148	0
Valneva Austria GmbH	\$0	\$40,407	\$0	\$0	0	25	0	0	2	0
Vanda Pharmaceuticals Inc.	\$28,478	\$245,425	\$0	\$0	228	70	0	0	197	3
Vapotherm Inc	\$59,616	\$0	\$5,020,000	\$218,179	105	0	5	5	40	0
Varian Medical Systems, Inc.	\$780,032	\$2,070,540	\$0	\$0	1,863	25	0	0	783	32
Vasamed, Inc	\$14,671	\$0	\$0	\$0	71	0	0	0	51	0
Vasc-Alert LLC	\$246,156	\$3,100	\$940,233	\$940,233	2	2	7	7	8	1
Vascular Dynamics, Inc.	\$6,344	\$0	\$0	\$0	15	0	0	0	9	0
Vascular Solutions, Inc.	\$271,937	\$0	\$0	\$0	2,011	0	0	0	1,307	11
Vector Surgical, LLC	\$6,969	\$0	\$65,000	\$1,300,000	53	0	1	1	39	0
Veniti, Inc.	\$28,616	\$0	\$321,149	\$1,361,254	34	0	8	8	10	0
Ventana Medical Systems, Inc.	\$943,213	\$3,371,545	\$0	\$0	986	452	0	0	157	27
Veran Medical Technologies, Inc.	\$155,605	\$10,322	\$0	\$0	299	1	0	0	227	1
Verathon Inc.	\$9,202	\$16,851	\$0	\$0	76	13	0	0	75	0
Vermillion, Inc.	\$118,265	\$0	\$0	\$0	1,803	0	0	0	1,458	0
Vertebral Technologies, Inc.	\$64,191	\$0	\$8,860,108	\$10,760,846	128	0	64	64	101	0
VERTEX PHARMACEUTICALS INCORPORATED	\$2,859,922	\$21,241,949	\$0	\$0	1,978	800	0	0	391	93
Verthermia, Inc.	\$0	\$0	\$1,023	\$857,581	0	0	3	3	3	0
Vertiflex, Inc.	\$100,243	\$38,962	\$19,663	\$8,923	363	22	3	3	59	0
Vidacare Corporation	\$101,313	\$46,505	\$0	\$0	40	10	0	0	20	1
VIEWRAY INC	\$313,531	\$58,334	\$1,875,684	\$2,843,311	86	1	13	13	55	0
Vifor (International) Ltd.	\$114,982	\$0	\$0	\$0	55	0	0	0	11	0
ViiV Healthcare Company	\$2,472,078	\$6,453,590	\$0	\$0	16,492	2,197	0	0	2,943	14
Vilex in Tennessee, Inc.	\$163,734	\$0	\$0	\$0	88	0	0	0	22	0
Vioptix Inc	\$18,820	\$0	\$0	\$0	152	0	0	0	152	0
Viracor-IBT Laboratories, Inc.	\$4,164	\$5,070	\$0	\$0	5	1	0	0	6	0
Virginia Blood Services	\$23,028	\$0	\$0	\$0	16	0	0	0	0	2

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
VISAGE IMAGING, INC	\$78	\$0	\$0	\$0	1	0	0	0	1	0
VISIONARY OPTICS LLC	\$50,599	\$0	\$0	\$0	32	0	0	0	30	0
VisionCare Ophthalmic Technologies, Inc.	\$266,426	\$1,206	\$0	\$0	531	1	0	0	355	1
VisionScope Technologies, LLC	\$95,959	\$0	\$0	\$0	36	0	0	0	36	0
Vista Orthopedics, LLC	\$81,000	\$0	\$208,245	\$95,996	2	0	10	10	9	0
Visualase, Inc.	\$158,005	\$0	\$0	\$0	810	0	0	0	283	1
VitaHEAT Medical, LLC	\$550	\$12,000	\$0	\$0	3	1	0	0	3	0
Vital Art and Science, LLC	\$3,165	\$13,972	\$10,000	\$331,940	2	1	1	1	1	1
Vital Images, Inc.	\$105,508	\$345,259	\$0	\$0	161	6	0	0	62	9
Vitaphone_USA_Corporation	\$7,053	\$0	\$0	\$0	191	0	0	0	157	0
Vitrolife Inc.	\$3,731	\$0	\$0	\$0	25	0	0	0	25	0
Vivex Biomedical, Inc.	\$330,518	\$0	\$2,364,000	\$3,710,005	76	0	19	19	24	0
VIVUS, Inc.	\$1,272,048	\$697,420	\$0	\$0	17,672	242	0	0	9,406	1
VOCO America Inc.	\$326,471	\$0	\$0	\$0	2,368	0	0	0	2,118	0
Volcano Corporation	\$1,798,862	\$999,008	\$0	\$0	4,552	73	0	0	1,605	17
Volpara Solutions Ltd	\$725	\$0	\$0	\$0	16	0	0	0	12	0
W. L. Gore & Associates, Inc.	\$6,360,466	\$1,293,995	\$0	\$0	28,102	333	0	0	6,084	80
Wako Life Sciences, Inc.	\$22,354	\$0	\$0	\$0	60	0	0	0	39	0
WARDLOW ENTERPRISES	\$28,211	\$0	\$0	\$0	91	0	0	0	62	0
Warner Chilcott LLC	\$0	\$9,371	\$0	\$0	0	3	0	0	0	1
Warner-Lambert Company LLC	\$90,213	\$0	\$0	\$0	21	0	0	0	0	1
Wavetec Vision Systems, Inc.	\$339,649	\$403,524	\$0	\$0	30	4	0	0	26	0
WBC Group, LLC	\$351	\$0	\$0	\$0	8	0	0	0	8	0
Welch Allyn	\$303,601	\$115,614	\$0	\$0	11	3	0	0	8	3
Wenzel Spine, Inc.	\$2,420	\$13,045	\$675	\$1,621,148	27	8	3	3	29	2
Werfen USA LLC	\$17,495	\$0	\$0	\$0	35	0	0	0	11	0
West Coast Cryotherapy LP	\$120,425	\$0	\$0	\$0	219	0	0	0	27	0
Westpac Partners, LP	\$0	\$0	\$435,000	\$610,437	0	0	8	8	8	0
Whip Mix Corporation	\$1,000	\$0	\$0	\$0	2	0	0	0	1	0
Whitehall International Inc	\$10,500	\$0	\$0	\$0	1	0	0	0	0	1
Wockhardt USA LLC	\$43,749	\$0	\$0	\$0	2,669	0	0	0	1,832	0
Wound Care Technologies, Inc.	\$11,555	\$12,000	\$392,948	\$1,118,634	72	1	7	7	78	1

Open Payments Program Report to Congress

AMGPO Making Payment Name	Dollar Amounts				Number of Transactions				No. of Physicians	No. of Teaching Hospitals
	General	Research	Investment	Interest	General	Research	Investment	Interest		
WRIGHT MEDICAL TECHNOLOGY, INC.	\$8,252,206	\$0	\$0	\$0	14,006	0	0	0	3,436	4
Wright Therapy Products, Inc.	\$67,305	\$0	\$300,007	\$750,007	119	0	2	2	89	0
Wyeth LLC	\$23,859	\$0	\$0	\$0	1	0	0	0	0	1
Wyeth Pharmaceuticals Inc	\$999	\$0	\$0	\$0	2	0	0	0	0	1
XenoPort Inc.	\$653,008	\$0	\$0	\$0	7,186	0	0	0	3,368	0
Xhale, Inc.	\$1,075	\$0	\$3,629,072	\$5,888,317	1	0	20	20	18	0
Xlumena	\$35,155	\$0	\$0	\$0	38	0	0	0	20	0
Xoran Technologies	\$132	\$0	\$0	\$0	1	0	0	0	1	0
X-spine Systems, Inc.	\$240,303	\$0	\$0	\$0	299	0	0	0	118	0
Young Dental Manufacturing I, LLC	\$39,165	\$0	\$0	\$0	66	0	0	0	51	0
Young OS LLC	\$193,274	\$0	\$0	\$0	17	0	0	0	4	1
Young's Valley Contax, Inc.	\$30,224	\$0	\$0	\$0	74	0	0	0	24	0
Ziehm Imaging, Inc.	\$8,360	\$0	\$0	\$0	23	0	0	0	21	0
Ziemer USA	\$14,199	\$0	\$0	\$0	16	0	0	0	11	0
ZILA, INC.	\$87,613	\$0	\$0	\$0	48	0	0	0	10	0
Zimmer Holding Inc	\$50,781,224	\$2,945,652	\$0	\$0	35,685	515	0	0	13,315	39
Zogenix Inc.	\$818,940	\$0	\$56,230	\$56,230	12,297	0	2	2	3,816	2
ZOLL Circulation Inc	\$944,321	\$245,637	\$0	\$0	189	100	0	0	67	43
ZOLL Medical Corporation	\$570,676	\$0	\$0	\$0	421	0	0	0	228	25
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp)	\$1,782,028	\$1,955,567	\$0	\$0	42,319	48	0	0	14,208	72
Zyga Technology Inc	\$207,698	\$20,885	\$0	\$1,950	216	2	1	1	175	2